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Chapter 1: General Introduction

Introduction
Genetic studies have led to many novel insights into genetic determinants of a wide variety of human behavior. Re-
cent genome-wide association studies (GWAS) have tremendously increased the rapid pace of scientific discovery, 
leading to thousands of novel loci being discovered that explain both normal variation and disease risk1. Although we 
have learned much about which genes and trait mechanisms are important in explaining individual variation, much 
of the heritability of these traits is yet unknown. This thesis aims to extend these existing novel discoveries by demon-
strating novel loci, genes, pathways and mechanisms that underlie a range of human complex behavioral phenotypes.
 
1. Population genetic studies of complex traits 
1.1 From genes to behavior
Human behavior has long been known to be strongly influenced by genetic factors2. After groundbreaking work by Gregor Mendel de-
scribing fundamental laws of inheritance in his ‘Experi-
ments on Plant Hybridization’ in 1866 (Fig. 1a), it was his 
half-cousin Sir Francis Galton who was among the first to 
study the heredity of human behavior3. Early work by Gal-
ton in the second half of the 19th century mainly focused 
on addressing the question whether behavior in offspring 
resembles that of their parents4. As such, he was among 
the first to consider the role of relatedness in the presence 
of certain behavioral characteristics5. Galton proposed 
that twins may be used to study the role of ‘nature and 
nurture’ (a term introduced by Galton himself) in the or-
igin of behavioral differences6. However, he did not con-
sider the comparison between monozygotic (i.e. identical) 
and dizygotic (i.e., fraternal) twins7 as he was unaware of 
the genetic differences between these two types of twins. 
The modern twin study design emerged several decades 
later when, in 1924, (Fig. 1a) two researchers, Curtis 
Merriman8 and Hermann Siemens9 independently pub-
lished descriptions of estimates of heritability by compar-
ing twins7. Using multiple sophisticated twin modelling 
designs that were developed in the following decades, it 
was concluded that all behavioral traits are more or less 
heritable, often referred to as the ‘first law of behavioral 
genetics’10. 
In 2015 (Fig. 1a), a large meta-analysis summarized the 
results of all twin studies until that time of 17,804 traits11: 
the influence of genetic factors estimated over 2,748 twin 
study publications was 49%, an equal contribution of ‘na-
ture’ and ‘nurture’ to the variation in human characteristics. 
After the importance of heredity in behavioral differences 
was ascertained in the twin study era, the first attempts of 
identifying specific genes involved in complex traits were 
carried out in candidate gene studies that aimed to link 
single genes to complex behavioral traits based on prior 
knowledge or expert opinion12. Although the concept of 
finding genes for disease by comparing genetic variants 
between patients and controls was promising, efforts 
from this type of hypothesis-driven gene finding studies 
in behavioral genetics would often not replicate in sub-
sequent analyses13, likely due to low statistical power and 
insufficient correction for the confounding effects of pop-
ulation stratification14 (i.e. false-positive associations due 
to allele frequency and phenotypic differences between 
ethnicities). 
More recently, a paradigm shift took place when around 
the year 2007 (Fig. 1a) a hypothesis-free design that si-
multaneously probes variants across the entire width of 
the genome in a genome-wide association study (GWAS)15 
design became more common, that quickly replaced prior 
hypothesis-driven approaches.
1.2 Genome-wide association studies
In the last decade, GWAS has proven to be the most im-
portant driver of scientific discovery in the field of com-
plex trait genetics1,16, and to date thousands of significant 
associations between single nucleotide polymorphisms 
(SNPs) and behavior have been found. Although these 
studies provide major steps forward in deciphering the 
genetic architecture of complex traits, for the majority 
of these traits most genomic loci are still undiscovered17, 
leading to a gap between the estimated and explained 
heritability (‘missing heritability’18). Given the small ef-
fect sizes of variants that were observed, it has been sug-
gested that most of the variation that can theoretically be 
explained by SNPs is in fact hidden and may only be dis-
covered when sample sizes increase19,20. 
In a period of just 10 years, the sample sizes of GWAS in 
humans has increased by approximately 200-fold, from a 
couple of thousand individuals in the first well-performed 
GWAS in 200721, to over a million in recent studies of ed-
ucational attainment22, blood pressure23 and alcohol use24 
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Fig. 1 | ‘Standing on the shoulders of giants’, a timeline of events in scientific discovery. A chronological overview of scientific 
milestones in the field of (a) genetics, and (b) neuroscientific research.
(Fig. 1a), equivalent to a population doubling time every 
1.3 years (a trend more rapid than Moore’s law25, the pre-
dicted doubling time of the number of transistors on a 
chip, a measure of processor speed).
Recently, two important big data initiatives have strongly 
accelerated this trend, and have led to a recent ‘Cambrian 
explosion’ in genetic discoveries in the last two to three 
years: 
The first is The UK Biobank (UKB)26, a large popu-
lation-based study that was initiated in 2005 collects 
health-related data in over 500,000 individuals. UKB re-
leased genotype data of the full cohort to researchers with 
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an approved application in 201727 (Fig 1a). This unique 
dataset of 500,000 genotypes in combination with the 
high dimensionality of phenotypic data collected in UKB 
participants allows well-powered GWAS on a massive 
collection of behavioral outcomes. The data release was a 
highly anticipated event by many research groups around 
the world that had approved access to the data, which 
subsequently continued the ‘gold rush’ in gene finding 
that was predicted ten years earlier28,29. UKB has proven 
to be a key data source not only in finding novel genes for 
certain behavior, but also for novel findings in the fields of 
neuroscience, neuroimaging and epidemiology. 
The second is 23andMe, Inc., a direct-to-consumer geno-
typing company30, that offers health information based 
on genome-wide genotyping. Customers of 23andMe 
are offered the possibility to opt-in for scientific re-
search by completing online questionnaires related to 
their health. The customer database currently contains 
over 3 million individuals, many of which opted-in for 
participating in scientific research. Genome-wide analy-
ses based on this data are performed on many traits by 
the 23andMe research team, and the full GWAS results 
are made available to researchers with an approved re-
search project. Given the enormous and still increas-
ing scale of the customer population, with potential 
sample sizes of millions of individuals worldwide, di-
rect-to-consumer genotyping companies have been an 
important source of GWAS results for many behavior-
al traits and will continue to be in the years to come.
Although GWAS has been crucial in the search for genes 
related to behavior, points of critique and shortcomings 
to this approach exist that need to be overcome to release 
its full potential. Much of the genetic signal observed in 
GWAS has been found to be located within or near genes 
without an obvious link to functional mechanisms that 
may explain differences in phenotypes, which lead to dif-
ficulties interpreting these genes. Also, the overwhelming 
polygenic findings often do not lead to a clear coherence 
in gene functions between the many discovered genes 
identified by GWAS31. A possible explanation has been 
proposed by a putative ‘omnigenic model’32 that describes 
core-genes in a gene regulatory network of disease biolo-
gy and many more peripheral genes in the network. The 
much larger number of peripheral genes that correlate 
with these core genes in the network may theoretically 
explain a significant part of the GWAS, which may ex-
plain the observation that many traits are highly polygen-
ic. This proposed model has been topic of debate in the 
genetics community, as it is argued to be an oversimpli-
fied representation of the complex biology of behavior33 
and provides only a vague distinction between core and 
peripheral genes. Although the validity of the omnigenic 
has been disputed, it emphasizes that a more sophisticat-
ed network analyses of the interplay between genes may 
aid in the interpretation of GWAS findings34. This requires 
more advanced methods and integration of high dimen-
sional omics data to study the effects of genetic variants 
and genes on various levels of biological complexity35.
1.3 Genetics of psychiatric disorders
For psychiatric disorders in particular, the last years have 
seen a tremendous increase in the understanding of the 
genetic architecture of psychiatric disorders, in which 
GWAS has served a major role. These debilitating disor-
ders with often devastating consequences due to insuf-
ficient treatment strategies are long known to be among 
the most heritable traits36. Early applications of the GWAS 
methods did not prove to be successful, and clearly 
showed that collaborative efforts were necessary, imposed 
by nature due to the small effect sizes of individual genetic 
variants, to reach sufficient power for discovering these 
variants. 
A major breakthrough in psychiatric genetics was 
achieved by a milestone paper in 2014 carried out by the 
Psychiatric Genomics Consortium (PGC37) that report-
ed 108 locations in the DNA that influence the risk of 
schizophrenia38. This report, that has been cited almost 
3,000 times in just a couple of years, laid the foundation 
for a new understanding of the genetics of schizophrenia. 
Importantly, the study paved the way for numerous fol-
low-up studies that could build forth on these insights by 
studying various aspects of the disease, ranging from the 
functional impact of these loci39 to epidemiological distri-
butions of genetic risk40, based on the publicly available 
GWAS results. 
Similar successes followed for other common psychiatric 
disorders, including 44 risk loci for major depression41, 
12 risk loci for attention-deficit hyperactivity disorder42 
and the first risk locus for autism spectrum disorder43. 
These GWAS studies confirmed the highly complex ge-
netic architecture of psychiatric disorders, influenced 
predominantly by many common variants of small effect 
and difficult to detect rare variants44. Continuation in this 
rapid pace of discovery of novel variants, genes and the 
pathways that modify disease risk of psychiatric disorders 
may hopefully lead to necessary improvements treatment 
options for patients that suffer from the incapacitating 
consequences from these disorders.
1.4 Post-GWAS annotation
The pace of discovery in recent GWAS studies has been 
difficult to keep up by (functional) follow-up studies to 
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better understand the characteristics of identified genetic 
variants45–47. An exciting area of genetic research emerged 
over the previous years that strives to extract more infor-
mation about the genetics of complex traits from GWAS 
summary statistics alone48. This has the clear advantage of 
making individual level genotypes unnecessary by reduc-
ing the data to SNP associations alone (SNP effect sizes 
and/or P-values). A major development in this area is the 
LD Score regression software, which is able to estimate 
genetic overlap between traits based on GWAS results49 
and to partition SNP heritability over functional annota-
tions of SNPs50 and continuous SNP measures51. 
To further facilitate the process of performing follow-up 
analyses based on GWAS as the starting point, the online 
GWAS annotation tool FUMA52 was developed in 2017 
that automates the process of GWAS follow-up analy-
sis, including functional annotation, gene-mapping and 
gene-expression analysis. This analysis pipeline has the 
clear advantage of automating each follow-up step, a reduc-
tion of the required time to run these analyses and having 
all individual datasets integrated into one easy to use tool. 
The development of exciting novel follow-up analyses to 
fully understand the detected genetic signal, using GWAS 
as the starting point, is an important area of current-day 
genetic research and it is expected that more and more 
information can be extracted from GWAS results to better 
understand the biology of a particular trait or disease53. 
Among these follow-up analyses, the analysis of gene-ex-
pression from sequencing of messenger RNA (mRNA) in 
relevant postmortem tissue types has been central to un-
derstanding the role of genes implicated by GWAS. More 
recently, it has become technologically feasible to probe 
mRNA levels within single neuronal cell-types by sin-
gle-cell RNA sequencing54 (scRNA-seq). By integrating 
gene findings from GWAS with expression data in classes 
of neurons, neuronal cell-types can be identified that are 
likely to be involved in trait mechanisms on the micro-
scopic scale. Availability of public RNA sequencing data 
has facilitated the analysis of neuronal enrichment of ge-
netic signal55. Analysis of gene-expression data in psychi-
atric disorders has identified specific cell-types related to 
disease, such as cortical interneurons and pyramidal neu-
rons in schizophrenia56, and high expression of genes re-
lated to Parkinson’s disease57 in substantia nigra neurons. 
1.5 Polygenic scoring
Among the primary aims of GWAS is to increase un-
derstanding of the role of the genome in illnesses, which 
could ultimately lead to new cures. In addition, knowing 
which variants influence disease risk may be used to es-
timate an individual’s total genetic risk of disease, and 
identify groups that are most at risk and may benefit most 
from preventive measures58. An estimate of overall genetic 
risk, based on GWAS variants, can be derived by calcu-
lation of a polygenic risk score (PRS)59, a sum of all risk 
alleles weighted by their effect size from GWAS. Whereas 
early PRS studies intuitively included only variants that 
passed a stringent genome-wide significance thresh-
old60 (P < 5 × 10-8), later studies showed that much more 
variation could be explained by a PRS that also included 
variants well below the significance line, suggesting that 
much of the genetic signal is concealed in variants that do 
not (yet) reach the Bonferroni threshold38,61,62. 
PRSs have shown to be promising for future clinical ap-
plications for common diseases, including breast cancer63, 
diabetes and cardiovascular disease64, showing compa-
rable relative risk on the highest part of the continuum 
of genetic predisposition as several rare variants with a 
Mendelian (monogenic) pattern of disease risk64. The 
overall genetic load has several useful applications in ge-
netic research, including new opportunities for studying 
gene-environment interactions65 (PRS x E) and finding 
genetic overlap between seemingly unrelated traits66. 
Moreover, using a PRS for diseases in the general pop-
ulation can lead to novel hypotheses about associations 
between genetic predisposition for disease such as psychi-
atric disorders, and disease-related manifestations in the 
general population59.
2. Genetics of complex traits (Part 1)
In the first part of the thesis, we study the genetics of three 
phenotypes related to behavior, which include: insomnia 
and sleep-related traits, neuroticism and depression, and 
intelligence.
2.1 Insomnia and sleep related traits
Sleep disorders including insomnia are known to be relat-
ed to all sorts of health outcomes67, ranging from disor-
ders related to metabolic syndrome, including obesity68, 
and type 2 diabetes69, to overall happiness70 and longev-
ity71. 
In the past few years, large GWAS studies have led to im-
portant new insights into the genetics of sleep, including 
novel genes for insomnia72–74, showing the strongest ge-
netic signal located in the MEIS1 gene. Also, many ad-
ditional loci have been found for traits related to sleep, 
including sleep duration75  and being a morning person76. 
The heritability of insomnia that can be explained by 
common variants (h2SNP) has been reported to be low, ap-
proximately 9%73, as estimated by LD Score regression77, 
which suggest that many more samples are needed to find 
more loci that influence the risk of insomnia. 
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2.2 Neuroticism and depression 
Personality traits and mental health are strongly inter-
related78 which is reflected in strong overlap in genetic 
etiology79. Personality traits have historically been de-
scribed according to a five-factor model along five axes 
of phenotypic variation (‘The Big Five’)80. Among these 
axes, neuroticism has been declared as the most prevalent 
trait as it plays a role in almost all personality types81. This 
personality feature is characterized by a tendency to have 
a negative perception and emotional response to negative 
stimuli82 and predisposes to the development of depres-
sion83. Although this trait is considered universal84, the 
term neuroticism may have origins in the Freudian con-
cept of ‘neurosis’85–87, and leads back to the Greek word 
νεῦρον (‘neuron’, meaning ‘tendon’), which shares this 
origin with the English word ‘nervous’ via the Latin word 
‘nervus’. 
Neurotic personality traits are considered highly herita-
ble11, with heritability increasing with age,88 and highly 
stable over a lifetime88,89. Subsequent gene finding studies 
of neuroticism test scores have shown that this person-
ality trait is a highly polygenic trait90 and that significant 
overlap exists in the polygenic background of the Big Five 
dimensions91. The increase in scale of GWAS in neurot-
icism research has led to a larger number of loci being 
discovered79,92–94 and confirmed shared genetic risk with 
psychiatric disorders79. Thus far, these gene discovery ef-
forts have not converged on a biologically interpretable 
model of neuroticism, which requires additional statisti-
cal power and detailed functional follow-up analysis.  
2.3 Intelligence
The first descriptions of heritability in an individual’s 
mental capacities was heavily studied by the aforemen-
tioned geneticist Francis Galton5. The first twin studies on 
the topic of intelligence confirmed a major role of genetic 
influence. Comparing twin study heritability estimates in 
children, adolescents and adults showed that the variance 
explained by genetic factors is not stable over the course 
of life, but increases as we age95. 
After several unsuccessful genome-wide attempts were 
done to capture genetic variants associated with intelli-
gence96,97, the first study that published an extensive list of 
loci and genes involved in intelligence was published in 
201798. These results implicated 18 genomic loci, and 52 
genes associated by positional mapping and gene-based 
association testing. Interestingly, gene-set analyses99 
showed that processes related to the regulation of cell de-
velopment were significantly enriched for genetic signal, 
which may indicate the importance of these genes early 
in development, suggesting an early-life window during 
which genes linked to intelligence operate. Although her-
itability had been estimated to be higher in adults com-
pared to children95, the genetic effects between these age 
groups were highly correlated (rg = 0.89) as estimated by 
LD Score regression100, which shows that largely the same 
genetic factors influence intelligence over the life course. 
The increase in the number of detected loci with increas-
ing sample size, suggests that more genomic loci are likely 
to be found currently residing under the genome-wide 
significance threshold101. This motivates further expan-
sion of the sample size and statistical power. Investigating 
normal cognitive functioning, one of the most important 
functions of the human brain, has significant implications 
for our understanding of the normal neurobiology of the 
brain, and of diseases that are characterized by impair-
ment in normal cognitive functioning, including schizo-
phrenia102, autism spectrum disorder103, and Alzheimer 
disease104.
3. Brain imaging studies (Part 2)
Brain imaging techniques such as magnetic resonance 
imaging (MRI) have proven to be an important modal-
ity in both clinical setting as in understanding the inner 
workings of the brain. In the second part of the thesis, we 
used multimodal brain imaging techniques to study asso-
ciations between genetic variation and brain morphology.
3.1 Magnetic resonance imaging of the brain 
In parallel to discoveries in behavioral genetics, the field 
of neuroscience has gone through equally rapid scientific 
advances in the last centuries (Fig. 1b). A major limita-
tion during most of this time was that the secrets of the 
brain’s inner workings were hidden in the skull, a ‘locked 
safe’ that was preventing scientists from making infer-
ences about the brain’s neurobiology in living persons. 
Until the mid 70’s, the only way to receive a glimpse of 
the brain was through the use of pneumoencephalogra-
phy (PEG), a procedure invented in 1919 (Fig. 1b) that 
included draining the cerebrospinal fluid and inserting 
air into the ventricles to increase the visibility of the brain 
on an x-ray image. The procedure was very painful, had 
a significant risk of morbidity105, and resulted in death in 
0.2% of the patients106. 
This method was rendered obsolete by the invention of 
computed tomography (CT) by Sir Godfrey Hounsfield, 
and magnetic resonance imaging (MRI) by Sir Peter Man-
sfield and Paul Lauterbur in the 70s that could non-inva-
sively visualize the brain while in the skull. Whereas the 
first brain imaging studies using MRI were concerned 
with imaging the structure of the brain, more applications 
for using the versatile MR signal for studying complex 
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features of the brain followed over the years, including 
functional MRI107 (fMRI) for studying brain activity in 
1992, diffusion tensor imaging108 (DTI) for tract analysis 
in 1994, and graph theoretical measures to analyze the 
brain as a connected network in 2005 (Fig. 1b)109. 
Next to the tremendous impact of brain imaging on di-
agnosis and decision making in neurological patients, 
the wide availability of brain imaging techniques has 
become the cornerstone in neuroscience for scientific 
investigations in the living brain. In epidemiology, pop-
ulation-based brain imaging is an indispensable tool for 
studying traditional risk factors related to brain develop-
ment at early age110, and brain disorders that occur later 
in life111. Examples of such large-scale MRI data collection 
efforts in different age categories are the Generation R co-
hort in The Netherlands110, consisting of 4,000 scanned 
children, up to 10,000 adolescents in the ABCD study 
in the USA112, and up to a planned 100,000 middle-aged 
adults from the UK Biobank, initiated in 2016 (Fig. 1b)113. 
Insights into the brains of these large numbers of individ-
uals provide unique clues of normal brain function and 
associations with insulting risk factors. In addition, the 
enormous scale of these imaging efforts provides suffi-
cient sample size and statistical power to study the mod-
est individual associations between genetic variants and 
the brain. 
Although the yield of knowledge from these large datasets 
is invaluable, high resolution imaging in large numbers 
of brain scans also has the downside of more unexpected 
findings that may either be unharmful or pose a signifi-
cant health risk for the participant114. 
3.2 Genetics of imaging-derived phenotypes 
With the advent of these large datasets and through in-
ternational collaborations such as the ENIGMA consor-
tium115, it has become feasible to investigate the influence 
of genetic variants on variation in brain structure de-
rived from brain images (imaging-derived phenotypes116, 
or IDP). These morphological features of the brain are 
shown to be under strong genetic control117, suggesting 
that gene-finding studies are likely to be successful when 
sufficient data are available. 
Involvement of genetic factors in individual differences 
in brain structure is further evidenced by abnormal brain 
development as a commonly observed symptom of rare 
monogenic disorders, including a small brain (micro-
cephaly) or an abnormally large brain (macrocephaly). 
Indeed, large imaging genetics studies of brain struc-
ture volume have shown evidence of a large number of 
common variants that moderate brain volumes115,118, and 
implicate several cell-signaling pathways to be involved 
in brain volume regulation. Interestingly, these SNP as-
sociations observed in intracranial volume are correlated 
with several complex traits, including intelligence119, edu-
cational attainment79 and neuroticism120.
3.3 Genetic risk and brain imaging
In vivo assessment of functional and structural charac-
teristics of the brain provides a unique tool to investigate 
genetic influences on normal variation in brain morphol-
ogy121 and the effects of genetic risk variants on neuro-
structural phenotypes. Involvement of a wide variety of 
brain structures have repeatedly been reported in the 
brains of patients suffering from psychiatric disorders, 
including major depression122,123, schizophrenia124 and 
attention-deficit hyperactivity disorder125. Since these 
psychiatric disorders are highly heritable, neurobiologi-
cal alterations on brain imaging in patients may suggest a 
shared genetic etiology between genetic liability for these 
traits and brain structure. Moreover, these alterations 
in brain structure have been found to a lesser degree in 
first-degree relatives of patients compared to controls 
without relatives with psychiatric disorders126–128 and im-
plies that genetic risk for the traits is closely related to 
variations in brain development. 
By calculating a PRS in individuals with available gen-
otype and brain imaging data, it has been shown that 
overall genetic risk for certain psychiatric disorders cor-
relates with brain morphology and function in the gener-
al population129. The usefulness of these PRSs for finding 
associations between total genetic risk and variation in 
imaging-derived phenotypes of the brain is expected to 
increase as more large well-powered GWAS results are ex-
pected to become available in the coming years.
4. Thesis objectives
The main goal of this thesis is to find associations be-
tween genes and behavioral outcomes and to identify 
mechanisms that explain these associations along the 
‘gene-brain-behavior axis’ (Fig. 2a). To bridge the gap 
between genes and behavior, the reported research proj-
ects include an extensive analysis pipeline that integrates 
various sorts of data from several large population-based 
samples, including genotype, brain imaging and ques-
tionnaire data, with bioinformatics data such as function-
al annotation, functional gene-sets and gene-expression 
data from tissues and single neuronal cell-types (Fig. 2b). 
GWAS results, the strength of SNP associations with a 
certain trait, are the most important starting point for all 
analyses that follow in this thesis, including several differ-
ent gene-mapping strategies (positional mapping, eQTL 
mapping, gene-based association tests, chromatin-chro-
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Fig. 2 | Overview of the main goals and analyses that were performed in this thesis. (a) The primary aim of this thesis is to find 
genes and pathways along the gene-brain-behavior axis that explain variation in behavioral outcomes. (b) Global analysis pipeline 
of analyses that were carried out, using GWAS results as the starting point. The rounded squares highlight analysis steps, while the 
colors indicate the software package that was used.
matin interaction gene mapping) that link GWAS results 
to gene discovery (Fig. 3), and polygenic risk score (PRS)
analysis.
The objectives of this thesis can be further subdivided 
into two parts, including genetic studies of behavior, and 
(genetic) studies that use population-based brain MRI 
imaging data.
4.1 Genetic studies of behavior
The first aim was to investigate the genetic factors that 
explain individual differences in complex traits, and to 
generate hypotheses about functional pathways that are 
associated with these genetic factors.
In Chapter 2, we use polygenic scores for psychiatric dis-
orders and educational attainment in a large population of 
children in the Generation R Study to investigate whether 
differences in genetic predisposition for psychiatric disor-
ders are reflected in high levels of behavioral problems al-
ready in early childhood from the age of 3 years onwards.
In Chapter 3, we increase the scale of genome-wide anal-
ysis of insomnia by 10-fold and use genotype and sleep 
questionnaire data in over 1 million adult individuals in UK 
Biobank and 23andMe to study the genetics of insomnia 
complaints and several traits related to sleep in adults, in-
cluding sleep duration, morningness and daytime napping. 
In Chapter 4, we carry out the largest genome-wide 
analysis of neuroticism and depression in adults thus 
far by comparing results in participants of UK Biobank, 
23andMe, the Psychiatric Genomics Consortium (PGC) 
and the Genetics of Personality Consortium (GPC) and 
study the biological implications of our findings by per-
forming extensive functional interpretation of the results.
In Chapter 5, we aimed to further uncover the genetic 
architecture of intelligence by combining GWAS analyses 
of cognitive test scores in even a larger number of indi-
viduals from 14 pediatric and adult cohorts and perform 
extensive novel bioinformatic follow-up analyses of the 
results, including gene-set and gene-expression analysis. 
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Fig. 3 | Gene-mapping methods used in this thesis. In the reported GWAS studies, we carried out a number of different 
gene-mapping strategies to link individual genetic variants to genes, including (a) positional mapping: mapping variants to 
genes by their physical position near or within a gene, (b) eQTL mapping: variants mapped to a gene through their influence on 
gene-expression of a gene, (c) gene-based association testing: combining variant associations within a gene into a gene-based test 
statistic, (d) chromatin-chromatin interaction: mapping a variant to a gene through a physical interaction with a close or distant 
region of the genome.
a b
c d
4.2. Population imaging studies
In Chapter 6, we investigate incidental findings in the 
general pediatric population by reviewing brain scan data 
in over 4,000 children between the age of 8 and 12 years 
that participate in large-scale population-based research 
of the Generation R Study cohort.
In Chapter 7, we used GWAS results of brain imaging 
data collected in thousands of adult individuals in UK 
Biobank to find genes that explain the observed genetic 
overlap between brain volume and intelligence130.
In Chapter 8, we used multimodal MRI data of the brain 
to investigate whether differences in polygenic
predisposition based on common variants for psychiatric 
disorders and cognitive traits are associated with 
differences in macrostructural morphology of the brain 
on T1-weighted imaging.
In Chapter 9, we studied the association between 
polygenic scores for psychiatric disorders and cognitive 
outcomes, and white matter microstructure using 
diffusion tensor imaging (DTI) data of the brain in over 
1,000 children from the Generation R Study between the 
age of 8 and 12 years.
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Population-based Genetic Studies of Complex Traits
Chapter 2
Polygenic Scores for Schizophrenia and Educational Attainment are 
Associated with Behavioural Problems in Early Childhood in the General 
Population
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Background: Genome-wide association studies in adults have identified numerous genetic variants relat-
ed to psychiatric disorders and related traits, such as schizophrenia and educational attainment. Howev-
er, the effects of these genetic variants on behaviour in the general population remain to be fully understood, 
particularly in younger populations. We investigated whether polygenic scores of five psychiatric disor-
ders and educational attainment are related to emotional and behaviour problems during early childhood. 
Methods: From the Generation R Study, we included participants with available genotype data and behavioural 
problems measured with the Child Behavior Checklist (CBCL) at the age of 3 (n=1,902), 6 (n=2,202) and 10 years 
old (n=1,843). Polygenic scores were calculated for five psychiatric disorders and educational attainment. These 
polygenic scores were tested for an association with the broadband internalizing and externalizing problem scales 
and the specific CBCL syndrome scale scores. 
Results: Analysis of the CBCL broadband scales showed that  the schizophrenia polygenic score was associated 
with significantly higher internalizing scores at 3, 6 and 10 years and higher externalizing scores at age 3 and 6. 
The educational attainment polygenic score was associated with lower externalizing scores at all time points and 
lower internalizing scores at age 3. No associations were observed for the polygenic scores of bipolar disorder, 
major depressive disorder and autism spectrum disorder. Secondary analyses of specific syndrome scores showed 
that the schizophrenia polygenic score was strongly related to the Thought Problems scores. A negative associa-
tion was observed between the educational attainment polygenic score and Attention Problems scores across all 
age groups. 
Conclusions: Polygenic scores for adult psychitric disorders and educational attainment are associated with vari-
ation in emotional and behavioral problems already at a very early age. 
Childhood emotional and behavioural problems are common and show moderate stability throughout childhood1. Although symptoms may fluctuate 
over time, early childhood problems have predictive value 
for psychiatric disorders later in life, as well as academic 
performance2 and risk-taking behaviour3. 
Variation in problem behaviour is influenced substantially 
by genetic factors. Twin study heritability estimates of be-
havioural problems are fairly constant over the course of 
childhood, and show that genetic factors explain around 
50% of the variance in externalizing (e.g. aggression and 
oppositional behaviour) and internalizing (e.g. depres-
sion and anxiety) behaviours4. However, no statistically 
significant genetic polymorphism has yet been identified 
specifically for common childhood emotional and be-
havioural problems5–7. In contrast, GWAS studies in adult 
behaviour-related phenotypes have identified variants 
for a wide variety of traits and show that the majority of 
neuropsychiatric traits are genetically complex and deter-
mined by many genetic variants, mostly of small effect8,9. 
Educational attainment is an important predictor for a 
variety of important life outcomes and is closely linked 
to psychopathology10. Recently, proxy phenotype meth-
ods have targeted educational attainment (i.e. years of 
schooling) to detect genetic variants related to psychiat-
ric and personality-related traits, including schizophrenia 
and neuroticism11. It was also shown that in school-aged 
children, a genetic predisposition to higher educational 
attainment is associated with higher cognitive perfor-
mance12. 
Although many genetic variants have been identified 
for adult psychiatric disorders, it is unclear whether the 
same genetic variants are also associated with problem 
behaviour at an early age. Moreover, it is unclear wheth-
er children at high risk for psychopathology already 
show differences in behaviour during childhood. Popu-
lation-based cohort studies in adolescents have demon-
strated that genetic risks for psychopathology, quantified 
by risk scoring methods, correlate with a diverse array 
of behavioural outcomes13. More specifically, studies us-
ing schizophrenia polygenic risk scores reported that 
this genetic risk is associated with negative symptoms in 
the general adolescent population14,15. However, a recent 
study investigating the schizophrenia polygenic score in 
young children, suggests that manifestations in behaviour 
and neurodevelopment may be present much earlier in 
life16. In addition, most studies in children have tested 
polygenic risk scores for single traits, without performing 
comparisons across traits. 
The aim of this study was to investigate whether polygenic 
risk scores of later life outcomes are associated with ear-
ly childhood behavioural and emotional problems in the 
general population. We focus on five psychiatric disor-
ders (schizophrenia, bipolar disorders, major depressive 
disorder, ADHD and autism spectrum disorder) and ed-
ucational attainment, as these traits have been shown to 
be associated with early life problem behaviour17,18. We 
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hypothesize that genetic variants, associated with psychi-
atric disorders and educational attainment, are related to 
variation in symptoms in internalizing and externalizing 
domains at early childhood, thus earlier in life than de-
scribed in most previous studies. This study will provide 
a better understanding of the association between risk 
variants and behavioural manifestations early in life and 
insight into the underlying neurobiology of these traits.
Methods
The Medical Ethics Committee of the Erasmus Medical 
Center approved all study procedures, and parents of the 
participants provided written informed consent. 
This study was conducted within the Generation R co-
hort, a large population-based longitudinal cohort fo-
cused on child development19. Emotional and behavioural 
problems were assessed prospectively at the approximate 
age of 3, 6 and 10 years in respectively 4,612, 6,199 and 
4,770 children. Of these children, 2,964, 3,926 and 3,058 
were subsequently selected based on the availability of 
genotype data. Of these, 1,902, 2,202 and 1,843 children 
passed genotype quality control procedures and were in-
cluded in the analyses.
Child behaviour measures 
Behaviour problems were assessed with the Child Behav-
ior Checklist (CBCL), a comprehensive list of items about 
various child emotional and behavioural problems, to be 
completed by the primary caregiver20. Each CBCL item 
can be scored as: 0 = ‘not true’, 1 = ‘somewhat or some-
times true’, 2 = ‘very true or often true’. CBCL items can 
be scored on two broadband scales: ‘Internalizing Prob-
lems’ and ‘Externalizing Problems’, and on more specific 
syndrome scales. During the first and second assessment 
wave, the preschool CBCL version (CBCL/1½-5) was 
used, as most children during the assessment were young-
er than 6 years, and other versions are not appropriate for 
this age21. The CBCL/1½-5 survey consists of 100 prob-
lem items. At the third assessment wave, the school-age 
(CBCL/6-18) version was used, consisting of 120 problem 
items. 
An overview of the CBCL syndrome scales and the num-
ber of items within each domain are shown in Table S1, 
available online. 
Genotyping and imputation 
Genotype calling procedures and subsequent processing 
for the Generation R Study have been described previous-
ly22. Briefly, genotype data were either collected from cord 
blood at birth (Illumina 610K Quad Chip) or via vena 
puncture (Illumina 660K Quad Chip) during a visit to the 
research centre. 
Additional quality control steps were performed on the 
genotype data in PLINK23. Variants were filtered for 
minor allele frequency (MAF < 0.01), Hardy-Weinberg 
disequilibrium (P < 0.00001) and missing rate (> 0.05). 
Individuals from European descent were selected within 
4 standard deviations on the first four genetic principal 
components of the HapMap Phase II Northwestern Eu-
ropean (CEU) population. Individuals were additionally 
filtered on relatedness, sex mismatch and genotype qual-
ity (< 0.1). 
P-value thresholds (pT) for inclusion of genetic variants 
in the score varied between pT < 0.01 and pT < 1. Table 
S3 shows the number of SNPs that were included in the 
final polygenic score for each P-value threshold. Pearson 
correlations between the polygenic scores of the six traits 
are shown in Figure S1. Polygenic scores were standard-
ized to a mean of 0 and standard deviation of 1 to increase 
interpretation of the score. 
Statistical analyses 
Statistical analyses were performed in R statistical soft-
ware24 (version 3.2.1). 
Polygenic scores for the six traits were tested individually 
in a linear regression model for association with CBCL 
Internalizing and Externalizing Problems, corrected for 
age, sex and four genetic principal components. Next, we 
tested the most significant P-value threshold of each trait 
for associations with individual syndrome scales. 
To account for varying degrees of skewness in CBCL 
scores, syndrome scores were transformed at each time 
point using Box–Cox transformation. This method uti-
lizes maximum likelihood estimation (MLE) to find the 
optimal transformation parameter to approximate a nor-
mal distribution25. 
False-discovery rate (FDR) was applied to correct for 
multiple comparisons26. Based on the total number of sta-
tistical tests across polygenic scores, P-value thresholds, 
broadband scales and specific syndrome scales, a cor-
rected P-value significance threshold was set to pFDR = 
0.0083, and P-values below this corrected threshold were 
considered statistically significant.
Results
Sample Characteristics 
Characteristics of the study sample at the three assess-
ment waves are shown in Table 1. The three groups had 
a mean age of 3.0 (s.d. = 0.1), 6.0 (s.d. = 0.4) and 9.7 (s.d. 
= 0.3) years at the time of the assessment, and sex was 
equally divided among groups (per cent boys: age 3: 52%, 
age 6: 50%, age 10: 49%). At all ages, boys scored higher 
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than girls on externalizing problems (mean difference: 
age 3: 0.12, P < 0.001; age 6: 0.07, P < .001; age 10: 0.17, P 
< 0.001); there were no significant sex differences on the 
internalizing problem scales at age 3, 6 and 10.
The explained variance (R2) of the broadband internaliz-
ing and externalizing problem scales by the six polygen-
ic scores for all P-value thresholds is shown in Figure 
1. Table S4a–c show the full regression results for these 
associations. Here we highlight the P-value threshold for 
each trait that showed the strongest association (i.e. larg-
est increase in R2) with the outcome across the different 
age groups 
Schizophrenia
Analyses in 3-year olds showed that the SCZ polygenic 
score was significantly associated with higher levels of in-
ternalizing problems (pT < 0.5: β = 0.061, P = 0.008) and 
externalizing problems (pT < 0.5: β = 0.067, P = 0.004). At 
the age of 6 years, an association between the SCZ poly-
genic score and internalizing scores (pT < 0.5: β = 0.088, 
P = < 0.5: β= 0.070, P < 0.001) was also present. At age 
10, we observed again the association with internalizing 
scores (pT < 0.5: β = 0.069, P = 0.003), whereas the asso-
ciation with externalizing scores was no longer significant 
(pT < 0.5: β = 0.039, P = 0.096).
ADHD
No significant associations were observed with external-
izing or internalizing scores at the age of 3. However, we 
observed a weak positive association with externalizing 
scores at age 6 (pT < 0.01: β = 0.042, P = 0.044) that was 
not significant after correction for multiple comparisons. 
This association became stronger and significant at the 
age of 10 (pT < 0.01: β = 0.076, P = 0.001). 
Bipolar disorder, major depressive disorder and autism 
spectrum disorder 
No association was observed between the BP, MDD and 
ASD polygenic scores and externalizing and internalizing 
scales in any age group. 
Educational attainment 
The EA polygenic score was negatively associated with 
externalizing (pT < 0.5: β = –0.089, P < 0.001) and inter-
nalizing scores (pT < 0.5: β = –0.067, P = 0.004) in 3-year 
olds. Again at the age of 6 years, the EA polygenic score 
was associated with lower levels of externalizing problems 
(pT < 0.5: β = –0.067, P = 0.001), but not with internaliz-
ing problems. Similarly, EA polygenic scores were associ-
ated with lower externalizing scores at the age of 10 years 
(pT < 0.5: β = –0.051, P = 0.027), but the association at 
this age did not survive multiple comparison correction. 
Again at this age, no associations with internalizing scores 
were observed.
Sex interaction 
In sensitivity analyses, we tested sex-specific associations 
of SCZ and EA polygenic scores and the externalizing and 
internalizing scores; the stratified results are shown in 
Figure S2a–f. Sex showed a weak interaction with the EA 
polygenic score on internalizing scores (P = 0.026) and 
externalizing scores (P = 0.024); however, these results 
Assessment
Age 3
n = 1,902
Age 6
n = 2,202
Age 10
n = 1,843
Characteristics
Mean age, years 3.04 ± 0.09 5.99 ± 0.37 9.69 ±0.27
Gender, % male 52% 51% 49%
Internalizing problems
Mean score 4.22 ± 3.86 5.21 ± 5.35 4.57 ± 4.79
Range 0 - 36 0 - 49 0 - 41
Median 3 4 3
Externalizing problems
Mean score 7.88 ± 5.97 6.87 ± 6.41 3.82 ± 4.73
Score range 0 - 42 0 - 43 0 - 39
Median 7 5 2
Table 1 | Sample characteristics.
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were not significant given the number of tests. 
Syndrome scales
To test whether specific syndrome scales of the CBCL 
were driving the associations between polygenic scores 
and internalizing and externalizing scores, we performed 
secondary analyses testing associations between the poly-
genic scores of SCZ, ADHD and EA and the individu-
al CBCL syndrome scales. Only the P-value thresholds 
that showed the strongest association for SCZ (pT < 0.5), 
ADHD (pT < 0.01) and EA (pT < 0.5) with the externaliz-
ing and internalizing scales in the primary analyses were 
tested in the secondary analyses. A visual representation 
of the regression coefficients is shown in Figure 2a–c, and 
an overview of the full regression results is available in 
Table S5a–c. 
The SCZ polygenic score was mainly associated with 
higher Emotionally Reactive scores at age 3 (pT < 0.5, β 
= 0.086, P < 0.001). There was a negative association be-
tween the SCZ polygenic score and all internalizing sub-
scales at the age 6, with the strongest association being 
with Withdrawn scores (pT < 0.5, β = 0.072, P < 0.001). 
Interestingly, at age 10, there was a strong positive asso-
ciation with Thought Problems scores of the school-aged 
CBCL version (pT < 0.5, β = 0.087, P < 0.001) (Figure 2c). 
As expected, the association between the ADHD polygen-
ic score and externalizing scores at the age 6 was mainly 
driven by Attention Problems (pT < 0.01, β = 0.065, P = 
0.002). At age 10, the ADHD polygenic score was mainly 
associated with higher levels of aggressive behavior (pT 
< 0.01, β = 0.083, P < 0.001). The previously observed as-
sociation with Attention Problems was no longer signifi-
cant (pT < 0.01, β = 0.045, P = 0.051). The EA polygenic 
score showed a strong negative association with Attention 
Problems scores in 3-year olds (pT < 0.5, β = –0.095, P < 
0.001). This association was observed again at 6 (pT < 0.5, 
β = –0.082, P < 0.001) and at age 10 (pT < 0.5, β = –0.082, 
P < 0.001) in the school-aged CBCL, in which Attention 
Problems scores are not part of the externalizing domain.
Discussion
This study presents evidence that in very young chil-
dren (age 3), a genetic predisposition for psychopathol-
ogy is associated with more emotional and behavioural 
problems in the general paediatric population, whereas 
the polygenic score of EA to lower levels of problem be-
haviour.
The SCZ polygenic score showed an association with in-
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Fig. 1 | Explained variance (%) in externalizing  and internalizing CBCL scores by polygenic scores at the age of 3 years (a) 6 
years (b) and 10 years (c). Regression results are corrected for age, gender and four principal components. SCZ, schizophrenia; 
ADHD, attention-deficit hyperactivity disorder; BP, bipolar disorder; MDD, major depressive disorder; ASD, autism spectrum 
disorder; EA, educational attainment.
a b c
ternalizing scores from age 3 onwards and was associated 
with CBCL Thought Problems scores at age 10. Prior re-
search investigating the SCZ polygenic score and problem 
behaviour has been performed mainly in adolescents14,15. 
Our study shows that genetic predisposition for schizo-
phrenia is associated with variation in behaviour already 
at an early age, and possibly as early as behaviour can be 
reliably assessed. This observation is in line with a re-
cent study that reported associations between the SCZ 
polygenic score and lower cognitive ability, more social 
impairments and more behavioural problems in 4- to 
9-year-old children16. Interestingly, this study showed 
associations with prosocial behaviour and conduct prob-
lems at age 4, but no associations with emotional prob-
lems were observed. Although we found similar associa-
tions with externalizing behaviours, our results add that 
the genetic predisposition for schizophrenia is associated 
with higher levels of emotional reactivity in 3-year olds. 
This discrepancy may be due to more specific items re-
lated to the emotional state of the child in the Emotional 
Reactivity scale of the CBCL. 
Given that the incidence of schizophrenia peaks between 
adolescence and young adulthood, the prominent effect of 
schizophrenia polygenic scores on internalizing problems 
at age 6 compared to age 10 was surprising. This suggests 
that the associations between schizophrenia polygenic 
risk scores and behaviour in the general population is 
best captured by the internalizing syndrome scale within 
the CBCL/1½-5 internalizing domain (such as Emotion-
ally Reactive scores) rather than the internalizing scales 
of the CBCL/6-18, which was used at the assessment at 
age 10. Differences in the subscale items (e.g. more items 
related to measures of affect regulation in the CBCL/1½-5 
Withdrawn scale) may contribute to the different findings 
between CBCL versions. 
The observed association between the SCZ polygenic 
score and the Thought Problems scale at age 10 is a re-
markable new finding and contrasts with two earlier stud-
ies in healthy populations that did not find an association 
between the SCZ polygenic score and positive symp-
toms14,15. The Thought Problems scale, containing items 
such as ‘sees things that aren’t there’ and ‘strange ideas’, re-
flects psychosis-like symptoms and similar behaviour that 
has previously been found to be a precursor of later life 
psychosis in prospective studies in similar age groups27,28. 
Where the two previous studies utilized psychotic symp-
toms as a binary outcome measure (presence/absence of 
psychotic experiences), our study aimed to measure psy-
chotic symptoms along a continuum, possibly yielding 
more power to detect the subtle effects of the polygenic 
Fig. 2 | Visual representation of associations between polygenic scores and the specific syndrome scores in the age 3 (a), age 
6 (b) and age 10 (c) assessment. Coefficients are standardized betas for the association between polygenic score on the individual 
syndrome scores, corrected for age, sex and four principal components.
a b c
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score on psychotic-like experiences in the general pop-
ulation. 
We expected to observe similar associations for schizo-
phrenia and bipolar disorder polygenic scores, as the ge-
netic overlap between psychiatric traits is substantial23,29. 
However, these differences are possibly a consequence of 
differences in sample size of the GWAS for schizophrenia 
(n = 77,096) compared to bipolar disorder (n = 16,731) 
and illustrate the importance of a well-powered discov-
ery GWAS for polygenic risk scoring30. The fact that no 
associations were observed for ASD and MDD polygen-
ic scores could also be due to the lack of a well-powered 
GWAS study. However, despite the smallest sample size 
of the ADHD discovery GWAS (Table S2), we observed 
evidence for significant associations with Attention Prob-
lems and Aggresive Behaviour for one P-value threshold. 
This finding may be explained by a higher prevalence of 
ADHD and ADHD-related symptoms in the age range of 
our study. Moreover, the high specificity of specific CBCL 
scales for measuring ADHD-related symptoms (such as 
the Attention Problems scale in the Externalizing Prob-
lems scale) may further lead to these observed associa-
tions. Previous studies showed higher ADHD polygenic 
scores in children with comorbid aggression31 and atten-
tion problems in the general population32. Interestingly, 
we observed that the ADHD polygenic score was related 
to attention problems in 3- and 6-year olds, but that this 
association shifted towards more aggression problems 
at the age of 10 years. While it is possible that these dif-
ferences are related to the two CBCL versions used, an 
alternative possibility is that polygenic scores are not nec-
essarily related to a fixed set of symptoms, but related to 
dynamics and changes during childhood. The association 
with both the attention and aggression scales could result 
from a shared genetic aetiology between ADHD symp-
toms and oppositional defiant disorder (ODD)-related 
symptoms, which has been described previously in twin 
research33. Furthermore, distinction between these be-
havioural scales can be challenging for the parents and 
may result in classifying attention problems as aggressive 
behaviour and vice versa. 
In our study, genetic variants for educational attainment 
were negatively associated with externalizing symptoms, 
which suggests that less externalizing problems early in 
life may be beneficial for achieving a higher level of educa-
tion. Indeed, externalizing problems are an important de-
terminant of poor academic performance and have been 
shown to precede school problems2. Our findings imply a 
shared genetic aetiology for this association and suggest 
this is partly explained by higher levels of attention prob-
lems. This has also been suggested by prospective studies 
that showed lower academic achievement in children with 
symptoms of hyperactivity and inattentiveness34 and im-
paired cognitive functioning in individuals with ADHD35. 
In addition, prior research reported that cognitive ability 
and behavioural scores are highly intertwined36 and sug-
gest that the association between educational attainment 
polygenic scores and lower externalizing problems could 
result from better cognitive abilities in these children. 
Besides a direct association between genetic predisposi-
tion and childhood behaviour, the observed associations 
could partially be explained by the parental polygenic 
scores: Children with high polygenic scores of psycho-
pathology are more likely to have parents with higher 
than average polygenic scores. Parental polygenic scores 
could subsequently lead to differences in environmental 
factors of the child (e.g. passive gene–environment cor-
relation, including parenting strategies). Studies on this 
complex interplay suggest that environmental factors 
such as parenting moderate the associations between 
polygenic scores and child behaviour37. Moreover, stud-
ies including genetic data of the mother suggest that the 
maternal ADHD polygenic score moderates the associa-
tion between the ADHD polygenic score of the child and 
educational achievement38. Applying polygenic scoring 
in a family-based setting could provide more insight into 
the dynamic interaction between the genetic profile of the 
child and the parents, family upbringing such as parent-
ing, and child behaviour. 
Our study suggest that the genetic risk for schizophrenia 
manifests as more internalizing problems, and to lesser 
degree as more externalizing problems, in children 3 years 
of age. Recent developmental studies of schizophrenia on-
set have focused on early puberty and the occurrence of 
psychotic experiences such as acoustic hallucinations39. 
However, based on the current results, we carefully spec-
ulate that nonspecific symptoms of emotional reactivity 
and anxiety may further help to tailor prevention pro-
grammes for high-risk children, e.g. as defined by family 
history. 
The strength of the study is that behaviour was assessed 
at multiple time points, providing information about be-
haviour during different stages of development. Given 
that childhood behaviour is dynamic, longitudinal stud-
ies are important to study the association between genetic 
predisposition and behaviour at different ages. Our results 
illustrate this by showing that associations with behaviour 
problems were found at specific ages that were not present 
at an earlier age or disappeared at an older age. Future 
genetic studies should aim to assess behaviour at multiple 
time points and study whether changes in behaviour are 
related to the genetic predisposition of the child. 
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A limitation of this study is that the analyses were restrict-
ed to observations from the primary caregiver. Integration 
of information from different observers could provide 
more complete information about the child’s behaviour. 
However, given the young age of children in our study, 
we expect scores reported by the primary caregiver to be 
the most accurate reflection of the children’s behaviour. 
In addition, due to low power of the discovery GWAS 
study, the observed associations for the ADHD polygenic 
score were not as robust as those found for schizophre-
nia and educational attainment. This is illustrated by the 
observation that associations were only found for the 
most stringent P-value threshold (pT < 0.01), but lacked 
broader support from other P-value thresholds. In con-
trast, the associations of schizophrenia and educational 
attainment showed stronger consistency across multiple 
P-value thresholds. 
Conclusion 
In conclusion, this study shows that genetic predisposi-
tions for psychiatric disorders and educational attainment 
are associated with early behavioural problems. These as-
sociations were present throughout early childhood and 
at an earlier age than described in most previous studies. 
Children with a high genetic predisposition for psychi-
atric traits show specific early manifestations of problem 
behaviour at a young age, which may further aid the early 
recognition of precursors of psychopathology in high-
risk individuals.
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Insomnia is the second most prevalent mental disorder1, with no sufficient treatment available. Despite substan-
tial heritability, insight into the associated genes and neurobiological pathways remains limited. Here, we use a 
large genetic association sample (n = 1,331,010) to detect novel loci and gain insight into the pathways, tissue and 
cell types involved in insomnia complaints. We identify 202 loci implicating 956 genes through positional, expres-
sion quantitative trait loci, and chromatin mapping. The meta-analysis explained 2.6% of the variance. We show 
gene set enrichments for the axonal part of neurons, cortical and subcortical tissues, and specific cell types, in-
cluding striatal, hypothalamic, and claustrum neurons. We found considerable genetic correlations with psychi-
atric traits and sleep duration, and modest correlations with other sleep-related traits. Mendelian randomization 
identified the causal effects of insomnia on depression, diabetes, and cardiovascular disease, and the protective 
effects of educational attainment and intracranial volume. Our findings highlight key brain areas and cell types 
implicated in insomnia, and provide new treatment targets.
Insomnia is the second most prevalent mental disorder. One-third of the general population reports insom-nia complaints. The diagnostic criteria for insomnia 
disorder2 (that is, difficulties with initiating or maintain-
ing sleep with accompanying daytime complaints at least 
three times a week for at least three months, which cannot 
be attributed to inadequate circumstances for sleep3) are 
met by 10% of individuals, and up to one-third of older 
age individuals4. Insomnia contributes significantly to the 
risk and severity of cardiovascular, metabolic, mood, and 
neurodegenerative disorders2 .
Despite evidence of a considerable genetic component 
(heritability 38–59%5), only a small number of genetic 
loci moderating the risk of insomnia have been identi-
fied thus far. Recent genome-wide association studies 
(GWAS)6,7 for insomnia complaints (n = 113,006) demon-
strated its polygenic architecture and implicated three 
genome-wide significant (GWS) loci and seven genes. A 
prominent role was reported for  MEIS1, which is asso-
ciated with insomnia complaints6,7 and restless legs syn-
drome (RLS)8  through pleiotropy and phenotypic over-
lap; yet, the role of other genes was not unambiguously 
shown. 
We set out to substantially increase the sample size to 
allow the detection of more genetic risk variants for in-
somnia complaints, which may aid in understanding its 
neurobiological mechanisms. By combining data col-
lected in the UK Biobank (UKB) version 29 (n = 386,533) 
and 23andMe, a privately held personal genomics and 
biotechnology company10,11 (n = 944,477), we obtained 
an unprecedented sample size of 1,331,010 individuals. 
Insomnia complaints were measured using question-
naire data; an independent sample (the Netherlands Sleep 
Register)12 which gives access to similar question data, as 
well as clinical interviews assessing insomnia disorder 
(see Supplementary Note), was used to validate the spe-
cific questions so that they were good proxies of insomnia 
disorder. 
We found 202 risk loci for insomnia; extensive function-
al in silico analyses showed the involvement of specific 
tissue and cell types. Mendelian randomization identified 
causal effects of insomnia on metabolic and psychiatric 
traits.
Results
Meta-analysis yields 202 risk loci
The UKB assessed insomnia complaints (hereafter re-
ferred to as ‘insomnia’) with a touchscreen device, where-
as 23andMe research participants completed online sur-
veys (Supplementary Tables  1  and  2). The assessment 
of insomnia in both samples shows high accuracy for 
insomnia disorder in the UKB and somewhat lower accu-
racy in 23andMe (sensitivity/specificity: UKB = 98/96%; 
23andMe = 84/80%) (see  Supplementary Note). The 
prevalence of insomnia was 28.3% in the UKB version 
2 sample, 30.5% in the 23andMe sample, and 29.9% in 
the combined sample, which is in keeping with previ-
ous estimates for people of advanced age in the UK4and 
elsewhere13,14. Older people dominate the UKB (mean 
age = 56.7, s.d. = 8.0) and 23andMe (two-thirds of the 
sample older than 45, one-third older than 60 years of 
age) samples. Prevalence was higher in females (34.6%) 
than males (24.5%), yielding an odds ratio (OR) of 1.6, 
which is close to the 1.4 OR reported in a meta-analysis15.
Quality control was conducted separately per sample, 
following standardized, stringent protocols (see  Meth-
ods). The GWAS was run separately per sample 
(UKB: n = 386,533; 23andMe: n = 944,477) (Supplemen-
tary Fig.  1), and then meta-analyzed with METAL16  by 
weighing the single nucleotide polymorphism (SNP) 
effect by sample size (see  Methods). We first analyzed 
males and females separately (Supplementary Fig.  2) 
and observed a high genetic correlation between the sexes 
(rg = 0.92, s.e.m. = 0.02; Supplementary Table 3), indicat-
ing strong overlap of genetic effects. Owing to the large 
sample size, the rgof 0.92 was significantly different from 
1 (one-sided Wald test, P = 2.54 × 10−6), suggesting a small 
role for sex-specific genetic risk factors, consistent with 
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Fig. 1 | SNP-based results from the GWAS meta-analysis on insomnia in 1,331,010 individuals. a, Manhattan plot of the 
GWAS meta-analysis of insomnia in the UKB and 23andMe cohorts, showing the –log10 transformed P-value for each SNP. 
SNP two-sided P-values from a linear model were calculated using METAL, weighting SNP associations by sample size. b, PGS 
prediction in three hold-out samples (n = 3,000), showing the increase in explained variance in insomnia (Nagelkerke’s pseudo R2) 
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our previous study6 However, since sex-specific effects 
were relatively small, we focused on identifying genetic 
effects important in both sexes and continued with the 
combined sample. (Supplementary Tables  4  and  5  and 
the  Supplementary Note  provide sex-specific results.) 
The genetic correlation of insomnia between the full UKB 
and 23andMe results was rg = 0.69 (s.e.m. = 0.02).  
We observed a significant polygenic signal in the GWAS 
(lambda inflation factor = 1.808), which could not be as-
cribed to spurious association (linkage disequilibrium 
score intercept = 1.075)17 (Supplementary Fig.  3a). Me-
ta-analysis identified 11,990 GWS SNPs (P < 5 × 10−8), rep-
resented by 248 independent lead SNPs (r2 < 0.1), located 
in 202 genomic risk loci (Fig. 1a, Supplementary Data 
Set 1, and Supplementary Tables 6 and 7). All lead SNPs 
showed concordant signs of effect in both samples (Sup-
plementary Fig. 3b). We confirmed two (chr2:66,785,180 
and chr5:135,393,752) out of six previously reported loci 
for insomnia6,7 (Supplementary Table 8). 
Polygenic score (PGS) prediction in three randomly se-
lected hold-out samples (n = 3 × 3,000) estimated the 
current results to explain up to 2.6% of the variance in 
insomnia (Fig.  1b, Supplementary Fig.  4, and Supple-
mentary Table 9).
The SNP-based heritability (h2SNP) was estimated at 7.0% 
(s.e.m. = 0.002). Partitioning the heritability by func-
tional categories of SNPs (see  Methods) showed the 
strongest enrichment of  h2SNP  in conserved regions (en-
richment = 15.8,  P = 1.57 × 10−14). In addition,  h2SNP  was 
enriched in common SNPs (minor allele frequency 
(MAF) > 0.3) and depleted in rarer SNPs (MAF < 0.01; 
Fig. 1c and Supplementary Table 10).
We used FUMA18 to functionally annotate all SNPs in the 
risk loci that were in linkage disequilibrium (r2 ≥ 0.6) with 
one of the independent significant SNPs (see Methods). 
The majority of the 22,068 annotated SNPs (76.8%) were 
in open chromatin regions19as indicated by a minimum 
chromatin state of 1–7 (Fig. 1d and Supplementary Ta-
ble 11). In line with findings for other traits6,20 about half 
of these SNPs were in intergenic (35.5%) or non-coding 
RNA (13.0%) regions (Fig. 1e); of these, 0.72% were highly 
likely to have a regulatory function as indicated by a Regu-
lomeDB score < 2 (see Methods). However, of these, 51.5% 
were located inside a protein-coding gene and 0.81% were 
exonic. Of the 177 exonic SNPs, 71 were exonic non-syn-
onymous (Supplementary Table 12 and Supplementary 
Note).  WDR90  included four exonic non-synonymous 
SNPs (rs7190775, rs4984906, rs3752493, and rs3803697) 
all in high linkage disequilibrium with the same indepen-
dent significant SNP (rs3184470). There were two exonic 
non-synonymous SNPs with extremely high combined 
annotation-dependent depletion (CADD) scores21, sug-
gesting a strong deleterious effect on protein function: 
rs13107325 in  SLC39A8  (locus 56,  P = 8.31 × 10−16) with 
the derived allele T (MAF = 0.03), associated with an in-
creased risk of insomnia; and rs35713889 in LAMB2 (lo-
cus 42,  P = 1.77 × 10−7), where the derived allele T of 
rs35713889 (MAF = 0.11) was also associated with an 
increased risk of insomnia complaints. Supplementary 
Table 13 provides a detailed overview of the functional 
impact of all variants in the genomic risk loci.
Genes implicated in insomnia
To obtain an insight into the (functional) consequences 
of individual GWS SNPs, we used FUMA18 to apply three 
strategies to map associated variants to genes (see Meth-
ods). Positional gene mapping aligned SNPs to 412 genes 
by location. Expression quantitative trait loci (eQTL) 
gene mapping matched cis-eQTL SNPs to 594 genes 
whose expression levels they influence. Chromatin in-
teraction mapping annotated SNPs to 159 genes based 
on three-dimensional DNA–DNA interactions between 
genomic regions of the GWS SNPs and nearby or dis-
tant genes (Supplementary Data Set 2, Supplementary 
Table  14, and  Supplementary Note). Ninety-two genes 
were mapped by all three strategies (Supplementary Ta-
ble  15), and 336 genes were physically located outside 
the risk loci but were implicated by eQTL associations 
(306 genes), chromatin interactions (16 genes), or both 
(14 genes). Several genes were implicated by GWS SNPs 
originating from two distinct risk loci on the same chro-
mosome (Fig. 2a,b): MEIS1, located on chromosome 2 in 
(continued from previous page) in a logistic regression model and 95% confidence intervals for each P-value threshold. 
All P-value thresholds were statistically significant. c, Heritability enrichment for functional SNP categories and MAF bins. 
Enrichment was calculated by dividing the proportion of heritability for each category by the proportion of SNPs in that category. 
The error bars show the 95% confidence interval around the estimate. Significant enrichments after Bonferroni correction (28 
functional categories + 6 MAF bins + 22 chromosomes) are indicated by an asterisk (P < 0.05/56 categories = 8.93 × 10−4). TFBS, 
transcription factor binding site; DHS, DNase I hypersensitive site; DGF, digital genomic footprint; PGC, Psychiatric Genomics 
Consortium; Hnisz, as reported in Hnisz et al.; CTCF, CCCTC-binding factor. d, Distribution of CADD scores and RegulomeDB 
categories of all annotated SNPs in linkage disequilibrium (r2 ≥ 0.6) with one of the GWS SNPs (n = 22,068). e, Functional 
consequences of these annotated SNPs.
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the strongest associated locus (locus 20), was positionally 
mapped by 51 SNPs and mapped by chromatin interac-
tions in 10 tissue types, including cross-loci interactions 
from locus 21, and is a known gene involved in insomnia6; 
and LRGUK, located on chromosome 7 in locus 106, was 
positionally mapped by 22 SNPs and chromatin interac-
tions in 3 tissue types, including cross-loci interactions 
from locus 105.  LRGUK  was also implicated by eQTL 
associations of 125 SNPs in 14 general tissue types. LR-
GUK was previously implicated in type 2 diabetes22 and 
autism spectrum disorder23 (disorders with prominent 
insomnia). However, it is not yet directly implicated in 
sleep-related phenotype, and is the most likely candidate 
to explain the observed association at loci 105 and 106.
Apart from linking individually associated genetic variants 
to genes, we conducted a genome-wide gene association 
analysis (GWGAS) using MAGMA24. GWGAS provides 
aggregate association P-values based on all variants locat-
ed in a gene, and complements the three FUMA mapping 
strategies (see Methods). GWGAS identified 517 associ-
ated genes (Fig.  2c and Supplementary Table  16). The 
top gene BTBD9 (P = 8.51 × 10−23) on chromosome 6 in lo-
cus 81 was also mapped using positional and eQTL map-
ping (tissue type: left ventricle of the heart), and is part 
of a pathway that regulates circadian rhythms. BTBD9 has 
been associated with RLS, periodic limb movement dis-
order25,26 , and Tourette syndrome27. Involvement in sleep 
regulation was shown in  Drosophila28; mouse mutants 
show fragmented sleep29 and increased levels of dynamin 
130, a protein that mediates the increased sleep onset la-
tency that follows presleep arousal31.
Of the 517 MAGMA-based associated genes, 222 
were outside of the GWAS risk loci, and 309 were also 
mapped by FUMA. In total, 956 unique genes were 
mapped by at least one of the three FUMA gene map-
ping strategies or by MAGMA (Supplementary Fig. 5). 
Of these, MEIS1, MED27, IPO7, and ACBD4 confirmed 
previous results6,7 (Supplementary Table  17). Sixty-two 
genes were implicated by all four mapping strategies, 
indicating that, apart from a GWS gene-based  P-value, 
there were: (1) GWS SNPs located in proximity of or in-
side these genes; (2) GWS SNPs associated with differ-
ential expression of these genes; and (3) GWS SNPs in-
volved in genomic regions interacting with these genes. 
We note that genes that were indicated by positional 
mapping and GWS gene-based  P-values, but not via 
eQTL or chromatin interaction mapping (n = 54 genes), 
may be of equal importance; yet, they are more likely to 
exert their influence on insomnia via structural changes 
in gene products (that is, at the protein level) and not via 
quantitative changes in the availability of gene products. 
Implicated pathways, tissues, and cell types
To test whether GWS genes converged in functional gene 
sets and pathways, we conducted gene-set analyses us-
ing MAGMA (see Methods). We tested the associations 
of 7,473 gene sets: 7,246 sets derived from the MSigDB-
32gene expression values from 54 tissues from the GTEx 
database33; and cell-specific gene expression in 173 types 
of brain cells (Fig.  2d  and Supplementary Table  18). 
Competitive testing was used and a Bonferroni-correct-
ed threshold of  P < 6.7 × 10−6 (0.05/7,473) to correct for 
multiple testing. Of the MSigDB gene sets, three Gene 
Ontology gene sets survived multiple testing: Gene On-
tology:locomotory behavior (P = 8.95 × 10−7); Gene On-
tology:behavior (P = 5.23 × 10−6); and Gene Ontology:ax-
on part (P = 4.25 × 10−6). This set includes 16 GWS genes: 
KIF3B, SNCA, GRIA1, CDH8, ROBO2,  DNM1,  RAN-
GAP1, GABBR1,  P2RX3,  NRG1,  POLG,  DAG, NFASC, 
and CALB2).
Tissue specific gene-set analyses showed strong enrich-
ment of genetic signal in genes expressed in the brain. 
Correcting for overall expression, four specific brain 
tissues reached the threshold for significance: the over-
all cerebral cortex (P = 3.68 × 10−6); Brodmann area 9 of 
the frontal cortex (P = 5.04 × 10−7); BA24 of the anteri-
Fig. 2 (previous page) | Gene-based and gene set analyses of insomnia in 1,331,010 individuals. a,b, Zoomed-in circos plots 
showing the genes implicated by two genomic risk loci on chromosome 2 (a) and chromosome 7 (b), with the genomic risk 
loci indicated as blue areas, eQTL associations in green, and chromatin interactions in orange. Genes mapped by both eQTL 
and chromatin interactions are red. The outer layer shows a Manhattan plot containing the –log10 transformed P-value of each 
SNP in the GWAS meta-analysis of insomnia in the UKB and 23andMe cohorts. Full circos plots of all autosomal chromosomes 
are provided in Supplementary Data Set 2. c, Genome-wide gene-based analysis (GWAS) of 18,185 genes that were tested for 
association with insomnia in MAGMA. The y axis shows the –log10 transformed two-sided P-value of the gene-based test, and 
the x axis shows the starting position on the chromosome. Gene-based two-sided P-values were calculated with MAGMA. The 
red line indicates the Bonferroni-corrected threshold for genome-wide significance (P = 0.05/18,185 genes = 2.75 × 10−6). The top 
15 most significant genes are highlighted. d, Gene set analysis of the top 10 for each of the MSigDB pathways, tissue expression of 
GTEx tissue types, and cell types from single-cell RNA sequencing. Gene set analyses were performed with MAGMA. The red line 
shows the Bonferroni significance threshold (P < 0.05/7,473 gene sets = 6.7 × 10−6), correcting for the total number of tested gene 
sets. The red bars indicate the significant gene sets.
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or cingulate cortex (P = 3.25 × 10−6); and the cerebellar 
hemisphere (P = 5.93 × 10−6). Several other brain tissues 
also showed strong enrichment just below the threshold, 
including three striatal basal ganglia structures (nucleus 
accumbens, caudate nucleus, putamen). To test whether 
genes expressed in all three basal ganglia structures to-
gether would show significant enrichment of low P-val-
ues, we used the first principal component (BGPC) of these 
basal ganglia structures (Methods) and found significant 
enrichment (P = 8.33 × 10−8).
When conditioning the three top cortical structures on 
the BGPC, they were no longer significantly associated af-
ter multiple testing correction (minimum P = 0.03), which 
was expected given that the BGPC correlated strongly with 
gene expression in cortical (and other) areas (r2 > 0.96). 
Similar results were obtained vice versa; that is, using the 
first principal component of all cortical areas and condi-
tioning the three basal ganglia structures on this resulted 
in no evidence of enrichment of low  P-values for basal 
ganglia structures (minimum  P = 0.53). These results 
show that (1) genes expressed in the brain are import-
ant in insomnia, (2) genes expressed in cortical areas are 
more strongly associated than genes expressed in basal 
ganglia, and (3) there is a strong correlation between gene 
expression patterns across brain tissues, which suggests 
involvement of general cellular signatures rather than 
specific brain tissue structures.
Brain cell type-specific gene-set analyses were first car-
ried out on 24 broad, cell-type categories. Cell type-spe-
cific gene expression was quantified using single-cell RNA 
sequencing of disassociated cells from the somatosenso-
ry cortex, hippocampus, hypothalamus, striatum, and 
midbrain from the mouse (see Methods), which closely 
resembles gene expression in humans39. Results indicat-
Fig. 3 | Genome-wide analyses of six sleep-related traits. a–f, Manhattan plots of the genome-wide analyses of (a) morningness 
(UKB and 23andMe cohorts, n = 434,835), (b) sleep duration (UKB, n = 384,317), (c) ease of getting up (UKB, n = 385,949), (d) 
napping (UKB, n = 386,577), (e) daytime dozing (UKB, n = 386,548), and (f) snoring (UKB, n = 359,916). The y axis shows the 
–log10 transformed SNP two-sided P-value from a linear or logistic regression model, and the x axis the base-pair position of the 
SNPs on each chromosome. The red line indicates the Bonferroni-corrected significance threshold (P < 5 × 10−8).
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ed that genes expressed specifically in the medium spiny 
neurons (MSNs, P = 4.83 × 10−7) were associated with in-
somnia; no other broad, cell type-specific gene set sur-
vived our strict threshold of P < 6.7 × 10−6. MSNs represent 
95% of neurons within the human striatum, which is one 
of the four major nuclei of the subcortical basal ganglia. 
Specifically, the striatum consists of the ventral (nucleus 
accumbens and olfactory tubercle) and dorsal (caudate 
nucleus and putamen) subdivisions. The association with 
MSNs thus likely explains the observed association of the 
basal ganglia striatal structures (nucleus accumbens, cau-
date nucleus, putamen).
Using broad cell classes risks not detecting associations 
that are specific to distinctive yet rare cell types. To ac-
count for this, we then tested 149 specific brain cell-type 
categories and found significant associations with 7 spe-
cific cell types: mediolateral neuroblasts type 3, 4, and 
5 (P = 2.36 × 10−6,  P = 1.88 × 10−6, and  P = 1.87 × 10−6, re-
spectively); D2-type MSNs (P = 2.12 × 10−6); claustrum 
pyramidal neurons (P = 3.09 × 10−6); hypothalamic Vglut2 
Morn4 Prrc2a neurons (P = 4.36 × 10−6); and hypothalam-
ic Vglut2 Hcn16430411 K18 Rik neurons (P = 4.98 × 10−6). 
The hypothalamus contains multiple nuclei that are key 
to the control of sleep and arousal, including the supra-
chiasmatic nucleus, which accommodates the biological 
clock of the brain40. These results suggest a role of distinct 
mature and developing cell types in the midbrain and hy-
pothalamus.
Fig. 4 | Genetic overlap of insomnia with other sleep-related traits and psychiatric and metabolic traits. Heatmap of genetic 
correlations between the insomnia GWAS meta-analysis, sleep-related phenotypes, and neuropsychiatric and metabolic traits 
studies. Genetic correlations and two-sided P-values were calculated using linkage disequilibrium score regression. Red indicates 
a positive rg, whereas green indicates a negative rg. Correlations that were significant after Bonferroni correction (P < 0.05/34 
traits = 1.47  ×  10−3) are indicated with an asterisk (see also Supplementary Tables 21 and 29).
Modest genetic overlap with sleep traits
Other sleep-related traits may easily be confounded with 
specific symptoms of insomnia, like early morning awak-
ening, and difficulties maintaining sleep. The most recent 
genome-wide studies for other sleep-related traits in-
cluded 59,128–128,266 individuals and assessed genetic 
effects on morningness41–43 (that is, being a morning per-
son), sleep duration7,43, and daytime sleepiness/dozing7. 
Using increased sample sizes for each of these sleep-relat-
ed traits (maximum n = 434,835), we investigated to what 
extent insomnia and other sleep-related traits are geneti-
cally distinct or overlapping. We performed GWAS analy-
ses for the following six sleep-related traits: morningness; 
sleep duration; ease of getting up in the morning; taking 
naps during the day; daytime dozing; and snoring (Sup-
plementary Note  and Supplementary Figs.  6  and  7). 
Of the 202 risk loci for insomnia, 39 were also GWS in 
at least one of the other sleep-related traits (Fig.  3  and 
Supplementary Table 20). The strongest overlap in loci 
was found with sleep duration; 14 out of 49 sleep dura-
tion loci overlapped with insomnia. Insomnia showed the 
highest genetic correlation with sleep duration (−0.47, 
s.e.m. = 0.02; Supplementary Table 21) compared to oth-
er sleep-related traits; this was not surprising given that 
insomnia also shared the largest number of risk loci with 
sleep duration (see further discussion of results for sleep 
phenotypes in the Supplementary Note)
Gene mapping of SNP associations of sleep-related traits 
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resulted in 973 unique genes (Supplementary Fig. 8 and 
Supplementary Tables  22–26). Gene-based analysis 
showed that, of the 517 GWS genes for insomnia, 120 
were GWS in at least one of the other sleep-related traits, 
and one gene (RBFOX1) was GWS in all traits except nap-
ping and daytime dozing (Supplementary Table 27). The 
largest proportion of overlap in GWS genes for insomnia 
was again with sleep duration, with 37 of the 134 (27%) 
GWS genes for sleep duration being GWS for insomnia 
also. 
There was overlap in tissue enrichment in cortical struc-
tures and basal ganglia between insomnia and both morn-
ingness and sleep duration. At the single-cell level, MSNs 
were also implicated for morningness and sleep duration, 
but not for the other sleep-related traits (Supplementary 
Table 28). Taken together, these results suggest that, at a 
genetic level, insomnia shows considerable genetic over-
lap with sleep duration, and modest overlap with other 
sleep-related traits.
Strong overlap between insomnia and psychiatric traits
We confirm previously reported genetic correlations 
between insomnia and neuropsychiatric and metabol-
ic traits, including type 2 diabetes, waist–hip ratio, and 
body mass index6,41 (Supplementary Table 29), and also 
identify several GWS SNPs for insomnia that have previ-
ously been associated with these traits (Supplementary 
Table  30). The strongest correlations were with depres-
sive symptoms (rg = 0.64, s.e.m. = 0.04,  P = 1.21 × 10−71), 
followed by anxiety disorder (rg = 0.56, s.e.m. = 0.11,  P = 
1.40 × 10−7), subjective well-being (rg = −0.51, s.e.m. = 0.0
3, P = 4.93 × 10−52), major depression (rg = 0.50, s.e.m. = 0.
07, P = 8.08 × 10−12), and neuroticism (rg = 0.48, s.e.m. = 0
.02, P = 8.72 × 10−80). Genetic correlations with metabolic 
traits ranged between 0.09 and 0.20. 
Notably, we observed a positive correlation with RLS 
(rg = 0.44, s.e.m. = 0.07, P = 4.36 × 10−10), a trait that shares 
phenotypic characteristics with insomnia6. This suggests a 
partial genetic overlap, which we discuss in more detail in 
the Supplementary Note and Supplementary Tables 31 
and  32. In this study, we show that although insomnia 
lead SNPs are enriched in RLS, there is only a partial ge-
nome-wide overlap between insomnia and RLS, in line 
with previous analyses6. The genetic correlations between 
insomnia and anxiety and depression-related traits (anxi-
ety, neuroticism, major depression, and depressive symp-
toms) were also stronger than the correlations between 
insomnia and the other sleep-related traits (Mann–Whit-
ney U-test Z score = −2.56, P = 0.01). Since a similar high 
reliability has been reported for both sleep and psychi-
atric phenotypes, the findings suggest that genetically 
insomnia more closely resembles neuropsychiatric traits 
than other sleep-related traits (Fig. 4). These genetic cor-
relations were consistent within the two meta-analyzed 
samples separately (Pearson’s  r2 = 0.98; Supplementary 
Fig. 9). 
To infer directional associations between insomnia and 
these correlated traits, we performed bidirectional multi-
SNP Mendelian randomization analysis44 (see Methods). 
The results support a direct risk effect of insomnia on 
metabolic syndrome phenotypes including body mass 
index (bxy = 0.36, s.e.m. = 0.05, P = 1.25 × 10−12), type 2 di-
abetes (bxy = 0.62, s.e.m. = 0.11,  P = 2.29 × 10−8), and cor-
onary artery disease (bxy = 0.61, s.e.m. = 0.09,  P = 2.88 × 1
0−12). We also found risk effects of insomnia on several 
psychiatric traits, including major depression (bxy = 1.57, 
s.e.m. = 0.07,  P = 1.73 × 10−111), schizophrenia (bxy = 0.68, 
s.e.m. = 0.10,  P = 5.12 × 10−11), attention-deficit hyperac-
tivity disorder (bxy = 0.77, s.e.m. = 0.06,  P = 2.50 × 10−45), 
neuroticism (bxy = 0.45, s.e.m. = 0.02, P = 3.56 × 10−92), and 
anxiety disorder (bxy = 0.47, s.e.m. = 0.10, P = 4.11 × 10−6), 
with evidence of a reverse risk effect of major depression 
(bxy = 0.06, s.e.m. = 0.003, P = 6.93 × 10−99) and neuroticism 
(bxy = 0.24, s.e.m. = 0.01, P = 7.90 × 10−157) on insomnia. In 
addition, insomnia was bidirectionally associated with 
educational attainment (bxy =−0.32, s.e.m. = 0.02, P = 4.12 
× 10−45) and vice versa (bxy =−0.10, s.e.m. = 0.01,  P = 2.27 
× 10−23); the same bidirectional pattern was observed for 
intelligence. Unidirectional protective effects were only 
observed for height (bxy =−0.03, s.e.m. = 0.02, P = 1.68 × 1
0−77) and intracranial volume (bxy =−0.03, s.e.m. = 0.01, P 
= 3.72 × 10−16). 
Using GWAS results from RLS in the 23andMe cohort, 
we observed patterns of bidirectional effects of insom-
nia on RLS (bxy = 0.35, s.e.m. = 0.05,  P = 2.53 × 10−12) and 
vice versa (bxy = 0.12, s.e.m. = 0.01, P = 1.21 × 10−35). Over-
all, only a small proportion of SNPs showed pleiotropy 
between insomnia and other traits (Supplementary Ta-
ble 33 and Supplementary Note).
Discussion
In the largest GWAS study to date of 1,331,010 partici-
pants, we identified 202 genomic risk loci for insomnia. 
Using extensive functional annotation of associated ge-
netic variants, we demonstrated that the genetic compo-
nent of insomnia points toward a role of genes enriched 
in locomotory behavior, and enriched in specific cell 
types from the claustrum, hypothalamus, and striatum, 
specifically in MSNs (Fig. 5). 
MSNs are γ-aminobutyric acid (GABA)ergic inhibi-
tory cells and represent 95% of neurons in the human 
striatum, one of the four major nuclei of the basal gan-
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glia (for reviews, see Vetrivelan et al.45, Lazarus et al.46, 
and Swardfager et al.47). MSNs were the first neurons 
in which the up and down states characteristic of slow-
wave sleep were described48. Cell body-specific striatal 
lesions of the rostral striatum induce profound sleep 
fragmentation, which is highly characteristic of insom-
nia45,49. As discussed more extensively in the  Supple-
mentary Note, fragmented REM sleep is highly charac-
teristic of insomnia and related to the ongoing thought-
like mental content that makes patients with insomnia 
underestimate sleep duration50–52. Consistently short 
objective sleep across nights occurs only in a minority 
of patients with insomnia53.
A role for the basal ganglia in sleep regulation is also 
suggested by the high prevalence of insomnia in neuro-
degenerative disorders, such as Parkinson’s disease and 
Huntington’s disease, where the basal ganglia are affect-
ed. Vetrivelan et al.45 proposed a cortex-striatum-globus 
pallidusexternal-cortex network involved in the control 
of sleep–wake behavior and cortical activation, where 
midbrain dopamine disinhibits the globus pallidusex-
ternal  and promotes sleep through the activation of D2 
receptors in this network. Furthermore, brain imaging 
studies have suggested that the caudate nucleus of the 
striatum is a key node in the neuronal network imbal-
ance of insomnia54; they also reported abnormal func-
tion in the cortical areas we found to be most enriched 
(BA955, BA2456). Our results support the involvement 
of the striato-cortical network in insomnia, by showing 
enrichment of risk genes for insomnia in cortical areas 
as well as the striatum, and specifically in MSNs. We re-
cently showed that, along with several other cell types, 
MSNs mediate the risk for mood disorders57and schizo-
phrenia39. MSNs are strongly implicated in reward pro-
cessing; future work should address whether the genetic 
overlap between insomnia and mood disorders is medi-
Fig. 5 | Overview of brain tissues and cell types associated with insomnia based on the GWAS results in 1,331,010 individuals.
For each associated gene set, the top five genes driving the association are reported for each brain area and cell type. The results 
for the GTEx brain tissue type gene expression are shown on the left side, whereas the results from the level 2 single-cell gene 
expression are shown on the right.
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ated by gene function in MSNs.
Our results also showed enrichment of insomnia genes 
in the pyramidal neurons of the claustrum. This sub-
cortical brain region is structurally closely associated 
with the amygdala and has been implicated in salience 
coding of incoming stimuli and binding of multisensory 
information into conscious percepts58. These functions 
are highly relevant to insomnia because the disorder 
is characterized by increased processing of incoming 
stimuli59. Claustrum activity during REM sleep is more-
over key to activation of the anterior cingulate cortex 
that was also enriched for insomnia gene expression60. 
We found enrichment of insomnia genes in mediolateral 
neuroblasts from the embryonic midbrain and in two hy-
pothalamic cell types. The role of the mediolateral neuro-
blasts is less clear; although they were obtained from the 
embryonic midbrain, at present it is unknown what type 
of mature neurons they differentiate into. We note that 
the midbrain is similar on a bulk transcriptomic level to 
the pons61, and lacking cells from that region we cannot 
conclusively say that midbrain cell types are enriched. 
The current findings provide an insight into the causal 
mechanism of insomnia, showing enrichment in spe-
cific cell types, brain areas, and biological functions. 
These findings are starting points for the development 
of new therapeutic targets for insomnia and may also 
provide valuable insights into other genetically related 
disorders.
Online Methods
Meta-analysis
A meta-analysis of the GWAS results of insomnia and 
morningness in the UKB and 23andMe cohorts was 
performed using fixed-effects meta-analysis METAL16, 
using SNP P-values weighted by sample size. To investi-
gate sex-specific genetic effects, we ran the meta-analysis 
between the UKB and 23andMe datasets for males and 
females separately
Genomic risk loci definition
We used FUMA18  version 1.2.4, an online platform for 
functional mapping and annotation of genetic variants, to 
define genomic risk loci and obtain functional informa-
tion of the relevant SNPs in these loci. FUMA provides 
comprehensive annotation information by combining 
several external data sources. We first identified indepen-
dent significant SNPs that had a GWS P-value (< 5 × 10−8) 
and were independent from each other at r2 < 0.6. These 
SNPs were further represented by lead SNPs, a subset of 
the independent significant SNPs that were in approxi-
mate linkage equilibrium with each other at r2 < 0.1. We 
then defined independent genomic risk loci by identify-
ing physical regions in linkage disequilibrium with these 
lead SNPs that were > 250 kilobases (kb) apart from each 
other. The borders of the genomic risk loci were defined 
by identifying all SNPs in linkage disequilibrium (r2 ≥ 0.6) 
with one of the independent significant SNPs in the lo-
cus; the region containing all these candidate SNPs was 
considered to be a single independent genomic risk locus. 
Linkage disequilibrium information was calculated us-
ing the UKB genotype data as a reference. Risk loci were 
defined based on evidence from independent significant 
SNPs available in both 23andMe and UKB datasets.
SNPs that were GWS but only available in the 23andMe 
dataset were not included when defining genomic risk 
loci and were not included in any follow-up annotations 
or analyses because there was no external replication in 
the UKB sample. If such SNPs were located in a risk lo-
cus, they are displayed in LocusZoom plots (gray, as there 
is no linkage disequilibrium information in the UKB). 
When risk loci contained GWS SNPs based solely on the 
23andMe dataset, we did not count that risk locus because 
there were no other SNPs available in both samples that 
supported these GWS SNPs.
Gene-based analysis
SNP-based  P-values from the meta-analysis were used 
as input for the GWGAS; 18,182–18,185 protein-coding 
genes (each containing at least one SNP in the GWAS, the 
total number of tested genes can thus be slightly different 
across phenotypes) from the NCBI 37.3 gene definitions 
were used as the basis for the GWGAS in MAGMA24. 
Bonferroni correction was applied to correct for multiple 
testing (P < 2.75 × 10−6).
Gene-set analysis
Results from the GWGAS analyses were used to test for 
association in three types of 7,473 predefined gene sets:
1. 7,246 curated gene sets representing known biologi-
cal and metabolic pathways derived from 9 data re-
sources, cataloged by and obtained from the MSigDB 
version 6.0 (ref.62).
2. Gene expression values from 53 tissues obtained 
from GTEx63 log2-transformed with pseudocount 1 
after winsorization at 50 and averaged per tissue (+1 
combined gene expression in the basal ganglia by 
taking the first principal component from principal 
component analysis of gene expression in three basal 
ganglia structures). We caution that only a limited set 
of brain tissues were included; thus, we cannot rule 
out associations with many important areas such as 
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the pons, midbrain, or thalamus based on this anal-
ysis.
3. Cell type-specific expression in 173 types of brain 
cells (24 broad categories of cell types ‘level 1’, and 
149 specific categories of cell types ‘level 2’), which 
were calculated following the method described by 
Skene et al.39. Briefly, brain cell-type expression data 
was drawn from single-cell RNA sequencing data 
from mouse brains. For each gene, the value for each 
cell type was calculated by dividing the mean unique 
molecular identifier counts for the given cell type 
by the summed mean unique molecular identifier 
counts across all cell types. Single-cell gene sets were 
derived by grouping genes into 40 equal bins based 
on specificity of expression. Mouse cell gene expres-
sion was shown to closely approximate gene expres-
sion in postmortem human tissue39
These gene sets were tested using MAGMA. MAG-
MA uses a continuous measure of association (gene-
based  P-value) of all genes that could be mapped by at 
least one SNP in the gene-based test and can perform 
gene-set analysis based on dichotomous gene sets (genes 
present in a gene set or not) or continuous values of gene 
expression in tissues and cells. We computed competi-
tive P-values, which represent the test of association for a 
specific gene set compared with genes not in the gene set 
to correct for the baseline level of genetic association in 
the data64. The Bonferroni-corrected significance thresh-
old was P = 0.05/7,473 gene sets = 6.7 × 10−6. Conditional 
analyses were performed as a follow-up using MAGMA 
to test whether each significant association observed was 
independent of all others. The association between each 
gene set in each of the three categories was tested condi-
tional on the most strongly associated set, and then, if any 
substantial (P < 0.05/number of gene sets) associations 
remained, by conditioning on the first and second most 
strongly associated set, and so on until no associations 
remained. Gene sets that retained their association after 
correcting for other sets were considered to represent in-
dependent signals. We note that this is not a test of as-
sociation per se, but rather a strategy to identify, among 
gene sets with known significant associations and overlap 
in genes, which set(s) are responsible for driving the ob-
served association.
SNP-based heritability and genetic correlation
Linkage disequilibrium score regression17  was used to 
estimate genomic inflation and SNP-based heritability of 
the phenotypes, and to estimate the cross-cohort genetic 
correlations. Precalculated linkage disequilibrium scores 
from the 1000 Genomes European reference population 
were obtained from https://data.broadinstitute.org/alkes-
group/LDSCORE/. 
Genetic correlation
Genetic correlations between sleep-related traits, and 
between sleep-related traits and previously published 
GWAS studies of sufficient sample size were calculated 
using linkage disequilibrium score regression on Hap-
Map 3 SNPs only. Genetic correlations were corrected 
for multiple testing based on the total number of correla-
tions (between 6 sleep-related phenotypes and 28 previ-
ous GWAS studies) by applying a Bonferroni-corrected 
threshold of P < 0.05/34 = 1.47 × 10−3.
Stratified heritability
To test whether specific categories of SNP annotations 
were enriched for heritability, we partitioned SNP her-
itability for binary annotations using stratified linkage 
disequilibrium score regression65. Heritability enrich-
ment was calculated as the proportion of heritability ex-
plained by an SNP category divided by the proportion 
of SNPs that are in that category. Partitioned heritabili-
ty was computed by 28 functional annotation catego-
ries, by MAF in six percentile bins, and by 22 chromo-
somes. Annotations for binary categories of functional 
genomic characteristics (for example, coding or regu-
latory regions) were obtained from the LD Score web-
site. The Bonferroni-corrected significance threshold 
for 56 annotations was set at  P < 0.05/56 = 8.93 × 10−4. 
 
Functional annotation
Functional annotation of SNPs implicated in the me-
ta-analysis was performed using FUMA18. We selected 
all candidate SNPs in genomic risk loci having an r2 ≥ 0.6 
with one of the independent significant SNPs (see above), 
a P-value (P < 1 × 10−5), a MAF > 0.0001 for annotations, 
and availability in both UKB and 23andMe datasets. The 
functional consequences for these SNPs were obtained 
by matching each SNP’s chromosome location, base-pair 
position, reference, and alternate alleles to databases con-
taining known functional annotations, including ANNO-
VAR66  categories, CADD scores, RegulomeDB21scores, 
and chromatin state67. ANNOVAR categories identify the 
SNP’s genic position (for example, intron, exon, intergen-
ic) and associated function. CADD scores predict how 
deleterious the effect of an SNP is likely to be for a protein 
structure/function, with higher scores representing high-
er deleteriousness. A CADD score > 12.37 is potentially 
pathogenic. The RegulomeDB score is a categorical score 
based on information from eQTLs and chromatin marks, 
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which ranges from 1a to 7 with lower scores indicating 
an increased likelihood of having a regulatory function. 
Scores are as follows: 1a = eQTL + transcription factor 
binding + matched transcription factor motif + matched 
DNase footprint + DNase peak; 1b = eQTL + transcription 
factor binding + any motif + DNase footprint + DNase 
peak; 1c = eQTL + transcription factor binding + matched 
transcription factor motif + DNase peak; 1d = eQTL + tran-
scription factor binding + any motif + DNase peak; 
1e = eQTL + transcription factor binding + matched 
transcription factor motif; 1f = eQTL + transcription 
factor binding/DNase peak; 2a = transcription factor 
binding + matched transcription factor motif + matched 
DNase footprint + DNase peak; 2b = transcription fac-
tor binding + any motif + DNase footprint + DNase peak; 
2c = transcription factor binding + matched transcription 
factor motif + DNase peak; 3a = transcription factor bind-
ing + any motif + DNase peak; 3b = transcription factor 
binding + matched transcription factor motif; 4 = tran-
scription factor binding + DNase peak; 5 = transcription 
factor binding or DNase peak; 6 = other; 7 = not available. 
The chromatin state represents the accessibility of genom-
ic regions (every 200 base pairs (bp)) with 15 categorical 
states predicted by a hidden Markov model based on 5 
chromatin marks for 127 epigenomes in the Roadmap 
Epigenomics Project68. A lower state indicates higher ac-
cessibility, with states 1–7 referring to open chromatin 
states. We annotated the minimum chromatin state across 
tissues to SNPs. The 15 core chromatin states as suggest-
ed by the Roadmap Epigenomics Project are as follows: 
1 = active transcription start site (TSS); 2 = flanking active 
TSS; 3 = transcription at gene 5’ and 3’; 4 = strong tran-
scription; 5 = weak transcription; 6 = genic enhancers; 
7 = enhancers; 8 = zinc finger genes and repeats; 9 = het-
erochromatic; 10 = bivalent/poised TSS; 11 = flanking 
bivalent/poised TSS/enhancer; 12 = bivalent enhancer; 
13 = repressed polycomb; 14 = weak repressed polycomb; 
15 = quiescent/low.
Gene-mapping 
GWS loci obtained by GWAS were mapped to genes in 
FUMA18 using three strategies:
1. Positional mapping maps SNPs to genes based on 
physical distance (within a 10-kb window) from 
known protein-coding genes in the human reference 
assembly (GRCh37/hg19).
2. eQTL mapping maps SNPs to genes with which they 
show a significant eQTL association (that is, allelic 
variation at the SNP is associated with the expression 
level of that gene). eQTL mapping uses information 
from 45 tissue types in 3 data repositories (GTEx33, 
Blood eQTL browser68, BIOS QTL browser69), and is 
based on cis-eQTLs that can map SNPs to genes up 
to 1 megabase apart. We used a false discovery rate of 
0.05 to define significant eQTL associations.
3. Chromatin interaction mapping was performed to 
map SNPs to genes when there is a three-dimension-
al DNA–DNA interaction between the SNP region 
and another gene region. Chromatin interaction 
mapping can involve long-range interactions since it 
does not have a distance boundary. FUMA currently 
contains Hi-C data of 14 tissue types from the study 
of Schmitt et al.70. Since chromatin interactions are 
often defined in a certain resolution, such as 40 kb, 
an interacting region can span multiple genes. If an 
SNP is located in a region that interacts with a re-
gion containing multiple genes, it will be mapped to 
each of those genes. To further prioritize candidate 
genes, we selected only interaction-mapped genes 
where one region involved in the interaction over-
laps with a predicted enhancer region in any of the 
111 tissue/cell types from the Roadmap Epigenom-
ics Project68, and the other region is located in a 
gene promoter region (250 bp upstream and 500 bp 
downstream of the TSS and also predicted by the 
Roadmap Epigenomics Project to be a promoter 
region). This method reduces the number of genes 
mapped but increases the likelihood that those iden-
tified will indeed have a plausible biological func-
tion. We used a  false discovery rate of < 1 × 10−5  to 
define significant interactions, based on previous 
recommendations70  and modified to account for 
the differences in the cell lines used in this study. 
GWAS catalogue look-up
We used FUMA to identify SNPs with previously report-
ed (P < 5 × 10−5) phenotypic associations in published 
GWAS listed in the NHGRI-EBI catalog71 which matched 
with SNPs in linkage disequilibrium with one of the inde-
pendent significant SNPs identified in the meta-analysis. 
Polygenic risk scoring
To calculate the explained variance in insomnia by our 
GWAS results, we calculated PGS based on the SNP ef-
fect sizes in the meta-analysis. The PGS were calculated 
using two methods: LDpred72  and PRSice73 a script for 
calculating P-value thresholded PGS in PLINK. PGS were 
calculated using a leave-one-out method, where summa-
ry statistics were recalculated each time with one sample 
of n = 3,000 from the UKB dataset excluded from the anal-
ysis. This sample was then used as a target sample for es-
timating the explained variance in insomnia by the PGS. 
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Mendelian randomization
To investigate causal associations between insomnia and 
genetically correlated traits, we analyzed the direction 
of effects using generalized summary-data-based Men-
delian randomization44. This method uses effect sizes 
from GWAS summary statistics (standardized betas or 
log-transformed ORs) to infer causality of effects between 
two traits based on GWS SNPs. Built-in HEIDI outlier 
detection was applied to remove SNPs with pleiotropic 
effects on both traits, since these may bias the results. 
We tested for causal associations between insomnia and 
traits that were significantly genetically correlated with 
insomnia (bzx). In addition, we tested for bidirectional 
associations by using other traits as the determinant and 
insomnia as the outcome (bzy). We selected independent 
(r2 < 0.1) lead SNPs with a GWS P < 5 × 10−8 as instrumen-
tal variables in the analyses. For traits with < 10 lead SNPs 
(that is, the minimum number of SNPs on which general-
ized summary-data-based Mendelian randomization can 
perform a reliable analysis) we selected independent SNPs 
(r2 < 0.1), with a P < 1 × 10−5. If the outcome trait is binary, 
the estimated bzx  and bzy  are approximately equal to the 
natural log of the OR. An OR of 2 can be interpreted as 
a doubled risk compared to the population prevalence of 
a binary trait for every s.d. increase in the exposure trait. 
For quantitative traits, bzx and bzy can be interpreted as a 1 
s.d. increase explained in the outcome trait for every s.d. 
increase in the exposure trait.
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Supplementary Fig. 1 | Manhattan and Q-Q plots of the genome-wide analysis of insomnia in 1,331,010 individuals. 
Results are shown for the genome-wide analysis in (a) UK Biobank (n = 386,533 individuals) and (b) 23andMe (n = 944,477 
individuals). The Manhattan plot shows the –log10-transformed P-value on the y-axis and the chromosomal position on the x-axis. 
Inflation in observed median P-value in the Q-Q plots were 1.307 (UKB) and 1.699 (23andMe). The LD Score intercepts were 
1.014 (UKB) and 1.075, indicating that the inflation in both analyses was largely explained by a highly polygenic trait.
Supplementary information
a
b
Supplementary Fig. 2 | Sex-specific Manhattan plot and Q-Q plot of the insomnia meta-analysis in males and females (UK 
Biobank + 23andMe). (a) Miami plot showing sex-specific –log10 transformed SNP P-values for females on the upper side (n = 
709,986 females) and males (n = 621,024 males) on the lower side. Two-sided SNP P-values were calculated using METAL. (b) 
Q-Q plot in females, and (c) in males. 
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Supplementary Fig. 3 | Q-Q plot and lead SNPs of the GWAS meta-analysis for insomnia in 1,331,010 individuals. (a) QQ-
plot of the insomnia meta-analysis showing the expected –log10 transformed P-value distribution on the x-axis, and the observed 
negative log10-transformed P-value on the y-axis, (b) effect size plot of the 248 lead SNP of the insomnia meta-analysis. The 
dots represent the SNP log-transformed odds ratio in UK Biobank on the x-axis, and in 23andMe on the y-axis. The error bars 
represent the 95% confidence intervals of the log-transformed odds ratios in both samples. 
a b
Supplementary Fig. 5 | Risk of insomnia per polygenic risk score decile in three independent holdout samples (n=3×3,000 
individuals). Odds ratios for deciles in polygenic risk score were calculated based on a logistic regression model, using the lowest 
polygenic risk score decile as the reference. The estimate represents the odds ratio of insomnia in each decile compared to the 
lowest polygenic risk score decile. The error bars represent the 95% confidence interval (CI) around the odds ratio. Polygenic risk 
scores were calculated based on GWAS after exclusion of the holdout sample (n = 1,228,010 individuals). 
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Supplementary Fig. 7 | Venn diagram showing the number of genes that were mapped by four gene-mapping strategies. Each 
square shows the number of overlapping genes (n represents the total number of genes mapped by that strategy) between three 
gene-mapping methods in FUMA (positional mapping, eQTL mapping and chromatin interaction mapping) and significant genes 
in gene-based tests in MAGMA. The number of genes in bold highlights the number of genes that were implicated by all four 
methods. 
Supplementary Fig. 8 | Manhattan plot and Q-Q plot of the genome-wide analysis of morningness in UK Biobank and 
23andMe. Results are shown for (a) UK Biobank (n = 345,552 individuals) and (b) 23andMe (n =89,283 individuals). 
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Supplementary Fig. 9 | Q-Q plots of the genome-wide analysis of six sleep related traits. (a) morningness (including UKB 
and 23andMe, n = 434,835 individuals), (b) sleep duration (n = 384,317 individuals), (c) ease of getting up (n = 385,949 
individuals) (d) daytime napping (n = 386,577 individuals), (e) daytime dozing (n = 385,333 individuals), (f) snoring (n = 359,916 
individuals). Manhattan plots of the genome-wide analyses are shown in Fig. 3.
a b
c d
e f
Supplementary Fig. 10 | Genome-wide gene-based association analysis of six sleep-related phenotypes. Manhattan plots of 
the genome-wide gene-based analysis (GWGAS) results for (a) morningness (n = 434,835 individuals), (b) sleep duration (n = 
384,317 individuals), (c) ease of getting up (n = 385,949 individuals), (d) daytime napping (n = 386,577 individuals), (e) daytime 
dozing (n = 385,333 individuals), (f) snoring (n = 359,916 individuals). Two-sided gene-based P-values were calculated using 
MAGMA. The analysis of morningness was based on GWAS meta-analysis of UKB and 23andMe, while other sleep-related 
phenotypes were analysed in UKB. The red line indicates Bonferroni corrected significance threshold depending on the number 
of genes tested.
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Supplementary Fig. 11 | Genetic correlations between previous GWAS studies and insomnia in UK Biobank and 23andMe 
separately. Heatmap showing genetic correlations as estimated by LD Score regression with insomnia in UK Biobank and 
23andMe. The Pearson correlation between the genetic correlations within each sample was 0.98.
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Neuroticism is an important risk factor for psychiatric traits including depression1, anxiety2,3, and schizophre-
nia4–6. Previous genome-wide association studies7–12 (GWAS) reported 16 genomic loci10–12. Here, we report the 
largest neuroticism GWAS meta-analysis to date (n = 449,484), and identify 136 independent genome-wide signif-
icant loci (124 novel at the time of analysis), implicating 599 genes. Extensive functional follow-up analyses show 
enrichment in several brain regions and involvement of specific cell types, including dopaminergic neuroblasts (P 
= 3.49 × 10-8), medium spiny neurons (P = 4.23 × 10-8) and serotonergic neurons (P = 1.37 × 10-7). Gene-set anal-
yses implicate three specific pathways: neurogenesis (P = 4.43 × 10-9), behavioural response to cocaine processes 
(P = 1.84 × 10-7), and axon part (P = 5.26 × 10-8).  We show that neuroticism’s genetic signal partly originates in 
two genetically distinguishable subclusters13 (depressed affect and worry, the former being genetically strongly 
related to depression, rg = 0.84), suggesting distinct causal mechanisms for subtypes of individuals. Mendelian 
randomization showed uni- and bidirectional effects between neuroticism and multiple psychiatric traits. These 
results vastly enhance our neurobiological understanding of neuroticism, and provide specific leads for function-
al follow-up experiments.
The neuroticism meta-analysis comprised data from the UK Biobank Study (UKB, full release14; n = 372,903; Online Methods; Supplementary 
Fig. 1-2), 23andMe, Inc.15 (n = 59,206), and the Genetics 
of Personality Consortium (GPC19; n = 17,375; Online 
Methods, n = 449,484 in total). In all samples, neurot-
icism was measured through (digital) questionnaires 
(Online Methods; Supplementary Note). To achieve op-
timal power, SNP associations were meta-analyzed using 
METAL16, weighted by sample size (Online Methods). 
We choose to meta-analyze the available samples, rather 
than use a two-stage discovery-replication strategy, be-
cause Skol et al.17 showed that this is almost always more 
powerful, even though less correcting for multiple testing 
is required in the replication stage. 
The quantile-quantile (Q-Q) plot of the genome-wide 
meta-analysis on 449,484 subjects and 14,978,477 SNPs 
showed inflation (LD Score regression (LDSC)18: λGC= 
1.65, mean χ2 statistic = 1.91; Fig. 1a; Supplementary 
Table 1), yet the LDSC intercept (1.02; SE=0.01) and ra-
tio (2.1%) both indicated that the inflation was largely 
explained by true polygenicity and large sample size19. 
The λGC= 1.65 is in line with values observed in recent 
large-sample GWAS studies (i.e. n > 100,000) for diverse 
and polygenic traits (see Supplementary Note). The 
LDSC SNP-based heritability (h2SNP) of neuroticism was 
0.100 (SE = 0.003). The GWAS meta-analysis identified 
9,745 genome-wide significant (GWS) SNPs (P < 5 × 108), 
of which 157 and 2,414 were located in known associat-
ed inversions on chromosomes 8 and 1710–12, respectively 
(see Supplementary Table 2 for cohort-specific informa-
tion; Fig. 1b; Supplementary Fig. 3). 
FUMA20, a tool to functionally map and annotate GWAS 
results  (Online Methods), extracted 170 independent 
lead SNPs (158 novel; see Online Methods for defini-
tion of lead SNPs), which mapped to 136 independent 
genomic loci (124 novel at the time of analysis; Online 
Methods; Supplementary Note; Supplementary Tables 
3-8). Of all lead SNPs, 4 were in exonic, 88 in intronic, 
and 52 in intergenic regions. Of the 17,794 SNPs in high 
LD with one of the independent significant SNPs (see On-
line Methods for definition), most were intronic (9,147: 
51,4%) or intergenic (5,460: 30,7%), and 3.8% was anno-
tated as potentially having a functional impact, with 0.9% 
(155 SNPs) being exonic (Fig. 1c, Supplementary Table 
9; see Supplementary Tables 10-11 for an overview of 
chromatin state and regulatory functions of these SNPs). 
Of these 155, 70 were exonic non-synonymous (ExNS) 
(Table 1, Supplementary Table 12). The ExNS SNP with 
the highest CADD (Combined Annotation Dependent 
Depletion21; indicating likelihood of being deleterious) 
score (34; see Online Methods) was rs17651549, locat-
ed on chromosome 17 in exon 6 of MAPT, with a GWAS 
P-value of 1.11×10-28, in high LD with the lead SNP in 
that region (r2 = 0.97). rs17651549 is a missense mutation 
leading to an arginine-to-tryptophan change with allele 
frequencies matching the inversion in that region. The an-
cestral allele C is associated with a lower neuroticism score 
(see Table 1 and Supplementary Table 12 for a detailed 
overview of all functional variants in genomic risk loci). 
Stratified LDSC22 (Online Methods), showed significant 
enrichment for h2 of SNPs located in conserved regions 
(enrichment = 13.79, P = 5.14 × 10-16), intronic regions 
(enrichment = 1.24 P= 1.27 × 10-6), and in H3K4me3 (en-
richment = 2.14, P = 1.02 × 10-5) and H3K9ac regions (en-
richment = 2.17, P = 3.06 × 10-4) (Fig. 1d; Supplementary 
Table 13). 
Polygenic scores (PGS) calculated using PRSice23 (clump-
ing followed by P-value thresholding) and LDpred24 in 
three randomly drawn hold-out samples (UKB only, n = 
3,000 each; Online Methods), explained up to 4.2%
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Fig. 1 | SNP-based associations with neuroticism in the GWAS meta-analysis.(a) Quantile-quantile plot of the SNP-based 
associations with neuroticism (n = 449,484 individuals). SNP P-values were computed in METAL using a two-sided, weighted 
z-score method. (b) Manhattan plot showing the –log10 transformed P-value of each SNP on the y-axis and base pair positions 
along the chromosomes on the x-axis (n = 449,484 individuals). SNP P-values were computed in METAL using a two-sided, 
weighted z-score method. The dashed line indicates genome-wide significance (P < 5 × 10-8), the dotted line the threshold for 
suggestive associations (P < 1 × 10-5). (c) Pie charts showing the distribution of functional consequences of SNPs in linkage 
disequilibrium (LD) with genome-wide significant lead SNPs in the meta-analysis, the minimum chromatin state across 127 tissue 
and cell types and the distribution of regulome DB score, a categorical score between 1a and 7, indicating  biological evidence of 
a SNP being a regulatory element, with a low score denoting a higher likelihood of being regulatory. (d) Heritability enrichment 
of 22 functional SNP annotations calculated with stratified LD Score regression (summary statistics of the meta-analysis of 
neuroticism were used as input for this analysis). The dots signify the estimated enrichment, whereas the dashed line indicates 
Enrichment = 1. Error bars represent 95% confidence intervals.
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 (P = 1.39 × 10-30) of the variance in neuroticism (Supple-
mentary Fig. 4; Supplementary Table 14; Supplemen-
tary Note). Although the current sample size is consid-
ered large for GWAS and PGS scores can be calculated 
with relatively low standard errors, the variance explained 
by all SNPs combined in the PGS is still relatively small, 
although this is not unexpected given the h2SNP of 10%. 
Our current results thus have little predictive power in in-
dependent samples, mostly due to the low average effect 
sizes of contributing SNPs, and indicate that the genetic 
architecture of neuroticism is extremely polygenic. We do 
note that our current meta-analysis did not include possi-
ble genetic interactions (as even with the current sample 
sizes, power would be limited) but that adding these in 
the future may increase the predictive value of PGS for 
neuroticism.  
We used four strategies to link our SNP results to genes: 
positional, eQTL, and chromatin interaction mapping 
(Online Methods), and genome-wide gene-based associ-
ation study (GWGAS; MAGMA25). GWGAS evaluates the 
joint association effect of all SNPs within a gene yielding 
a gene-based P-value. Based on our meta-analytic results, 
283 genes were implicated through positional mapping, 
369 through eQTL-mapping, and 119 through chromatin 
interaction-mapping (Fig. 2a; Supplementary Table 15). 
GWGAS identified 336 GWS genes (P < 2.75 × 10-6, Figs. 
2b-c; Supplementary Table 16; Supplementary Note), of 
which 203 overlapped with genes implicated by FUMA, 
resulting in 599 unique neuroticism-related genes. Of 
these, 50 were implicated by all four methods, of which 49 
had chromatin interaction and eQTL associations in the 
same tissue/cell type (Fig. 2a; Supplementary Table 15).
19 of the 119 genes implicated through chromatin inter-
action mapping are especially interesting as they are im-
plicated via interactions between two independent GWS 
genomic risk loci. There are several chromatin interac-
tions in 7 tissue types (aorta, hippocampus, left ventricle, 
right ventricle, liver, spleen, pancreas) across two risk loci 
on chromosome 6 (Fig. 3a). Two genes are located in lo-
cus 45 and are mapped by chromatin interactions from 
risk locus 46 (HFE and HIST1H4C), and 16 genes encode 
histones in locus 46 and are mapped by interactions from 
locus 45 (Supplementary Table 15). One gene, XKR6, is 
located on chromosome 8 in risk locus 61, and is implicat-
ed by chromatin interactions in 5 tissue types (aorta, left 
ventricle, liver, pancreas and spleen) including cross-lo-
cus interactions from locus 60 (Fig. 3b; Supplementary 
Table 15). This gene is also mapped by eQTLs in blood 
and transformed fibroblasts. This gene is also mapped 
by eQTLs in blood and transformed fibroblasts. Out of 
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Fig. 2 | Mapping of genes and tissue- and cell expression profiles. (a) Venn diagram showing overlap of genes implicated by 
positional mapping, eQTL mapping, chromatin interaction mapping, and genome-wide gene-based association (GWGAS). (b) 
Quantile-quantile plot of the GWGAS (n = 449,484 individuals). Gene P-values were computed using MAGMA’s gene-based test. 
(c) Manhattan plot of the GWGAS on neuroticism (n = 449,484 individuals). Gene P-values were computed using MAGMA’s 
gene-based test. The y-axis shows the –log10 transformed P-value of each gene, and the chromosomal position (start position) 
on the x-axis. The dashed line indicates the threshold for genome-wide significance of the gene-based test (P < 2.76 × 10-6; 
0.05/18,128), and the dotted line indicates the suggestive threshold (P < 2.76 × 10-5; 0.5/18,128). (d) Gene expression profiles 
of identified genes for 53 tissue types. Expression data were extracted from the Genotype-Tissue Expression (GTEx) database. 
Expression values (RPKM) were log2 transformed with pseudocount 1 after winsorization at 50 and averaged per tissue. Gene-set 
tests for tissue expressions were calculated using MAGMA (Online Methods). (e) Enrichment of genetic signal for neuroticism in 
24 cell types derived from mouse brain. The dashed line indicates the Bonferroni-corrected significance threshold (P = 0.05/7,323 
= 6.83 × 10-6).
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the 19 genes mapped by two loci, 4 are located outside 
of the risk loci (HIST1 H2AI,  HIST1H3H,  HIST1H2AK 
and HIST1H4L), and 7 are also implicated by eQTLs in 
several tissue types (HFE in adipose subcutaneous, aor-
ta, esophagus muscularis, lung, tibial nerve, sub-exposed 
skin and thyroid; HIST1H4J in blood and adrenal gland; 
and HIST1H4K, HIST1H2AK, HIST1H2BO and XKR6 in 
blood).
Gene-based P-values were used for gene-set analysis in 
MAGMA25, testing 7,246 pre-defined gene sets derived 
from MsigDB26, gene expression profiles in 53 tissue 
types obtained from the GTEx Project27, and 24 cell type 
a b e
c
d
Fig. 3 | Genomic risk loci, eQTL associations and chromatin interaction for chromosome 6 and 8, containing cross-locus 
interactions. Circos plot showing genes on (a) chromosome 6 and (b) chromosome 8 that were implicated by the genomic risk 
(blue areas) loci by chromatin interaction (CTI; orange), eQTL (green) or implicated by both eQTL and CTI mapping (red). 
The outer layer shows a Manhattan plot containing the –log10 transformed P-value of each SNP in the GWAS meta-analysis of 
neuroticism (n = 449,484 individuals). Empty regions in the Manhattan plot layer indicate regions where no SNPs with P < 0.05 
are situated.
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b
a
specific expression profiles using RNAseq information28 
(Online Methods). Neuroticism was significantly as-
sociated with genes predominantly expressed in 6 brain 
tissue types (Fig. 2d; Supplementary Table 17-18) and 
with 7 gene ontology (GO) gene sets, with the strongest 
association for neurogenesis (P = 4.43 × 10-9) and neu-
ron differentiation (P = 3.12 × 10-8) (Supplementary 
Table 17). Conditional gene-set analyses (Online Meth-
ods) suggested that 3 of the 7 gene sets (neurogenesis, P 
= 4.43 × 10-9; behavioral response to cocaine, P = 1.84 × 
10-7; axon part, P = 5.26 × 10-8) had largely independent 
associations, implying a role in neuroticism (Supplemen-
tary Table 19). Conditional analyses of the tissue-specific 
expression ascertained general involvement of (frontal) 
cortex expressed genes (Supplementary Table 20; Sup-
plementary Fig. 5).
Cell-type-specific gene-set analysis showed significant as-
sociation with genes expressed in multiple mice-derived 
brain cell types (Online Methods; Fig. 2e; Supplementa-
ry Table 21), with dopaminergic neuroblasts (P= 3.49 × 
10-8), medium spiny neurons (P = 4.23 × 10-8), and sero-
tonergic neurons (P = 1.37 × 10-7) showing the strongest 
associations. Conditional analysis indicated that these 
three cell types were also independently associated with 
neuroticism. 
Aiming to further specify neuroticism’s neurobiological 
interpretation, we compared the genetic signal of the full 
neuroticism trait to that of two genetically distinguishable 
neuroticism subclusters depressed affect and worry (On-
line Methods), which we previously established through 
hierarchical clustering of the genetic correlations between 
the 12 neuroticism items13. As a validation of the depressed 
affect dimension, we also compared the genetic signal of 
neuroticism and the two subclusters to that of depression. 
GWA analyses of the subclusters were conducted on the 
UKB-data only (dictated by item-level data availability; 
Online Methods; depressed affect, n = 357,957; worry, n 
= 348,219). For depression, our meta-analysis comprised 
data from the UKB14 (n = 362,696; Supplementary Fig. 
6), 23andMe15 (n = 307,354), and the Psychiatric Genetics 
Consortium (PGC29; n = 18,759) (total n = 688,809, not 
previously published, largest N for depression to date; rg 
between samples: 0.61-0.80; Online Methods; Supple-
mentary Table 22, see Supplementary Note for details 
on the depression GWAS results ). 
Genetic correlations of neuroticism with all three pheno-
types were considerable (depression: rg = 0.79; depressed 
affect: rg=0.88, worry: rg = 0.87; Supplementary Table 23). 
The positive genetic correlations between neuroticism 
and depression might in part be due to overlap in item 
content between the instruments used to gauge these phe-
notypes, reducing their operational distinctness13.
The subclusters showed notable differences in genetic sig-
nal (e.g., exclusive GWS associations on chromosomes 2 
and 19 for depressed affect, and chromosomes 3 and 22 
for worry; Supplementary Figs. 7-13; Supplementary 
Tables 24-26). Of the 136 genetic loci associated with 
neuroticism, 32 were also GWS for depressed affect (7 
shared with depression) but not for worry, and 26 were 
also GWS for worry (3 shared with depression) but not for 
depressed affect (Supplementary Table 27; Supplemen-
tary Fig. 13). These results were mirrored by gene-based 
analyses (Supplementary Note; Supplementary Tables 
28-30; Supplementary Fig. 14), suggesting that part of 
neuroticism’s genetic signal originates specifically in one 
of the two subclusters, possibly implicating different caus-
al genetic mechanisms. 
To further verify the biological distinctness of the two 
clusters, cluster-specific functional annotation was con-
ducted, demonstrating that with respect to those SNPs 
that are highly likely to have functional consequences 
(ExNS), the clusters are 1) distinct and 2) adding infor-
mation to the results of neuroticism sum-score analysis 
(Supplementary Note; Supplementary Tables 31-34; 
Supplementary Fig. 15). 
To test whether the signal of the gene-sets implicated in 
neuroticism rather originated from one of the specific 
subclusters, we conducted conditional analyses correct-
ing neuroticism for depressed affect, and worry scores, 
respectively (Supplementary Table 35; Supplementary 
Fig. 16). The association with ‘axon-part’ was markedly 
lower after correction for worry scores (uncorrected P = 
5.26 × 10-8; corrected for depressed affect P = 2.42 × 10-6; 
corrected for worry P = 0.0013), suggesting that the in-
volvement of ‘axon-part’ in neuroticism originates pre-
dominantly from the worry-component.
To examine the genetic correlational pattern of neuroti-
cism, and to compare it to the patterns observed for de-
pression, depressed affect and worry, we used LDSC18,30 
to calculate genetic correlations with 35 traits for which 
large-scale GWAS summary statistics were available (Sup-
plementary Table 36; Online Methods). We observed 
11 Bonferroni-corrected significant genetic correlations 
between neuroticism and other traits (α=0.05/(4 × 35); P 
< 3.6 × 10-4) (Fig. 4; Supplementary Table 37), covering 
previously reported psychiatric traits (rg range: 0.20-0.82) 
and subjective well-being (rg = –0.68). These correlations 
were supported by enrichment of neuroticism genes in 
sets of genes previously implicated in psychiatric traits 
(Supplementary Table 38). The rg’s of depression and de-
68 | CHAPTER 4 
Fig. 4 | Genetic correlations between neuroticism and other traits. Genetic correlations of neuroticism, depression, depressed 
affect and worry with various traits and diseases. LD Score regression (Online Methods) tested genome-wide SNP associations 
for the neuroticism score against previously published results for 35 neuropsychiatric outcomes, antropometric and health-related 
traits, and brain morphology (Supplementary Table 36-37). Genetic correlations among neuroticism, depression, depressed affect 
and worry are displayed in the top part of this figure. Red and blue indicate positive and negative genetic correlations, whereas hue 
indicates the strength of the genetic correlations. Sample sizes for the traits in this figure are presented in Supplementary Table 
36). *P<0.01; **Bonferroni corrected P-value threshold (P < 3.6 × 10-4).
pressed affect strongly mirrored eachother (correlation be-
tween their rg’s is r = 0.98; Supplementary Note), validat-
ing the depressed affect cluster. The correlational patterns 
for depressed affect and worry were markedly different 
(e.g., anorexia nervosa, schizophrenia, ever smoker) and 
sometimes in opposite directions (e.g., BMI). The genetic 
correlations of the full neuroticism trait appeared a mix of 
the genetic signal of both clusters, with neuroticism’s rg’s 
generally falling in between the cluster-specific rg’s.
To investigate whether these genetic correlations reflect 
directional effects, we performed Mendelian randomiza-
tion (MR) using the GSMR package31 (Online Methods). 
Among things, we observed unidirectional effects of BMI 
on depression and depressed affect (bxy = 0.061, P = 4.96 
× 10-12 and bxy = 0.049, P = 5.35 × 10-6, respectively), and 
bidirectional associations between neuroticism and de-
pression, and between all four main traits and subjective 
well-being, cognition and several psychiatric disorders 
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(Supplementary Table 39, Supplementary Note). 
We aimed to identify gene-drug interactions (DGIdb32,33; 
Online Methods), of genes identified for each of the four 
traits, and observed a large number of potential targets for 
pharmatherapeutic intervention that were either shared 
between traits or distinct for each phenotype (Supple-
mentary Note; Supplementary Tables 40-41; Supple-
mentary Fig. 17).
In conclusion, we identified 124 novel genetic loci for 
neuroticism (73 taking into account a simultaneously 
conducted study by Luciano et al.34 (see Supplementary 
Note; Supplementary Table 42). Extensive functional 
annotations highlighted several genes being implicated 
through multiple routes. We demonstrated the involve-
ment of specific neuronal cell types and three inde-
pendently associated genetic pathways, and established 
the genetic multidimensionality of the neuroticism phe-
notype, and its link with depression. The current study 
provides new leads, and testable functional hypotheses 
for unraveling the neurobiology of neuroticism, its sub-
types, and genetically associated traits.
Online Methods
Samples
UK Biobank: The UK Biobank (UKB) Study is a major 
data resource, containing genetic and a wide range of 
phenotypic data of ~500,000 participants aged 39-73 at 
recruitment14. We used data released in July 2017, and se-
lection (discussed below) resulted in final sample sizes of 
n = 372,903 and n = 362,696 individuals for neuroticism 
and depression, respectively (Supplementary Note). The 
UKB received ethical approval from the National Re-
search Ethics Service Committee North West–Haydock 
(reference 11/NW/0382), and all study procedures were 
performed in accordance with the World Medical Asso-
ciation for medical research. The current study was con-
ducted under UKB application number 16406.
23andMe: 23andMe, Inc. is a large personal genomics 
company that provides genotype and health-related in-
formation to customers. For the neuroticism and depres-
sion meta-analyses, we used neuroticism and depression 
GWAS summary statistics, respectively, from a subset of 
23andMe research participants (neuroticism: n = 59,206; 
depression: n = 307,354), described in more detail else-
where10,35. All included participants provided informed 
consent and were of European ancestry, and related indi-
viduals were excluded. Online data collection procedures 
were approved by the Ethical & Independent Review Ser-
vices (E&I Review), an AAHRPP-accredited private insti-
tutional review board. 
Genetics of Personality Consortium: The Genetics of 
Personality Consortium (GCP) is a large body of cooper-
ation concerning GWAS on personality. We used summa-
ry statistics of neuroticism from the first GPC personal-
ity meta-analysis (GPC1)9, on 10 discovery cohorts (Sar-
diNIA, NTR/NESDA, ERF, SAGE, HBCS, NAG, IRPG, 
QIMR, LBC1936, BLSA, EGPUT), including in total n 
=17,375 participants of European descent. All included 
studies were approved by local ethic committees, and in-
formed consent was obtained from all participants.
Psychiatric Genetics Consortium: The Psychiatric Ge-
netics Consortium (PGC) unites investigators worldwide 
to conduct genetic meta- and mega-analyses for psychi-
atric disorders. We used summary statistics from the lat-
est published PGC meta-analysis on depression29, which 
included data from 8 cohorts (Bonn/Mannheim, GAIN, 
GenRED, GSK, MDD2000, MPIP, RADIANT, STAR*D), 
covering n = 18,759 participants of European descent.  All 
included studies were approved by local ethic committees, 
and informed concent was obtained from all participants.
Phenotype assessment – Neuroticism
UK Biobank: Neuroticism was measured with 12 di-
chotomous (yes/no) items of the Eysenck Personality 
Questionnaire Revised Short Form (EPQ-RS36, using a 
touchscreen-questionnaire at the UKB assessment centers 
(Supplementary Note). Participants with valid respons-
es to <10 items were excluded from analyses. A weight-
ed neuroticism sum-score was calculated by adding up 
individual valid item responses, and dividing that sum 
by the total number of valid responses. In addition, we 
constructed two scores based on subsets of genetically 
homogeneous neuroticism items, as established previ-
ously13 through hierarchical clustering analysis of the ge-
netic correlations between the 12 neuroticism items (see 
Supplementary Note). Specifically, scores on 4 EPQ-RS 
items (i.e., “Do you often feel lonely?”, “Do you ever feel 
‘just miserable’ for no reason?”, “Does your mood often 
go up and down?”, and “Do you often feel ‘fed-up’?”) were 
summed to obtain scores for the cluster depressed affect. 
Similarly, scores on 4 other EPQ-RS items (i.e., “Are you a 
worried?”, “Do you suffer from nerves?”, “Would you call 
yourself a nervous person?”, and “Would you call yourself 
tense or highly strung”) were summed to obtain scores for 
the cluster worry. In the item-cluster analyses, only par-
ticipants with complete scores on all 4 items were includ-
ed, resulting in n = 357,957 and n = 348,219 for depressed 
affect and worry, respectively.
23andMe: Neuroticism was operationalized as of the sum 
of 8 neuroticism items (5-point Likert scale; ‘Disagree 
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strongly’ to ‘Agree strongly’) from the Big Five Inventory 
(BFI37,38), as obtained in an online survey. Only partici-
pants with valid responses to all items were included in 
the analyses (Supplementary Note).
Genetic Personality Consortium: All 10 cohorts in-
cluded in the first meta-analysis of the GPC used sums 
of the scores on 12 items (5-point Likert scale; ‘Strongly 
disagree’ to ‘Strongly agree’) of the NEO-FFI39 to measure 
neuroticism. If <4 item scores were missing, data on in-
valid items were imputed by taking an individual’s aver-
age score on valid items. Participants were excluded from 
analyses if they had invalid scores on >3 items9 (Supple-
mentary Note).
Phenotype assessment - Depression
UK Biobank: Depression was operationalized by adding 
up the scores on two continuous items (“Over the past 
two weeks, how often have you felt down, depressed or 
hopeless?”, “Over the past two weeks, how often have you 
had little interest or pleasure in doing things?”; both eval-
uated on a 4-point Likert scale; ‘Not at all’ to ‘Nearly every 
day’), resulting in a continuous depression score (as used 
previously12). Only participants with scores on both items 
were included in the analyses, resulting in n = 362,696 
(Supplementary Note).
23andMe: This concerns a case-control sample. Four 
self-report survey items were used to determine case-con-
trol status. Cases were defined as replying affirmatively to 
at least one of these questions, and not replying negatively 
to previous ones. Controls replied negatively to at least 
one of the questions, and did not report being diagnosed 
with depression on previous ones (Supplementary Note).
Psychiatric Genetics Consortium: This concerns a 
case-control sample. Cases had a DSM-IV lifetime (some-
times (early onset) recurrent) major depressive disorder 
(MDD) diagnosis, either established through structured 
diagnostic interviews or clinician-administered DSM-
IV checklists. Most cases were ascertained from clinical 
sources, while controls were randomly selected from 
population resources and screened for lifetime history of 
MDD29 (Supplementary Note).
Genotyping and imputation
UK Biobank - Neuroticism: We used genotype data 
released by the UKB in July 2017. The genotype data 
collection and processing are described in detail by the 
responsible UKB group14. In short, 489,212 individuals 
were genotyped on two customized SNP arrays (the UK 
BiLEVE Axiom array (n = 50,520) and UK Biobank Axi-
om array (n = 438,692)), covering 812,428 unique genetic 
markers (95% overlap in SNP content). After quality con-
trol procedures14, 488,377 individuals and 805,426 geno-
types remained. Genotypes were phased and imputed by 
the coordinating team to approximately 96 million geno-
types using a combined refence panel including the Hap-
lotype Reference Consortium and the UK10K haplotype 
panel. Imputed and quality controlled genotype data was 
available for 487,422 individuals and 92,693,895 genetic 
variants. As recommended by the UKB team, variants 
imputed from the UK10K reference panel were removed 
from the analyses due to technical errors in the imputa-
tion process.
In our analyses, only individuals from European descent 
(based on genetic principal components) were included. 
Therefore, principal components from the 1000 Genomes 
reference populations40 were projected onto the called 
genotypes available in UK Biobank. Subjects were iden-
tified as European if their projected principal component 
score was closest (based on the Mahalanobis distance) to 
the average score of the European 1000 Genomes sam-
ple41. European subjects with a Mahalanobis distance > 
6 S.D. were excluded. In addition, participants were ex-
cluded based on withdrawn consent, UKB provided re-
latedness (subjects with most inferred relatives, 3rd degree 
or closer, were removed until no related subjects were 
present), discordant sex, sex aneuploidy. After selecting 
individuals based on available neuroticism sum-score and 
active consent for participation, 372,903 individuals re-
mained for the analyses.
To correct for population-stratification, 30 principal 
components were calculated on the subset of QC-ed un-
related European subjects based on 145,432 independent 
(r2<0.1) SNPs with MAF>0.01 and INFO=1 using Flash-
PC242. Subsequently, imputed variants were converted to 
hard call using a certainty threshold of 0.9. Multi-allelic 
SNPs, indels, and SNPs without unique rs id were exclud-
ed, as well as SNPs with a low imputation score (INFO 
score <0.9), low minor allele frequency (MAF<0.0001) 
and high missingness (>0.05). This resulted in a total of 
10,847,151 SNPs used for downstream analysis.
UK Biobank - Depression: Similar genotyping / imputa-
tion/filtering procedures as described above for the UKB 
neuroticism GWAS were followed for the UKB depres-
sion GWAS, resulting in n = 362,696.
Genome-wide association analyses
UK Biobank - Neuroticism: Genome-wide association 
analyses were performed in PLINK43,44, using a linear 
regression model of additive allelic effects with age, sex, 
townsend deprivation index, genotype array, and 10 ge-
netic European-based principal components as covariates 
(Supplementary Note).
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UK Biobank - Depression, depressed affect, worry:  The 
settings, covariates, and exclusion criteria for the UKB 
depression, UKB depressed affect, and UKB worry GWAS 
were the same as described above for UKB neuroticism 
GWAS, with 10,847,151 SNPs remaining after all exclu-
sion steps (Supplementary Note).
Other samples: Summary statistics were used for 23and-
Me, GPC and PGC. Details on the genome-wide associ-
ation analyses of these samples can be found elsewhere 
(23andMe neuroticism10; 23andMe depression35; GPC 
neuroticism9; PGC depression29).
Meta-analysis
In order to maximize the statistical power to detect asso-
ciated genetic variants of small effect, we conducted me-
ta-analyses for both neuroticism and depression17 (Sup-
plementary Note). All meta-analyses were carried out in 
METAL16.
Neuroticism: The meta-analysis of the neuroticism 
GWAS in UKB, 23andMe, and GPC was performed on 
the P-value of each SNP using a sample size-weighted 
fixed-effects analysis. Bonferroni correction was applied 
to correct for multiple testing. The genetic signal correlat-
ed strongly between the three samples (rg range: 0.83 – 
1.07; Supplementary Table 1), supporting the decision to 
meta-analyze.
Depression: As the UKB GWAS concerned a continuous 
operationalization of the depression phenotype, while 
23andMe and PGC used case-control phenotypes, the 
odds ratio from the 23andMe and PGC summary statis-
tics were converted to log odds, reflecting the direction 
of the effect. The meta-analysis was then performed on 
the P-value of each SNP using a sample size weighted 
fixed-effects analysis. Bonferroni correction was applied 
to correct for multiple testing. Genetic correlations be-
tween the three samples were moderate to strong (rg 
range: 0.61 – 0.80; Supplementary Table 22).
Genomic risk loci and functional annotation 
Functional annotation was performed using FUMA17, an 
online platform for functional mapping of genetic vari-
ants. We first defined independent significant SNPs which 
have a genome-wide significant P-value (5 × 10-8) and 
are independent at r2<0.6. A subset of these independent 
significant SNPs, that were independent from each other 
at r2<0.1, was marked as lead SNPs (based on LD infor-
mation from UK Biobank genotypes; see Supplementa-
ry Note for a more detailed explanation). Subsequently, 
genomic risk loci were defined by merging lead SNPs 
that physically overlapped or for which LD blocks were 
less than 250 kb apart. Note that when analyzing multi-
ple phenotypes, as in the current study, a locus may be 
discovered for different phenotypes, whilst different lead 
SNPs are identified.
All SNPs in the meta-analysis results that were in LD (r2 
> 0.6) with one of the independent significant SNPs, had a 
P-value lower than 1.0×10-5 and minor allele frequency 
(MAF) > 0.0001 were selected for annotation. The ratio-
nale behind this inclusive approach is that the most sig-
nificant SNP in the locus is not necessarily the causal SNP, 
but may be in LD with the causal SNP. We thus annotated 
all SNPs in LD with the most significant SNP to get in-
sight into the possible biological reasons for observing a 
statistical association. We note that liberalizing the r2 and 
P-value thresholds can dilute the functional annotation 
results, while more stringent thresholds may result in ex-
clusion of possibly interesting functional variants. Func-
tional consequences for these SNPs were obtained by 
performing ANNOVAR45 gene-based annotation using 
Ensembl genes. In addition, CADD scores (indicating the 
deleteriousness of a SNP, with scores >12.37 seen as likely 
deleterious21) and RegulomeDB scores46 (where a higher 
probability of having a regulatory function is indicated 
by lower scores) were annotated to SNPs by matching 
chromosome, position, reference and alternative alleles. 
CADD scores integrate a number of diverse annotations 
into a single measure that correlates with pathogenicity, 
disease severity and experimentally measured regulatory 
effects and complex trait associations21.
Gene-mapping
SNPs in genomic risk loci that were GWS or were in LD 
(r2 > 0.6) with one of the independent significant SNPs 
were mapped to genes in FUMA20 using either of three 
strategies.
First, positional mapping uses the physical distances (i.e., 
within 10kb window) from known protein coding genes 
in the human reference assembly (GRCh37/hg19) to map 
SNPs to genes. The second strategy, eQTL mapping, uses 
information from 3 data repositories (GTEx, Blood eQTL 
browser BIOS QTL browser), and maps SNPs to genes 
based on a significant eQTL association (i.e. the expres-
sion of that gene is associated with allelic variation at 
the SNP). eQTL mapping is based on cis-eQTLs which 
can map SNPs to genes up to 1Mb apart. FUMA applied 
a false discovery rate (FDR) of 0.05 to define significant 
eQTL associations. Thirdly, chromatin interaction map-
ping mapped SNPs to genes based on a significant chro-
matin interaction between a genomic region in a risk lo-
cus and promoter regions of genes (250bp up- and 500bp 
downstream of transcription start site (TSS)). This type of 
mapping does not have a distance boundary (as in eQTL 
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mapping), and may therefore involve long-range interac-
tions. Currently, FUMA contains Hi-C data of 14 tissue 
types from the study of Schmitt et al. (2016)47. Important-
ly, as chromatin interactions are usually defined in a cer-
tain resolution (in the current study; 40kb), an interacting 
region may span several genes. Hence, this method would 
map all SNPs within these regions to genes in the cor-
responding interaction region. By integrating predicted 
enhancers and promoters in 111 tissue/cell types from the 
Roadmap Epigenomics Project48 we aimed to prioritize 
candidate genes from chromatin interaction mapping. 
Using this information FUMA selected chromatin inter-
actions for which one region involved in the interaction 
overlaps with predicted enhancers and the other with pre-
dicted promoters in 250bp up- and 500bp downstream of 
TSS site of a gene. Like with the eQTL mapping, we used a 
FDR of 1 × 10-5 to define significant interactions.
Gene-based analysis
A genome-wide gene-based association analysis (GW-
GAS) can identify genes in which multiple SNPs show 
moderate association to the phenotype of interest without 
reaching the stringent genome-wide significance level. At 
the same time, as a GWGAS takes all SNPs within a gene 
into account, a gene harbouring a genome-wide signifi-
cant SNP may not be implicated by a GWGAS analyses 
when multiple other SNPs within that gene show only very 
weak association signal. The P-values from the SNP-based 
GWAS meta-analyses for neuroticism and depression, and 
the GWAS for depressed affect and worry, were used as in-
put for the genome-wide gene-based association analysis 
(GWGAS) in MAGMA25, and all 19,427 protein-coding 
genes from the NCBI 37.3 gene definitions were used. We 
annotated all SNPs in our GWA (meta-) analyses to these 
genes, resulting in 18,187, 18,187, 18,182, and 18,182 
genes that were represented by at least one SNP in the 
neuroticism meta-analysis, the depression meta-analysis, 
the depressed affect GWAS, and the worry GWAS, respec-
tively. We included a window around each gene of 2 kb 
before the transcription start site and 1 kb after the tran-
scription stop site. Gene association tests were performed 
taking into account the LD between SNPs, and a stringent 
Bonferroni correction was applied to correct for multi-
ple testing (0.05/number of genes tested: P < 2.75 × 10-6). 
Gene-set analysis
We used MAGMA25 to test for association of predefined 
gene sets with neuroticism, depression, depressed affect, 
and worry. A total of 7,246 gene sets were derived from 
several resources, including  BioCarta, KEGG, Reactome49 
and GO. All gene sets were obtained from the MsigDB 
version 6.0). Additionally, we performed gene-set analysis 
on 53 tissue expression profiles obtained from the GTEx 
portal, and 24 cell-type specific expression profiles.
For all gene sets, we computed competitive P-values, 
which result from testing whether the combined effect of 
genes in a gene set is significantly larger than the com-
bined effect of a same number of randomly selected genes 
(in contrast to testing against the null hypothesis of no ef-
fect; self-contained test). Here, we only report Bonferroni 
corrected (a=0.05/7,323= 6.83 × 10-6) competitive P-val-
ues, which are more conservative compared to self-con-
tained P-values.
Cell type specific expression analysis 
Definition and calculation of gene sets for cell type specif-
ic expression is described in detail elsewhere28,50. Briefly, 
brain cell type expression data was drawn from scRNA-
seq data from mouse brain28. For each gene, the value for 
each cell type was calculated by dividing the mean Unique 
Molecular Identifier (UMI) counts for the given cell type 
by the summed mean UMI counts across all cell types28. 
MAGMA25 was used to calculate associations between 
gene-wise P-values from the meta-analysis and cell type 
specific gene expression. Genes were grouped into 40 
equal bins by specificity of expression, and subsequent-
ly bin-membership was regressed on gene-wise associa-
tion with neuroticism in the meta-analysis. Results were 
deemed significant if the association P-values were small-
er than the relevant Bonferroni threshold.
Conditional gene-set analyses
Conditional gene-set analyses were performed using 
MAGMA25 to determine which tissue expression levels 
and MsigDB gene-sets represent independent associa-
tions. In these regression-based analyses, the effect of a 
gene-set (or tissue expression) of interest is conditioned 
on the effects of another gene-sets (or tissue expressions) 
to correct the association of the tested gene-set for any 
effect it shares with the conditioned-on gene-sets. 
For the MSigDB gene-sets we conducted two series of con-
ditional analyses. First, we performed a forward selection 
on the initially significant gene-sets, in each step selecting 
the most strongly associated gene-set after conditioning 
on all already selected gene-sets. (Supplementary Table 
19). Second, to test whether the association of gene-sets 
to neuroticism is primarily driven by association signal 
of one specific subcluster, we also reran the GO gene-set 
analyses conditioning on the gene Z-scores of depressed 
affect or worry, respectively (Supplementary Table 35). 
If the gene-set association decreases after conditioning on 
one cluster but not, or less so, when conditioning on the 
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other, then this suggests that neuroticism’s association to 
that gene-set is primarily driven by the genetic effects of 
the first, and not the second, item cluster.
Genetic correlations
Genetic correlations (rg) were computed using LD Score 
regression18,30. The significance of the genetic correlations 
of neuroticism, depression, depressed affect and worry 
with 35 behavioral, social and (mental) health pheno-
types for which summary statistics were available was 
determined by correcting for multiple testing through 
a stringent Bonferroni corrected threshold of P < 0.05 /
(4×35) = 3.6 × 10-4).  
Mendelian randomization analyses
We performed Mendelian randomization (MR) to test 
whether genetic correlations could be explained by direc-
tional effects between traits. Generalised summary-data 
based Mendelian randomization (GSMR31) was used for 
MR analysis: a summary statistics-based MR method 
that uses independent genome-wide significant variants 
as instrumental variables. Causal associations were test-
ed between the four traits, and the 21 traits that showed 
significant genetic correlations (rg) in LD Score regres-
sion analysis with at least one of the four traits. To test 
for uni- and bidirectional effects, we performed both 
forward and reverse GSMR analysis (i.e., using the four 
GWAS traits either as predictor or as outcome). Associ-
ations were Bonferroni corrected for multiple testing P < 
0.05/(21*4*2) = 2.98 × 10-4).
Partitioned heritability
To investigate the relative contribution to the overall SNP-
based heritability annotated to 22 specific genomic cate-
gories, we partioned SNP heritability by binary annota-
tions using stratified LD Score regression22. Information 
about binary SNP annotations were obtained from the 
LD Score website. Enrichment results reflect the X-fold 
increase in h2 proportional to the number of SNPs (e.g., 
enrichment = 13.79 for SNPs in conserved regions im-
plies that a 13,79-fold increase in h2 is carried by SNPs 
in these region, corrected for the proportion of SNPs in 
these regions compared to all tested SNPs).
Gene drug targets
We aimed to identify potential druggable targets by 
performing lookup of implicated genes (by one of the 
gene-mapping strategies) in the drug-gene interaction 
database (DGIdb32,33, version 3.0). The DGIdb database 
contains mined data from several resources, and provides 
a comprehensive overview of the druggability of gene 
targets. First, we searched 20 drug-gene databases for 
interactions with existing medicines based on 48 known 
interaction types with genes that were implicated in each 
of the four phenotypes. Filtering was performed based on 
known interaction types, and interactions with FDA-ap-
proved pharmaceutical compounds. Second, to identify 
genes that may form targets for novel therapies in addi-
tion to existing medicines, we searched for potential gene 
druggability of gene targets and performed an addition-
al search in 10 DGIdb databases containing information 
about gene targetability. 
Polygenic risk scoring
To test the predictive accuracy (ΔR2) of the our me-
ta-analytic results for neuroticism, we calculated a poly-
genic risk score (PGS) based on the SNP effect sizes of 
the current analysis. As independent samples we used 
3 holdout samples; we removed 3,000 individuals from 
the discovery sample (UKB only, as we only had access 
to individual-level data from this sample) and reran the 
genome-wide analyses. We repeated this three times, to 
create 3 randomly drawn, independent hold-out sam-
ples. Next, we calculated a PGS on the individuals in 
each of the 3 holdout samples. PGS were calculated using 
LDpred24 and  PRSice23 (clumping followed by P-value 
thresholding). 
For LDpred, PGS were calculated based on different LD-
pred priors (PLDpred = 0.01, 0.05, 0.1, 0.5, 1 and infinitesi-
mal). The explained variance (R2) was derived from the 
linear model, using the neuroticism summary score as the 
outcome, while correcting for age, gender, array, townsend 
deprivation index and genetic principal components. 
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Supplementary Fig. 1 | Flow chart of analyses conducted in the study of neuroticism. Schematic representation of the analyses 
conducted for neuroticism. Additional analyses performed on the depression, depressed affect, and worry phenotypes are not 
included in this chart.
Supplementary Fig. 2 | Distribution of missingness and weighted sum-score for neuroticism in the UK biobank sample. (a) 
Distribution of the number of items missing. Individuals with invalid responses to more than two items missing were excluded 
from further analysis. (b) For the remaining participants, the neuroticism sum-score was established by summing the individual 
item responses and dividing by the total number of completed items for that participant. The distributions of these scores is shown 
in panel b.
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Supplementary Fig. 4 | Explained variance in neuroticism by polygenic risk scores (PGS) in 3 holdout samples (n = 3,000). 
To estimate the variation in neuroticism that could be explained by our GWA meta-analysis in independent samples, we re-ran 
out GWA meta-analysis for neuroticism three times, each time excluding a UKB hold-out sample of n = 3,000 randomly drawn 
individuals (n = 449,484-3,000 = 446,484). We then calculated polygenic scores (PGS) using two methods: (a) PRSice23 (P-value 
thresholding and clumping) and (b) LDpred24. See Supplementary Table 14.
Supplementary Fig. 5 | Conditional gene-set analyses on 6 significant brain tissues. Conditional gene-set analysis was 
conducted in MAGMA, using the gene-based analysis results as input. The dotted line indicates nominal significance at a = 0.05; 
the dashed line indicates the Bonferroni corrected significance threshold (a=0.05/7,299=6.85 × 10-6) used in the initial gene 
expression analysis (base).
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Supplementary Fig. 6 | Distribution of the depressive symptoms score in the UK Biobank sample. The distribution of the 
continuous depressive symptoms score that we calculated in the UKB sample. Depression was operationalized by adding up the 
scores on two continuous items (both evaluated on a 4-point Likert scale), resulting in a continuous depression score. Individuals 
that did not complete both items were excluded from further analysis. For the remaining participants, the depressive symptoms 
score was established by summing the individual item responses.
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Supplementary Fig. 7 | Manhattan and Q-Q plots of SNP-based association with neuroticism in the individual cohorts. 
SNP Association results from the GWAS on neuroticism in (a) UK Biobank (n = 372,903 individuals) (b) 23andMe (n = 
59,206 individuals) and (c) GPC1 (n = 17,375 individuals) cohorts. P-values for the UKB cohort were computed using a linear 
regression model of additive allelic effects and covariates in PLINK (see Online Methods for covariates and more information 
on the 23andMe and GPC1 cohorts). Dashed lines indicate genome-wide significance (P<5×10-8) and dotted lines indicate the 
‘suggestive’ significance threshold (P < 1 × 10-5).
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Supplementary Fig. 8 | Manhattan and Q-Q plots of SNP- and gene-based association with depression (n = 688,809 
individuals). (a) SNP-based association results from the GWA meta-analysis (UK biobank, 23andMe and PGC) on depression. 
SNP P-values were computed in METAL using a two-sided, weighted z-score method. Dashed lines indicate genome-wide 
significance (P < 5 × 10-8) and dotted lines indicate the ‘suggestive’ significance threshold (P < 1 × 10-5). An overview of these 
genome-wide significant (GWS) SNPs and their P-values can be found in Supplementary Table 24. (b) Gene-based association 
results from the meta-analysis (UK biobank, 23andMe and PGC) on depression. Gene-based P-values were computed using 
MAGMA’s gene-based test (where the summary statistics from GWAS were used as input). Dashed lines indicate genome-wide 
significance (P < 2.75 × 10-6) and dotted lines indicate the ‘suggestive’ significance threshold (P < 2.75 × 10-5). An overview of 
these GWS genes and their P-values can be found in Supplementary Tables 16 and 28.
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Supplementary Fig. 9 | Manhattan and Q-Q plots of SNP-based association with depression in the individual cohorts. 
SNP Association results from the GWAS on depression in (a) UK Biobank (n = 362,696 individuals) (b) 23andMe (n = 
307,354 individuals) and (c) PGC (n = 18,759 individuals) cohorts. P-values for the UKB cohort were computed using a linear 
regression model of additive allelic effects and covariates in PLINK (see Online Methods for covariates and more information 
on the 23andMe and PGC cohorts). Dashed lines indicate genome-wide significance (P < 5 × 10-8) and dotted lines indicate the 
‘suggestive’ significance threshold (P < 1 × 10-5).
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Supplementary Fig. 10 | Manhattan and Q-Q plots of SNP- and gene-based association with depressed affect (n = 357,957 
individuals). (a) SNP-based association results from the GWAS on depressed affect in the UK biobank sample SNP P-values 
were computed using a linear regression model of additive allelic effects and covariates in PLINK. Dashed lines indicate genome-
wide significance (P < 5 × 10-8) and dotted lines indicate the ‘suggestive’ significance threshold (P < 1 × 10-5). (b) Gene-based 
association results from the GWAS on depressed affect in the UK Biobank sample. Gene-based P-values were computed in 
MAGMA using a two-sided, weighted z-score method. Dashed lines indicate genome-wide significance (P < 2.75 × 10-6) and 
dotted lines indicate the ‘suggestive’ significance threshold (P < 2.75 × 10-5).
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Supplementary Fig. 11 | Manhattan and Q-Q plots of SNP- and gene-based association with worry (n = 348,219 individuals), 
(a) SNP-based association results from the GWAS on worry in the UK biobank sample. SNP P-values were computed using a 
linear regression model of additive allelic effects and covariates in PLINK. Dashed lines indicate genome-wide significance (P < 
5 × 10-8) and dotted lines indicate the ‘suggestive’ significance threshold (P < 1 × 10-5). (b) Gene-based association results from 
the GWAS on worry in the UK biobank sample. Gene-based P-values were computed in MAGMA using a two-sided, weighted 
z-score method. Dashed lines indicate genome-wide significance (P < 2.75 × 10-6) and dotted lines indicate the ‘suggestive’ 
significance threshold (P < 2.75 × 10-5).
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Supplementary Fig. 12 | Manhattan plots showing SNP associations for neuroticism, depression, depressed affect and worry 
on 4 chromosomes. Color-coded SNP-based association results of all 4 phenotypes plotted in the same plot. SNP P-values 
were computed in METAL using a two-sided, weighted z-score method (neuroticism and depression meta-analyses) or linear 
regression in PLINK (clusters). Dashed lines indicate genome-wide significance (P < 5 × 10-8) and dotted lines indicate the 
‘suggestive’ significance threshold (P < 1 × 10-5). significance threshold (P < 2.75 × 10-5). SNP-based association results on (a) 
chromosome 2, (b) chromosome 3, (c) chromosome 19 and (d) chromosome 22. 
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Supplementary Fig. 13 | Venn diagram showing overlap in associated genomic loci for neuroticism, depression, depressed 
affect and worry. Loci for neuroticism include the two low confidence loci, discussed in the Supplementary Note.
Supplementary Fig. 14 | Venn diagram showing overlap in associated genes for neuroticism, depression, depressed affect and 
worry.
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Supplementary Fig 15 | Functional categories, chromatin state and regulome DB score for SNPs that were GWS for the 
depressed affect and worry clusters. The functional annotation indicates the functional consequences on the gene to which a 
given SNP was annotated (Supplementary Table 31). The chromatin state refers to the minimum (i.e., most active) chromatin 
state across 127 tissues for all genome-wide significant SNPs. The lower the regulome DB (database) score, the more likely it is that 
the SNP has a regulatory function. Coding of the chromatin states and regulome DB scores is presented in Supplementary Tables 
32-33. Annotation was performed in FUMA20.
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Supplementary Fig. 16 | Gene-set analysis conditional on depressed affect and worry. Association P-values of gene-sets 
for neuroticism, conditional on the scores on the neuroticism item clusters depressed affect and worry. The initial conditional 
gene-set analysis (Supplementary Table 35) showed that 3 of the 6 gene-sets (axon part, behavioral response to cocaine and 
neurogenesis) had largely independent associations with neuroticism. Repeating the conditional analyses, now conditioning on 
depressed affect and worry scores, respectively, shows that the involvement of ‘axon part’ in neuroticism may largely originate in 
the worry component of neuroticism (compared to conditioning on depressed affect,  the P-value drops
more substantially). Conditional gene-set analyses were conducted in MAGMA using theresults of the gene-based analyses as 
input.
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Supplementary Fig. 17 | Potentially druggable gene categories for all four traits. Bar plot showing the number of potentially 
druggable gene-targets based on data from the drug-gene interaction database32,33 (DGIdb). The search in the DGIdb was 
performed on all genes that were implicated by one of the gene-mapping strategies for each of the four traits. These
categories highlight gene-targets that may form a potential drug-target, but which is not necessarily already targeted by currently 
approved drugs. A full overview of the results is provided in Supplementary Table 41.
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Intelligence is highly heritable1 and a major determinant of human health and wellbeing2. Recent genome-wide 
meta-analyses have identified 24 genomic loci linked to variation in intelligence3-7, but much about its genetic 
underpinnings remains to be discovered. Here, we present a large-scale genetic association study of intelligence (n 
= 269,867), identifying 205 associated genomic loci (190 new) and 1,016 genes (939 new) via positional mapping, 
expression quantitative trait locus (eQTL) mapping, chromatin interaction mapping, and gene-based associa-
tion analysis. We find enrichment of genetic effects in conserved and coding regions and associations with 146 
nonsynonymous exonic variants. Associated genes are strongly expressed in the brain, specifically in striatal me-
dium spiny neurons and hippocampal pyramidal neurons. Gene set analyses implicate pathways related to ner-
vous system development and synaptic structure. We confirm previous strong genetic correlations with multiple 
health-related outcomes, and Mendelian randomization analysis results suggest protective effects of intelligence 
for Alzheimer’s disease and ADHD and bidirectional causation with pleiotropic effects for schizophrenia. These 
results are a major step forward in understanding the neurobiology of cognitive function as well as genetically 
related neurological and psychiatric disorders.
We performed a genome-wide association study (GWAS) meta-analysis of 14 independent ep-idemiological cohorts of European ancestry 
and 9,295,118 genetic variants passing quality control 
(Table 1, Supplementary Fig. 1, and Supplementary Ta-
ble 1). A flowchart of the study methodology is present-
ed in Supplementary Fig. 2, and additional details of the 
methods and results are presented in the Supplementary 
Note. Intelligence was assessed using various neurocog-
nitive tests, primarily gauging fluid domains of cognitive 
functioning (Supplementary Note). Despite variation in 
form and content, cognitive test scores display a positive 
manifold of correlations, a robust empirical phenomenon 
that is observed in multiple populations8. Statistically, the 
variance common across cognitive tasks can be modeled 
as a latent factor denoted as g (the general factor of in-
telligence)9,10. In addition, twin and family studies show 
strong genetic correlations across diverse cognitive do-
mains11, suggesting pleiotropy, and across levels of abil-
ity11, substantiating the view of general intelligence as 
an etiological continuum (with rare syndromic forms of 
severe intellectual disability being the exception12). Addi-
tionally, g factors extracted from different sets of cognitive 
tests correlate very strongly (>0.9813,14), supporting the 
universality of g15,16. In performing meta-analysis of cog-
nitive scores obtained using a variety of tests, we aimed 
to boost the statistical power to detect genetic variants 
underlying g, which are likely to have pleiotropic effects 
across multiple domains of cognitive functioning. 
Despite sample and methodological variations, genet-
ic correlations (rg) between cohorts were considerable 
(mean = 0.67), and there was no evidence of heterogene-
ity between cohorts in the SNP associations (Supplemen-
tary Table 2 and Supplementary Note). Age -stratified 
meta -analyses indicated high genetic correlations (rg 
> 0.62) and comparable heritability across age groups, 
as captured by the SNPs included in the analysis (rg = 
0.19–0.22) (Supplementary Table 3 and Supplementa-
ry Note). The full -sample was 0.19 (standard error (s.e.) 
= 0.01), in line with previous findings4,5, and a linkage 
disequilibrium (LD) score intercept17 of 1.08 (s.e. = 0.02) 
indicated that most of the inflation (λ = 1.92) could be ex-
plained by polygenic signal6 (Supplementary Fig. 3 and 
Supplementary Table 4).
In the meta-analysis, 12,110 variants indexed by 242 
lead SNPs in approximate linkage equilibrium (r < 0.1) 
reached genome-wide significance (P < 5 × 10-8) (Fig. 1a, 
Supplementary Figs. 4 and 5, and Supplementary Ta-
bles 5–7). These were located in 205 distinct genomic loci 
(Supplementary Note). We tested for replication using 
the proxy phenotype of educational attainment, which is 
correlated phenotypically (rg ~0.40)18 and genetically (rg 
~0.70)19 with intelligence. We confirmed this high genet-
ic correlation (rg = 0.73) and observed sign concordance 
with educational attainment for 93% of genome- wide 
significant SNPs (P < 1 × 10-300), with replication for 48 
loci (Supplementary Table 8 and Supplementary Note). 
Using polygenic score (PGS) prediction20,21, the current 
results explain up to 5.2% of the variance in intelligence 
in four independent samples (Supplementary Table 9 
and Supplementary Note). We observed enrichment 
for heritability of SNPs in conserved regions (P = 2.01 
× 10-12), coding regions (P = 1.67 × 10-6), and acetylated 
Lys9 of histone H3 (H3K9ac) histone regions/peaks (P < 
6.26 × 10-5), and among common (minor allele frequen-
cy (MAF) > 0.3) variants (Fig. 1b, Supplementary Figs. 
6 and 7, Supplementary Table 10, and Supplementary 
Note). Conserved and regulatory regions have previous-
ly been implicated in cognitive functioning22, but coding 
regions have not. 
Functional annotation of all candidate SNPs in the asso-
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ciated loci (SNPs with r2 ≥ 0.6 with one of the indepen-
dent significant SNPs, a suggestive P-value (P < 1 × 10-5), 
and MAF > 0.0001; n = 21,368) showed that these were 
mostly intronic or intergenic (Fig. 1 and Supplementary 
Table 6), yet 146 (81 genome- wide significant) SNPs were 
exonic nonsynonymous (ExNS) (Supplementary Table 
11 and Supplementary Note). Convergent evidence of 
strong association (z = 9.49) and the highest observed 
probability of a deleterious protein effect (CADD23 score 
= 34) were found for rs13107325. This missense mutation 
(MAF = 0.065, P = 2.23 × 10-21) in SLC39A8 was the lead 
SNP in locus 71, and the ancestral C allele was associat-
ed with higher scores on intelligence measures. The effect 
sizes for ExNS SNPs were individually small, with each 
effect allele accounting for a difference of 0.01 to 0.08 s.d. 
A detailed catalog of variants in the associated genomic 
loci is presented in Supplementary Tables 6 and 11 and 
in the Supplementary Note. 
To link the associated variants to genes, we applied three 
gene- mapping strategies implemented in FUMA24. Po-
sitional gene mapping aligned SNPs to 522 genes by ge-
nomic location, eQTL gene mapping matched cis -eQTL 
SNPs to 684 genes whose expression levels they influence, 
and chromatin interaction mapping annotated SNPs to 
227 genes on the basis of 3D DNA–DNA interactions 
(Fig. 2, Supplementary Figs. 8 and 9, Supplementary 
Tables 12–14, and Supplementary Note). This resulted 
in 859 unique mapped genes, 435 of which were impli-
cated by at least two mapping strategies and 139 of which 
were implicated by all three (Fig. 3). Although not all of 
these genes are certain to have a role in intelligence, they 
point to potential functional links for the GWAS-asso-
ciated variants and give higher credibility to genes with 
convergent evidence of association from multiple sourc-
es. The FUMA- mapped genes were enriched for brain 
tissue expression and several regulatory biological gene 
sets (Supplementary Note). Fifteen genes are particularly 
notable as they are implicated via chromatin interactions 
between two independent genomic risk loci (Fig. 2 and 
Supplementary Note). Cross- locus interactions impli-
cated ELAVL2, PTCH1, ATF4, FBXL17, and MAN2A1 in 
the left ventricle of the heart, SATB2 in liver tissue, and 
MEF2C in five tissues. Multiple interactions in multiple 
tissue types were seen for a cluster of eight genes on chro-
mosome 6 encoding zinc-finger proteins and histones.
We performed genome -wide gene- based association 
study (GWGAS) analysis using MAGMA25 to estimate 
aggregate associations on the basis of all SNPs in a gene 
(whereas FUMA annotates individually significant 
SNPs to genes). GWGAS analysis identified 507 associ-
ated genes (Fig. 3a, Supplementary Table 15, and Sup-
plementary Note), of which 350 were also mapped by 
FUMA (Fig. 3b). In total, 105 genes were implicated by 
all four strategies (Supplementary Table 16). 
In gene set analysis, six Gene Ontology26 gene sets were 
significantly associated with intelligence: neurogenesis (P 
= 4.78 × 10-7), neuron differentiation (P = 4.82 × 10-6), 
central nervous system neuron differentiation (P = 3.31 
× 10-6), regulation of nervous system development (P = 
9.30 × 10-7), positive regulation of nervous system devel-
opment (P = 1.00 × 10-6), and regulation of synapse struc-
ture or activity (P = 5.42 × 10-6) (Supplementary Tables 
17 and 18, and Supplementary Note). Conditional anal-
ysis indicated that there were three independent associa-
tions—regulation of nervous system development, central 
nervous system neuron differentiation, and regulation of 
synapse structure or activity—that together accounted for 
the associations of the other sets. 
Linking gene- based P-values to tissue -specific gene ex-
pression, we observed strong associations with gene ex-
pression across multiple brain areas (Fig. 3c, Supplemen-
Fig. 1 (previous page) | SNP-based associations with intelligence in the GWAS meta-analysis of n = 269,867 independent 
individuals. a, Manhattan plot showing the –log10  transformed two -tailed P-value of each SNP from the GWAS meta -analysis 
(of linear and logistic regression statistics) on the y axis and base- pair positions along the chromosomes on the x axis. The dotted 
red line indicates Bonferroni- corrected genome -wide significance (P < 5 × 10-8); the dotted blue line indicates the threshold 
for suggestive association (P < 1 × 10-5). Independent lead SNPs are indicated by a diamond. b, Heritability enrichment of 28 
functional annotation categories for SNPs in the meta -analysis, calculated with stratified LD Score regression. Error bars show 
95% confidence intervals around the enrichment estimates. The dashed horizontal line indicates no enrichment of the annotation 
category. Red dots represent significant Bonferroni -corrected two-tailed P-values, and beige dots represent suggestive (P < 0.05) 
values. TSS, transcription start site; CTCF, CCCTC binding factor; DHS, DNase I– hypersensitive site; TFBS, transcription factor 
binding site; DGF, DNase I digital genomic footprint. c, Distribution of the functional consequences of SNPs in genomic risk loci 
in the meta -analysis. d, Distribution of RegulomeDB scores for SNPs in genomic risk loci, with a low score indicating a higher 
likelihood of the SNP having a regulatory function (Methods). e, The minimum chromatin state across 127 tissue and cell types 
for SNPs in genomic risk loci, with lower states indicating higher accessibility and states 1–7 referring to open chromatin states 
(Methods).
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Fig. 2 | Cross-locus interactions for genomic regions associated with intelligence in 269,867 independent individuals. a–e, 
Circos plots showing genes on chromosomes 2 (a), 5 (b), 6 (c), 9 (d), and 22 (e) that were linked to genomic risk loci in the GWAS 
meta -analysis (blue regions) by eQTL mapping (green lines connecting an eQTL SNP to its associated gene) and/or chromatin 
interactions (orange lines connecting two interacting regions) and showed evidence of interaction across two independent 
genomic risk loci. Genes implicated by eQTLs are in green, by chromatin interactions are in orange, and by both eQTLs and 
chromatin interactions are in red. The outer layer shows a Manhattan plot containing the –log  transformed two- tailed P-value of 
each SNP from the GWAS meta- analysis (of linear and logistic regression statistics), with genome- wide significant SNPs colored 
according to LD patterns with the lead SNP. Circos plots for all chromosomes are provided in Supplementary Fig. 8.
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tary Table 19, and Supplementary Note), particularly 
the frontal cortex (P = 3.10 × 10-9). In brain single- cell 
expression gene set analyses, we found significant asso-
ciations of striatal medium spiny neurons (P = 2.02 × 10-
14), and hippocampal CA1 pyramidal neurons in the CA1 
hippocampal (P = 5.67 × 10-11) and cortical (P = 2.72 × 
10-9) somatosensory regions (Fig. 3d, Supplementary Ta-
ble 20, and Supplementary Note). Conditional analysis 
showed that the independent association signal in brain 
cells was driven by medium spiny neurons, neuroblasts, 
and pyramidal CA1 neurons. 
Intelligence has been associated with a wide variety of hu-
man behaviors15 and brain anatomy27. Confirming previ-
ous reports5, 6, we observed negative genetic correlations 
with attention deficit/hyperactivity disorder (ADHD; rg = 
−0.36, P = 4.58 × 10-23), depressive symptoms (rg = −0.27, 
P = 6.20 × 10-10), Alzheimer’s disease (rg = −0.27, P = 2.03 
× 10-5), and schizophrenia (rg = −0.21, P = 3.82 × 10-17) and 
positive correlations with longevity (rg = 0.43, P = 7.96 × 
10-8) and autism (rg = 0.25, P = 3.14 × 10-7), among oth-
ers (Supplementary Fig. 10 and Supplementary Table 
21). Comparison with previous GWAS28 supported these 
correlations, showing numerous shared genetic variants 
across phenotypes (Supplementary Tables 22 and 23, 
and Supplementary Note). Low enrichment (87 of 1,518 
genes, P = 0.05) was found for genes previously linked to 
intellectual disability or developmental delay, indicating 
largely distinct biological processes. However, our results 
extend previous genetic research on normal variation in 
general intelligence, as catalogued in Supplementary Ta-
bles 24 and 25. 
We used Generalized Summary- statistic -data- based 
Mendelian Randomization29 to test for potential credible 
causal associations between intelligence and genetically 
correlated traits (Supplementary Figs. 11 and 12, Sup-
plementary Table 26, and Supplementary Note). We ob-
served a strong bidirectional effect of cognitive ability on 
educational attainment (bxy = 0.549, P < 1 × 10-320) and of 
educational attainment on intelligence (bxy = 0.480, P = 
6.85 × 10-82). Such findings are consistent with previous 
studies implicating bidirectional causal effects30, 31. There 
was also a bidirectional association showing a strong pro-
tective effect of intelligence on schizophrenia (odds ratio 
(OR) = 0.50, bxy = −0.685, P = 2.02 × 10-57) and a relative-
ly smaller reverse effect (bxy = −0.214, P = 4.19 × 10-52), 
with additional evidence for pleiotropy (Supplementary 
Note). A number of previous reports support both a caus-
al link and genetic overlap between these phenotypes32, 
33. Our results also suggested that higher intelligence had 
a protective effect on ADHD (OR = 0.48, bxy = −0.734, P 
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Table 1 | Overview of the cohorts included in a GWAS meta-analysis of general intelligence.
Cohort Cohort name n Age (years) Phenotype
1 UKB 195,653 39 - 72 Verbal and mathematical reasoning
2 COGENT 35,289 8 - 96 One or more neuropsychological tests from three or more domains of cog-
nitive performance
3 RS 6,182 45 - 98 Letter–digit substitution, Stroop, verbal fluency, delayed recall
4 GENR 1,929 5 - 9 SON-R (spatial visualization and abstract reasoning subsets)
5 STR 3,215 18 Logical, verbal, spatial, and technical ability subtests
6 S4S 2,818 17 - 18 SAT test scores
7 HiQ/HRS 9,410 NAa High-IQ cases/unselected population controls
8 TEDS 3,414 12 WISC-III verbal and nonverbal reasoning; Raven’s progressive matrices
9a DTR-MADT 737 55 - 80 Verbal fluency, digit span, immediate and delayed recall tests
9b DTR-LSADT 253 73 - 94 Verbal fluency, digit span, immediate and delayed recall tests
10 IMAGES 1,343 14 WISC-IV, CANTAB factor score
11a BLTS-children 530 12 - 13 VSRT-C factor score
11b BLTS-adolescents 2,598 15 - 30 MAB-II IQ score
12 NESCOG 252 18 - 79 WAIS IQ score
13 GfG 5,084 15 - 91 ICAR verbal reasoning test
14a STSA-SATSA+GENDER 703 50 - 94 Verbal, spatial, episodic memory, and processing speed tests
14b STSA-HARMONY 448 65 - 96 Verbal, spatial, episodic memory, and processing speed tests
a The HiQ/HRS sample used a case–control design rather than a cognitive test score ascertained at a specific age; see the Methods and Supplementary Note.
= 2.57 × 10-46) and Alzheimer’s disease (OR = 0.65, bxy = 
−0.435, P = 3.59 × 10-14), but was associated with higher 
risk of autism (OR = 1.38, bxy = 0.321, P = 1.12 × 10-3). 
In the present study, we have affirmed and expanded ex-
isting knowledge of the genetics of general intelligence, 
identifying 190 new loci and 939 new associated genes 
and replicating previous associations with 15 loci and 77 
genes. The combined strategies of functional annotation 
and gene mapping using biological data resources provide 
extensive information on the likely consequences of rele-
vant genetic variants and put forward a rich set of plausi-
ble gene targets and biological mechanisms for function-
al follow- up. Gene set analyses contribute novel insight 
into underlying neurobiological pathways, confirming 
the importance of brain- expressed genes and neurodevel-
opmental processes in fluid domains of intelligence and 
pointing toward the involvement of specific cell types. 
Our results indicate overlap in the genetic processes in-
volved in both cognitive functioning and neurological 
and psychiatric traits and provide suggestive evidence 
of causal associations that may drive these correlations. 
These results are important for understanding the biolog-
ical underpinnings of cognitive functioning and contrib-
ute to understanding of related neurological and psychi-
atric disorders.
Online Methods
Methods Study cohorts 
The meta -analysis included new and previously report-
ed GWAS summary statistics from 14 cohorts: UK Bio-
bank (UKB), the Cognitive Genomics Consortium (CO-
GENT), the Rotterdam Study (RS), the Generation R 
Study (GENR), the Swedish Twin Registry (STR), Spit for 
Science (S4S), the HighIQ/Health and Retirement Study 
(HiQ/HRS), the Twins Early Development Study (TEDS), 
the Danish Twin Registry (DTR), IMAGEN, the Brisbane 
Longitudinal Twin Study (BLTS), the Netherlands Study 
of Cognition, Environment, and Genes (NESCOG), 
Genes for Good (GfG), and the Swedish Twin Studies of 
Aging (STSA). All samples were obtained from epidemi-
ological cohorts ascertained for research on a variety of 
physical and psychological outcomes. Participants ranged 
from children to older adults, with older samples being 
screened for cognitive decline to exclude the possibili-
ty of dementia affecting performance on cognitive tests. 
Different measures of intelligence were assessed in each 
cohort but were all operationalized to index a common la-
tent g factor underlying multiple dimensions of cognitive 
functioning. With the exception of HiQ/HRS, all cohorts 
extracted a single sum score, mean score, or factor score 
from a multidimensional set of cognitive performance 
tests and used this normally distributed score as the phe-
notype in a covariate- adjusted (for example, age, sex, an-
cestry principal components) GWAS using linear regres-
sion methods. For HiQ/HRS, a logistic regression GWAS 
was run with ‘case’ status reflecting whether participants 
were drawn from an extreme -sampled population of very 
high intelligence (i.e., at the upper ~0.03% of the tail of the 
normal distribution) versus an epidemiological sample of 
unselected population ‘controls’. Detailed descriptions of 
the samples, measures, genotyping, quality control, and 
analysis procedures for each cohort are provided in the 
Supplementary Note, Supplementary Table 1, and in 
the Nature Research Reporting Summary. 
Meta-analysis 
Stringent quality control measures were applied to the 
summary statistics for each GWAS cohort before combin-
ing. All files were checked for data integrity and accuracy. 
SNPs were filtered from further analysis if they met any of 
the following criteria: imputation quality (INFO/R2) score 
< 0.6, Hardy–Weinberg equilibrium P < 5 × 10-6 , study -
-specific minor allele frequency (MAF) corresponding to 
a minor allele count (MAC) < 100, and mismatch of al-
leles or allele frequency difference greater than 20% from 
the Haplotype Reference Consortium (HRC) genome 
reference panel16. Some cohorts used more stringent cri-
teria (Supplementary Note). Indels and SNPs that were 
duplicated, multiallelic, monomorphic, or ambiguous 
(A/T or C/G with MAF > 0.4) were also excluded. Visual 
inspection of the distribution of the summary statistics 
was performed, and Manhattan plots and quantile–quan-
tile plots were created for the cleaned summary statistics 
from each cohort (Supplementary Fig. 1). The SNP asso-
ciation P-values from the GWAS cohorts were subjected 
to meta-analysis with METAL34 in two phases. First, we 
performed meta-analysis on all cohorts with quantita-
tive phenotypes (all except HiQ/HRS) using a sample -
-size- weighted scheme. In the second phase, we added 
the HiQ/HRS study results to the results from the first 
phase, weighting each set of summary statistics by their 
respective non -centrality parameter (NCP). This method 
improves power when using an extreme case sampling 
design such as that in HiQ35 and provides a comparable 
metric with which to combine information from differ-
ent analytic designs while accounting for their differenc-
es in power/effective sample size. NCPs were estimated 
using the Genetic Power Calculator36, as described by 
Coleman et al.37. After combining all data, meta -analysis 
results were further filtered to exclude any variants with 
n < 50,000. We additionally included a random- effects 
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meta- analysis for each phase, as implemented in METAL, 
to evaluate potential heterogeneity in the SNP associa-
tion statistics between cohorts. The X-chromosome was 
treated separately in the meta -analysis because imputed 
genotypes were not available for the X-chromosome in 
the largest cohort (UKB), and there was little overlap be-
tween the UKB called genotypes and imputed data from 
other cohorts (n < 500). We therefore included only the 
called X-chromosome variants in UKB for these analyses 
after performing X-chromosome -specific quality control 
steps38. We conducted a series of meta- analyses on subsets 
of the full sample using the same methods as above. Age- 
group -specific meta -analyses were run in the cohorts of 
children (age < 17 years; GENR, TEDS, IMAGEN, BLTS; 
n = 9,814), young adults (age ~17–18 years; S4S, STR; n 
= 6,033), adults (age > 18 years, primarily middle -aged 
or older: UKB, RS, DTR, NESCOG, STSA; n = 204,228), 
and older adults (mean age > 60 years, RS, DTR, STSA; 
n = 8,323), excluding studies whose samples overlapped 
children/young adult and adult groups (COGENT, HiQ/
HRS, GfG; n = 49,792). To create independent discovery 
samples for use in polygenic score validation, we also 
conducted meta -analyses with a ‘leave -one out’ strategy 
in which summary statistics from four validation datasets 
were each excluded from the meta- analysis (see “Polygen-
ic scoring”). 
Cohort heritability and genetic correlation 
LD Score regression17 was used to estimate genomic in-
flation and heritability of the intelligence phenotypes in 
each of the 14 cohorts using their post- quality-control 
summary statistics and to estimate the cross -cohort ge-
netic correlations39. Pre-calculated LD scores from the 
1000 Genomes European reference population were ob-
tained online. Genetic correlations were calculated on 
HapMap 3 SNPs only. LD Score regression was also used 
on the age sub-group meta- analyses to estimate heritabili-
ty and cross- age- group genetic correlations. 
Genomic risk locus definition 
Independently associated loci from the meta -analysis 
were defined using FUMA24, an online platform for func-
tional mapping of genetic variants. We first identified 
‘independent significant SNPs’, which had a Bonferroni- 
corrected genome- wide significant two- tailed P-value (P 
< 5 × 10 ) and represented signals that were independent 
from each other at r2 < 0.6. These SNPs were further rep-
resented by ‘lead SNPs’, which are a subset of the inde-
pendent significant SNPs that are in approximate linkage 
equilibrium with each other at r2 < 0.1. We then defined 
associated ‘genomic loci’ by merging any physically over-
lapping lead SNPs (LD blocks < 250 kb apart). Borders of 
the associated genomic loci were defined by identifying 
all SNPs in LD (r2 ≥ 0.6) with one of the independent sig-
nificant SNPs in the locus, and the region containing all 
of these ‘candidate SNPs’ was considered to be a single 
independent genomic locus. All LD information was cal-
culated from UKB genotype data. 
Proxy replication with educational attainment 
We conducted GWAS of educational attainment, an out-
come with a high genetic correlation with intelligence5, 
in a non overlapping European subset of the UKB sam-
ple (n = 188,435) who did not complete the intelligence 
measure. Educational attainment was coded as maximum 
years of education completed, using the same methods 
as earlier analyses40, and GWAS was conducted using the 
same quality control and analytic procedures as described 
for the UKB intelligence phenotype (Supplementary 
Note). To test replication of the SNPs with this proxy phe-
notype, we performed a sign concordance test for all ge-
nome-wide significant SNPs from the meta- analysis using 
the two -tailed exact binomial test. For each independent 
genomic locus, we considered it to be evidence for repli-
cation if the lead SNP or another correlated SNP in the 
region was sign concordant with the corresponding SNP 
in the intelligence meta -analysis and had a two -tailed P- 
value of association with educational attainment smaller 
than 0.05/242 independent tests = 0.0002. 
Polygenic scoring
We calculated polygenic scores (PGSs) based on the SNP 
effect sizes of the leave- one- out meta- analyses, from 
which four cohorts were (separately) excluded and re-
served for score validation. These included child (GENR), 
young adult (S4S), and adult (RS) samples. We also in-
cluded the UKB- wb sample to test for validation in a very 
large (n = 53,576) cohort with the greatest phenotypic 
similarity to the largest contributor to the meta- analysis 
statistics (UKB- ts), to maximize potential predictive 
power. PGSs were calculated on the genotype data using 
LDpred21, a Bayesian PGS method that uses a prior on ef-
fect size distribution to remodel the SNP effect size and 
account for LD, and PRSice20, a PLINK41  based program 
that automates optimization of the set of SNPs included in 
the PGS based on high- resolution filtering of the GWAS 
P -value threshold. LDpred PGSs were applied to the 
called, cleaned, genotyped variants in each of the valida-
tion cohorts with UKB as the LD reference panel. PRSice 
PGSs were calculated on hard -called imputed genotypes 
using P- value thresholds from 0.0 to 0.5 in steps of 0.001. 
The explained variance (ΔR2) was derived from a linear 
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model in which the GWAS intelligence phenotype was 
regressed on each PGS while controlling for the same co-
variates as in each cohort -specific GWAS, compared to a 
linear model with GWAS covariates only. 
Stratified heritability
We partitioned SNP heritability using stratified LD sS-
core regression42 in three ways: (i) by functional annota-
tion category, (ii) by MAF in six percentile bins, and (iii) 
by chromosome. Annotations for 28 binary categories of 
putative functional genomic characteristics (for example, 
coding or regulatory regions) were obtained from the LD 
score website. With this method, enrichment/depletion of 
heritability in each category is calculated as the propor-
tion of heritability attributable to SNPs in the specified 
category divided by the proportion of total SNPs annotat-
ed to that category. The Bonferroni-corrected significance 
threshold was 0.05/56 annotations = 0.0009. 
Functional annotation of SNPs 
Functional annotation of SNPs implicated in the meta -
-analysis was performed using FUMA24. We selected all 
candidate SNPs in associated genomic loci having r ≥0.6 
with one of the independent significant SNPs, a sugges-
tive P-value (P < 1 × 10-5), and MAF > 0.0001 for annota-
tions. Predicted functional consequences for these SNPs 
were obtained by matching SNPs’ chromosome, base- pair 
position, and reference and alternate alleles to databas-
es containing known functional annotations, including 
ANNOVAR43 categories, combined annotation dependent 
depletion (CADD) scores23, RegulomeDB44 (RDB) scores, 
and chromatin states45, 46. ANNOVAR categories identify 
the SNP’s genic position (for example, intron, exon, inter-
genic) and associated function. CADD scores predict how 
deleterious the effect of a SNP is likely to be for protein 
structure/function, with higher scores referring to higher 
deleteriousness. A CADD score above 12.37 is the thresh-
old to be potentially pathogenic23. The RegulomeDB score 
is a categorical score based on information from eQTLs 
and chromatin marks, ranging from 1a to 7, with low-
er scores indicating an increased likelihood of having a 
regulatory function. Scores are as follows: 1a, eQTL + 
transcription factor (TF) binding + matched TF motif + 
matched DNase footprint + DNase peak; 1b, eQTL + TF 
binding + any motif + DNase footprint + DNase peak; 1c, 
eQTL + TF binding + matched TF motif + DNase peak; 
1d, eQTL + TF binding + any motif + DNase peak; 1e, 
eQTL + TF binding + matched TF motif; 1f, eQTL + TF 
binding/DNase peak; 2a, TF binding + matched TF motif 
+ matched DNase footprint + DNase peak; 2b, TF bind-
ing + any motif + DNase footprint + DNase peak; 2c, TF 
binding + matched TF motif + DNase peak; 3a, TF bind-
ing + any motif + DNase peak; 3b, TF binding + matched 
TF motif; 4, TF binding + DNase peak; 5, TF binding 
or DNase peak; 6, other; 7, not available. The chroma-
tin state represents the accessibility of genomic regions 
(every 200 bp) with 15 categorical states predicted by a 
hidden Markov model based on 5 chromatin marks for 
127 epigenomes in the Roadmap Epigenomics Project46. 
A lower state indicates higher accessibility, with states 
1–7 referring to open chromatin states. We annotated the 
minimum chromatin state across tissues to SNPs. The 15 
core chromatin states as suggested by Roadmap are as fol-
lows: 1, active transcription start site (TSS); 2, flanking 
active TSS; 3, transcription at gene 5' and 3' ends; 4, strong 
transcription; 5, weak transcription; 6, genic enhancer; 7, 
enhancers; 8, zinc- finger gene and repeats; 9, heteroch-
romatic; 10, bivalent/poised TSS; 11, flanking bivalent/
poised TSS/enhancer; 12, = bivalent enhancer; 13, re-
pressed Polycomb; 14, weak repressed Polycomb; 15, qui-
escent/low. Standardized SNP effect sizes were calculated 
for the SNPs with the greatest impact by transforming the 
sample size- weighted meta -analysis z score, as described 
by Zhu et al.47. 
Gene mapping 
Genome- wide significant loci obtained by the GWAS 
meta- analysis were mapped
to genes in FUMA24 using three strategies:
1. Positional mapping maps SNPs to genes based on 
physical distance (within a 10 kb window) from 
known protein -coding genes in the human reference 
assembly (GRCh37/hg19)
2. eQTL mapping maps SNPs to genes with which they 
show a significant eQTL association (i.e., allelic vari-
ation at the SNP is associated with the expression 
level of that gene). eQTL mapping uses information 
from 45 tissue types in 3 data repositories (GTEx48, 
Blood eQTL browser49, BIOS QTL browser50) and is 
based on cis eQTLs that can map SNPs to genes up to 
1 Mb away. We used a false discovery rate (FDR) of 
0.05 to define significant eQTL associations
3. Chromatin interaction mapping was performed to 
map SNPs to genes when there was a 3D DNA–DNA 
interaction between the SNP region and a gene re-
gion. Chromatin interaction mapping can involve 
long- range interactions, as it does not have a dis-
tance boundary. FUMA currently contains Hi C data 
for 14 tissue types from the study of Schmitt et al.51. 
Because chromatin interactions are often defined in 
a certain resolution, such as 40 kb, an interacting 
region can span multiple genes. If a SNP is located 
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in a region that interacts with a region containing 
multiple genes, it will be mapped to each of those 
genes. To further prioritize candidate genes, we se-
lected only interaction -mapped genes in which one 
region involved in the interaction overlapped with a 
predicted enhancer region in any of the 111 tissue/
cell types from the Roadmap Epigenomics project46 
and the other region was located in a gene promoter 
region (from 250 bp upstream to 500 bp downstream 
of the TSS and also predicted by Roadmap to be a 
promoter region). This reduced the number of genes 
mapped but increased the likelihood that those iden-
tified would have a plausible biological function. We 
used an FDR of 1 × 10-5 to define significant interac-
tions, based on previous recommendations51 modi-
fied to account for the differences in cell lines used 
here. Functional annotation of mapped genes Genes 
implicated by mapping of significant GWAS SNPs 
were further investigated using the GENE2FUNC 
procedure in FUMA24, which provides hypergeomet-
ric tests of enrichment of the list of mapped genes in 
53 GTEx48 tissue -specific gene expression sets, 7,246 
MSigDB gene sets52, and 2,195 GWAS catalog gene 
sets28. The Bonferroni corrected significance thresh-
old was 0.05/9,494 gene sets = 5.27 × 10-6. Gene-
based analysis
SNP- based P-values from the meta -analysis were used 
as input for GWGAS. 18,128 protein -coding genes (each 
containing at least 1 GWAS SNP) from the NCBI 37.3 
gene definitions were used as the basis for GWGAS in 
MAGMA25. The Bonferroni -corrected genome -wide sig-
nificance threshold was 0.05/18,128 genes = 2.76 × 10-6 . 
Gene set analysis
Results from the GWGAS analyses were used to test for 
association in three types of predefined gene sets: 
1. 7,246 curated gene sets representing known biologi-
cal and metabolic pathways were derived from 9 data 
resources, catalogued by and obtained from MSigDB 
version 5.229; 
2. Gene expression values from 53 tissues obtained 
from GTEx48, log transformed with pseudo-count 1 
after Winsorization at 50 and averaged per tissue; 
3. Cell -type- specific gene expression in 24 types of 
brain cells, which were calculated following the 
method described in Skene et al.53 and Coleman et 
al.37. Briefly, brain- cell type expression data were 
drawn from single-cell RNA seq data from mouse 
brains. For each gene, the value for each cell type 
was calculated by dividing the mean unique molec-
ular identifier (UMI) counts for the given cell type 
by the summed mean UMI counts across all cell 
types. Single -cell gene sets were derived by grouping 
genes into 40 equal bins by specificity of expression. 
These gene sets were tested for association with the GW-
GAS gene- based test statistics using MAGMA. We com-
puted competitive P-values, which represent the test of 
association for a specific gene set in comparison to oth-
er gene sets. This method is more robust to type I error 
than self -contained tests that only test for association of 
a gene set against the null hypothesis of no association25. 
The Bonferroni -corrected significance threshold was 
0.05/7,323 gene sets = 6.83 × 10-6 . Conditional analyses 
were performed as a follow- up using MAGMA to test 
whether each significant association observed was inde-
pendent of all others. The association between each gene 
set was tested conditional on the most strongly associated 
set, and then—if any substantial (P < 0.05/number of gene 
sets) associations remained—by conditioning on the first 
and second most strongly associated set, and so on until 
no associations remained. Gene sets that retained their 
association after correcting for other sets were considered 
to be independent signals. We note that this is not a test of 
association per se, but rather a strategy to identify, among 
gene sets with known significant associations whose de-
fining genes may overlap, which set(s) are responsible for 
driving the observed association. 
Cross-trait genetic correlation 
Genetic correlations (rg) between intelligence and 38 phe-
notypes were computed using LD Score regression39, as 
described above, based on GWAS summary statistics ob-
tained from publicly available databases   (Supplemen-
tary Table 18). The Bonferroni -corrected significance 
threshold was 0.05/38 traits = 1.32 × 10-3. 
GWAS catalog lookup 
We used FUMA to identify SNPs with previously report-
ed (P < 5 × 10-5) phenotypic associations in published 
GWAS listed in the NHGRI EBI catalog28 that overlapped 
with the genomic risk loci identified in the meta-analy-
sis. As an additional relevant phenotype of interest, we 
examined whether the genes associated with intelligence 
in this study (by FUMA mapping or GWGAS) were over-
represented in a set of 1,518 genes linked to intellectu-
al disability and/or developmental delay, as compiled by 
Region-Annotater. Many of these have been identified 
by non- GWAS sources and are not represented in the 
NHGRI catalog. We tested for enrichment using a hyper-
geometric test with a background set of 19,283 genomic 
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protein -coding genes, as in FUMA. Manual lookups were 
also performed to identify overlapping loci/genes with 
known previous GWAS of intelligence. 
Mendelian randomization 
To infer credible causal associations between intelligence 
and traits that are genetically correlated with intelli-
gence, we performed Generalized Summary-data- based 
Mendelian Randomization29 (GSMR). This method uses 
summary- level data to test for causal associations be-
tween a putative risk factor (exposure) and an outcome 
by using independent genome- wide significant SNPs as 
instrumental variables. HEIDI outlier detection was used 
to filter genetic instruments that showed clear pleiotro-
pic effects on both the exposure phenotype and the out-
come phenotype. We used a threshold P-value of 0.01 for 
the outlier detection analysis in HEIDI, which removes 
1% of SNPs by chance if there is no pleiotropic effect. To 
test for a potential causal effect of intelligence on various 
outcomes, we selected traits in non overlapping samples 
that showed significant genetic correlations (rg) with in-
telligence. We tested for bidirectional causation by re-
peating the analyses while switching the role of each 
correlated phenotype as an exposure and intelligence as 
the outcome. For each trait, we selected independent (rg ≤ 
0.1), genome -wide significant lead SNPs as instrumental 
variables in the analyses. For traits with fewer than ten 
genome-wide significant lead SNPs (i.e., the minimum 
number of SNPs on which GSMR can perform a reliable 
analysis), the genome- wide significance threshold was 
lowered to 1 × 10-5 , allowing a sufficient number of SNPs 
to conduct the reverse GSMR analysis for former smoker 
status, autism, and intracranial volume, and ADHD. The 
method estimates a putative causal effect of the exposure 
on the outcome (bxy) as a function of the relationship 
between the SNPs’ effects on the exposure (bzx) and the 
SNPs’ effects on the outcome (bzy), given the assumption 
that the effect of non -pleiotropic SNPs on an exposure (x) 
should be related to their effect on the outcome (y) in an 
independent sample only via mediation through the phe-
notypic causal pathway (bxy). The estimated causal effect 
coefficients (bxy) are approximately equal to the natural 
log odds ratio (OR) for a case–control trait29. An OR of 
2 can be interpreted as a doubled risk in comparison to 
the population prevalence of a binary trait for every s.d. 
increase in the exposure trait. For quantitative traits, bxy 
can be interpreted as a 1 s.d. increase explained in the 
outcome trait for every s.d. increase in the exposure trait. 
This method can help differentiate the likely causal direc-
tion of association between two traits but cannot make 
any statement about the intermediate mechanisms in-
volved in any potential causal process.
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Supplementary information
Supplementary Fig. 1 | Manhattan and QQ plots of the individual cohort GWAS results included in a meta-analysis 
of intelligence in 269,867 independent individuals. For each of 14 cohorts included in the GWAS meta-analysis, –log10 
transformed two-tailed P-values of SNP associations with intelligence measures in a linear or logistic regression model are 
presented against their chromosomal position in a Manhattan plot (left) and against expected null P -values in a QQ plot (right). 
Sample sizes and details of the statistical analyses for each cohort are presented in Supplementary Information 1.1. The dotted 
red line indicates Bonferroni-corrected genome-wide significance (P < 5 × 10-8), the blue line the threshold for suggestive 
associations (P<1×10-5).
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Supplementary Fig. 2 | Flowchart of study methodology and results of a GWAS meta-analysis of intelligence in 269,867 
independent individuals. White boxes indicate study cohorts, grey boxes indicate assessment measures, blue boxes indicate 
groups of analytic procedures, orange boxes indicate sub-analyses, green boxes indicate results. GWAS = genome-wide 
association; LDSC = linkage disequilibrium (LD) score regression; FUMA = functional mapping and annotation; GWGAS = 
genome-wide gene-based association; SNP = single nucleotide polymorphism; EA = educational attainment; ExNS = exonic non-
synonymous; eQTL = expression quantitative trait locus.
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Supplementary Fig. 3 | QQ-plots of SNP and gene association results in a meta-analysis of intelligence in 269,867 
independent individuals. Observed –log10 transformed two-tailed P-values of associations with intelligence measures are plotted 
against expected null P -values for a) all SNPs in the GWAS meta-analysis, and b) all genes in the gene-based meta-analysis. 
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Supplementary Fig. 6 | Heritability of intelligence in a GWAS meta-analysis of 269,867 independent individuals, stratified 
by minor allele frequency (MAF) bins. Tests of enrichment/depletion of SNP heritability within a bin relative to the proportion 
of SNPs in the bin were conducted with LD score regression. Two-tailed P-values are presented above the bins; red bins are 
significant after Bonferroni correction for 56 total strata. Horizontal line (=1.0) indicates no enrichment.
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Supplementary Fig. 7 | Heritability of intelligence in a GWAS meta-analysis of 269,867 independent individuals, stratified by 
chromosome. Tests of enrichment/depletion of SNP heritability within a chromosome relative to the proportion of SNPs on the 
chromosome were conducted with LD score regression. The chromosome size (proportion of total SNPs) is on the x-axis and the 
proportion of total heritability (h2) attributable to each chromosome is on the y-axis. The X-chromosome was not available in the 
reference panel for LD scores. Chromosomes are colored by two-tailed P-values; none were significant after Bonferroni correction 
for 56 total strata. Diagonal line indicates no enrichment.
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Supplementary Fig. 9 | Tissue enrichment for differential gene expression in genes associated with intelligence in a GWAS 
meta-analysis of 269,867 independent individuals. Hypergeometric tests of enrichment were conducted for 53 GTEx tissue 
types for 872 genes implicated by positional, eQTL, or chromatin interaction mapping of GWS SNPs in LD (r2 >= 0.6) with one 
of the independent GWS SNPs. Enrichment difference are shown for higher (Upregulated), lower (Downregulated), or two-sided 
differences in gene expression. The tests do not include genes implicated only by GWGAS. Two-tailed P-values are presented; 
categories in blue are significant after Bonferroni correction for 9,494 total gene-sets.
Supplementary Fig. 10 | Genetic correlations between intelligence and other traits previously investigated with GWAS. 
Correlations were calculated with LD score regression using SNP summary statistics from the GWAS meta-analysis of intelligence 
in 269,867 individuals and publically available summary statistics for other traits (Supplementary Table 21). Point estimates 
for correlations and 95% confidence intervals are shown; black dots indicate significant two-tailed P-values after Bonferroni 
correction for 38 pairs of traits.
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Supplementary Fig. 11 | Mendelian Randomization tests for the effect of intelligence on other correlated traits. Plots of effect 
sizes of independent lead SNPs from a GWAS meta-analysis of intelligence in 269,867 independent individuals (bzx) on the x-axis 
and SNP GWAS effect sizes for correlated traits on the y-axis (bzx). The dotted line represents a line with slope of (bxy) and an 
intercept of 0. Error bars show 95% confidence intervals for the effect sizes for each trait.
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Supplementary Fig. 12 | Mendelian Randomization reverse tests for the effect of other correlated traits on intelligence. Plots 
of effect sizes of independent lead SNPs from a GWAS meta-analysis of intelligence in 269,867 independent individuals (bzy) on 
the y-axis and SNP GWAS effect sizes for correlated traits on the x-axis (bzx). The dotted line represents a line with slope of (bxy) 
and an intercept of 0. Error bars show 95% confidence intervals for the effect sizes for each trait.
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Brain Imaging and Genetics
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Incidental Findings on Brain Imaging in the General Pediatric Population.
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Introduction
Incidental findings discovered on brain magnetic res-onance imaging (MRI) in otherwise healthy individu-als pose important medical and ethical considerations 
regarding the management of these findings1-4. It has been 
estimated that incidental findings requiring medical fol-
low-up are found in approximately three percent of the 
adult population5. However, the current literature on in-
cidental findings in children is limited, as most large-scale 
studies to date focus exclusively on adults. Although the 
prior probability of finding asymptomatic abnormalities 
is expected to be substantially lower in children compared 
to adults, the discovery of unfavorable anomalies at ear-
ly age may subsequently lead to life-long and potentially 
preventable health consequences, and generate substan-
tial levels of distress for the children and their parents6,7. 
Thus, obtaining more precise information on the frequen-
cy of brain incidental findings in children is important for 
well-informed medical decision making and tailoring 
adequate management protocols. Moreover, accurate in-
formation about the probability of finding clinically im-
portant abnormalities is necessary for informing families 
before participation in imaging studies, and to provide 
consistent information when incidental findings are dis-
closed. 
Available data from brain MRI studies in children report 
varying prevalence rates between 0.3 to 4.4 percent of 
intracranial findings on MRI scans that require clinical 
follow-up8-12. Large variation in these estimates is due to 
a combination of differences in the applied threshold of 
considering findings as ‘clinically relevant’, the relatively 
small sample size of most studies that often cover a wide 
age range, the careful selection of healthy participants as 
controls for scientific research, and the image resolution 
of the collected data. 
Here we report the prevalence of incidental findings on 
brain MRI in children from an unselected sample of the 
general population. For this purpose, we used a large 
population-based imaging study of nearly 4,000 nine-to-
twelve year-old children who underwent brain MRI scan-
ning. Such findings are expected to become increasingly 
important, as the utilization of MRI in children for both 
clinical and scientific purposes is expected to continue to 
expand in the coming years and the neuroimaging field 
moves into the era of ‘big data’13,14. 
Methods
Population
The participants involved nine to twelve year old children 
from the Generation R Study, a large prospective pop-
ulation-based cohort investigating the development of 
children15. MRI scanning was performed between April 
2013 and November 2015, and participants were invited 
when they were approximately 10 years of age. The exclu-
sion criteria for the MRI study only included contraindi-
cations for MRI and claustrophobia. Children who fully 
completed the T1-weighted sequence were included in 
the current analyses. Informed consent for participation 
in the imaging study was obtained from the legally autho-
rized representative of all study participants.
Brain Imaging Protocol
MRI scanning was preceded by a mock scan that simu-
lated a real MRI scanner, allowing children to become 
accustomed to the scanning environment16. Study par-
ticipants were scanned on a single wide-bore 3 Tesla 
Background: While the prevalence of incidental findings on brain magnetic resonance imaging (MRI) is well 
described in adult populations, not much is known about these findings in children. Here, we describe the preva-
lence of incidental findings on brain MRI in the general pediatric population. 
Methods: Between April 2013 and November 2015, nine-to-twelve year-old children of the Generation R Study 
underwent MRI scanning of the brain. Scans were systematically reviewed for the presence of incidental findings, 
and prevalence estimates were derived. Cases were referred to the hospital when clinical follow-up or treatment 
was deemed necessary. 
Results: A total of 3966 participants (mean age: 10.1 years, range: 8.6 - 11.9) underwent high resolution MRI and 
were evaluated for incidental findings. Incidental findings were observed in 1,015 children (25.6%). The most 
common findings were cysts of the pineal gland (diameter <1cm: 16.4%; >1 cm: 0.33%), arachnoid cysts (2.16%) 
and developmental venous anomalies (1.59%). A total of 17 children (0.43%) were referred to a pediatric neurol-
ogist for clinical imaging and followup, where indicated. Seven of these children (0.18%) had suspected primary 
brain tumors, of whom two children (0.05%) underwent surgical intervention.
Conclusions: Incidental findings requiring clinical referral were present in 1 out of 233 children, of whom approx-
imately 1 in 3 cases involved suspected primary brain tumors. These results indicate that clinically relevant find-
ings are present in the non-clinical, general population, and adequate managment protocols should be developed 
by researchers and clinicans that collect neuroimaging data in children. 
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MR750W Discovery scanner (GE, Milwaukee, Wiscon-
sin). For the current study, incidental findings evaluation 
was performed using three of the collected sequences. 
First, a high-resolution 3D T1-weighted sequence was 
obtained using a coronal inversion recovery fast spoiled 
gradient recalled (IR-FSPGR, BRAVO) sequence (scan 
parameters: TR=8.77ms, TE=3.4ms, TI=600ms, flip 
angle=10°, field of view=220x220mm, acquisition ma-
trix=220x220, slice thickness=1mm, number of slic-
es=230, acceleration factor=2). A small number of scans 
were acquired with slightly different parameters due 
to small adjustments in the protocol: (n = 20 children, 
TR=7.82ms, TE=2.13ms, TI=600ms, flip angle=10°, field 
of view=220x220mm, acquisition matrix=220x220, slice 
thickness=1mm, number of slices=226, acceleration fac-
tor=3). Next, a structural 3D T2-weighted image was 
collected using a sagittal fast spin echo sequence (3D 
CUBE T2, TR=1440ms, TE=130ms, flip angle=90°, field 
of view=256x256mm, acquisition matrix=256x256, slice 
thickness = 1mm, number of slices =176, acceleration 
factor=3). In addition, a resting-state fMRI sequence (rs-
FMRI) was collected using echo-planar imaging (EPI), 
with the following parameters: TR=2000ms, TI=350, 
TE=30ms, flip angle=85°, acquisition matrix=230x230, 
slice thickness=4mm. 
Ratings of incidental findings on MRI
Brain images were reviewed for incidental findings by 
a group of researchers (PJ, KB, RM, DK, TJ) who were 
trained in evaluating scans by an experienced neurora-
diologist (AvdL). Before rating MRI scans, raters had be-
come experienced by rating a training set consisting of 
a large dataset of scans containing confirmed incidental 
findings. The rating protocol was designed to systemat-
ically evaluate brain scans and raters were instructed to 
report any finding that was seen on the scan. Imaging 
findings of potential clinical relevance, defined as imag-
ing findings that could potentially lead to negative health 
consequences for the participant, were subjected to ad-
ditional evaluation by a radiologist. First, the structural 
T1-weighted scan was reviewed in the coronal, sagittal 
and axial planes. Next, the T2-weighted image was as-
sessed for findings not detected on the T1 scans. Finally, 
the first volume of the echo-gradient functional MRI se-
quence was evaluated. Evaluation of the MRI scans was 
performed using Synedra View Personal DICOM viewer, 
version 16.0.0  (Munich, Germany). No clinical informa-
tion about the study participants was available to the rat-
ers at the time of assessment. 
Clinical management
The protocol regarding the management of incidental 
findings was decided upon before initiation of the MRI 
study. In those cases where a potentially clinically relevant 
finding was found, the scans were reviewed by a neurora-
diologist (AvdL, AvdB, MD) and discussed with a pedi-
atric neurologist when necessary (MW). Subsequently, 
a multidisciplinary case-consensus decision was made 
whether clinical follow-up was indicated based on expert 
opinion. 
Statistical Analyses
Baseline characteristics of the study population are ex-
pressed as mean (s.d.), range, or as a percentage. Preva-
lence rates were calculated with 95% confidence intervals 
(CI) to indicate the precision of the estimate, based on 
the total number of children that had completed the T1-
weighed sequence. 
All statistical analyses were performed using the R statis-
tical software package, version 3.3.117. 
Results
Sample characteristics
In total, 3,992 children participated in the brain imaging 
study of the Generation R cohort. Of these participants, 
3966 (99.3%) had fully completed the T1-weighted se-
quence and were included in the current analyses. Sample 
characteristics of the study population are shown in Ta-
ble 1. Participants were on average 10.12 years old (range: 
8.55 – 11.99), and the sample consisted of an approxi-
mately equal distribution of gender (49,5% boys). 
Overall & Clinical referral rates
A complete overview of the observed prevalence of the 
incidental findings is shown in Table 2. Of the total num-
ber of reviewed MRI scans, the vast majority (n = 2,951, 
74.4%, 95% CI [73.0, 75.8]) did not show any intracrani-
al incidental findings. In 1,015 children (25.6%, 95% CI 
[24.3, 27.0]) at least one incidental finding was found. In 
75 participants (1.9%, 95% CI [1.5, 2.4]), two incidental 
findings were found, and two participants (0.05%, 95% 
CI [0.01, 0.20]) had three coexisting findings. Of the total 
sample, 17 children (0.43%, 95% CI [0.26, 0.70]), i.e. ap-
proximately 1 out of 233 children, were referred for clin-
ical follow-up as a direct consequence of participation in 
the MRI study. All referred cases were discussed in mul-
tidisciplinary meetings, and clinical work-up often in-
cluded neurological examination and an additional con-
trast-enhanced MRI scan (CE-MRI). One case showed 
imaging findings suspicious for central skull base fibrous 
dysplasia and was referred for clinical follow-up, includ-
126 | CHAPTER 6 
ing additional CT-scanning, evaluation of the neuro-en-
docrine axis and genetic testing. None of the referred 
participants showed neurological symptoms at the time 
of clinical follow-up 
Common incidental findings
Among the most common intracranial findings were pi-
neal gland cysts (n = 665, 16.8%, 95% CI [15.6, 18.0]). The 
majority of the pineal gland cysts were smaller than 1 cen-
timeter in diameter (n = 652, 16.4%, 95% CI [15.3, 17.6]), 
while only a small number (n = 13, 0.33%, 95% CI [0.18, 
0.58]) was larger than 1 centimeter (largest diameter: 1.5 
centimeter). Only one cyst had a solid component and 
was referred for subsequent CE-MR imaging, which did 
not show contrast enhancement. Arachnoid cysts were 
most often located in the middle cranial fossa and in the 
retro-cerebellar region and were referred for further clin-
ical assessment in two cases (0.05%, 95% CI [0.01, 0.20]), 
as these exhibited a very large cyst with marked shifting of 
surrounding structures (Figure 1A).
Less common findings
Less frequent findings included a Chiari I malformation 
(n = 25, 0.63%, 95% CI [0.42, 0.94]), defined as tonsil-
lar ectopia more than 5 millimeters below the foramen 
magnum18. One case with a large tonsillar herniation 
was referred for neurological evaluation (Figure 1B). An 
additional MRI scan in this subject did not reveal syrinx 
formation in the spinal cord, which commonly co-occurs 
with this abnormality. 
Focal white matter damage, showing image characteristics 
that were most likely to be related to perinatal injury, was 
considered to be present in 7 participants (n = 7, 0.18%, 
95% CI [0.08, 0.38]). One case was identified with lesions 
suggestive of demyelinating disease, classified as a Radio-
logically Isolated Syndrome19. Other infrequent findings 
were migration disorders (Figure 1A), including cortical 
dysplasia (n = 1, 0.03%, 95% CI [0.01, 0.16]) and subep-
endymal heterotopia (n=19, 0.48%, 95% CI [0.30, 0.76]), 
partial agenesis of the corpus callosum (n = 2, 0.05%, 95% 
CI [0.01, 0.20]) (Figure 1C), and partial agenesis of the 
septum pellucidum (n = 3, 0.08%, 95% CI [0.02, 0.24]),
Incidental neoplasms
Incidental brain tumors were observed in 7 participants 
(0.18%, 95% CI [0.08, 0.38]) (Figure 2A-D). In two cas-
es, after a detailed clinical assessment and CE-MRI, di-
rect neurosurgical intervention was warranted due to 
the location, signal characteristics and mass effect on the 
surrounding structures. In the first case, a large heteroge-
neous lobulated mass was located near the temporal horn 
of the lateral ventricle that was histopathologically prov-
en to be an ependymoma (WHO Grade II) (Figure 2A). 
In the second case, a tumor was found in the suprasellar 
region, which was later classified by histopathological ex-
amination as a craniopharyngeoma (WHO Grade I) (Fig-
ure 2B).  In the other five cases, no surgical interventions 
were performed and the patients are followed up with 
Table 1 | Sample characteristics of the study population.
Characteristic Total sample (n = 3,966)
Child
Age of MRI (mean, range) 10.1 (8.6 – 11.9)
Gender (N boys, %) 1,963 (49.5)
Ethnicity
Dutch ( %) 61.7
Other Western (N, %) 8.5
Non-Western (N, %) 29.8
Gestational age (weeks) (mean, sd) 39.8 (1.9)
Child IQ (mean, sd) 102.5 (14.9)
Mother
Maternal age at delivery (mean, range) 31.1 (15.3 – 46.3)
Maternal education
Low (%) 5.8
Middle (%) 33.8
High (%) 60.4
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additional CE-MRI scans. Clinical follow-up period in 
these children ranged between 1.96 to 3.12 years. Of the 
five children who did not undergo surgical intervention, 
one child with a presumed dysembryoplastic neuroepi-
thelial tumor (DNET) developed epileptic symptoms that 
were adequately controlled by pharmacological treatment 
(Figure 2D). None of the tumors in these five children 
showed signs of growth, and no subsequent surgical treat-
ment was performed until the last follow-up. 
Discussion
We reported the prevalence of incidental findings in the 
largest single-site brain imaging study of the general pe-
diatric population to date. Our results showed a relative-
ly high prevalence of a variety of common findings in 
approximately 1 out of 4 (25.6%) children, although the 
prevalence of findings requiring clinical follow-up was 
much lower at 1 in 233 (0.43%) children. 
The low prevalence of intracranial findings requiring clin-
ical work-up of 0.43 percent is in line with previous stud-
ies in children (overview of previous studies in Table 3), 
although the present rates are relatively lower than those 
previously published. Reported referral rates range be-
tween 0.48 and 0.90 percent in samples from the general 
population11,12, and between 0.3 and 3.2 percent in clin-
ical studies9,10,20. Out of 3,966 included children, 17 par-
ticipants had findings that after careful multidisciplinary 
evaluation were considered potentially clinically relevant. 
From the referred cases, subsequent clinical management 
in 15 children included additional radiological imaging, 
Table 2 | Overview of incidental findings in the study population (n=3,966).
Category Finding N cases Prevalence (%) [95%CI]
Clinical 
referral Clinical Management
Normal variations Cavum septum pellucidum 79 1.99 [1.59, 2.49] none -
Mega cisterna magna 104 2.62 [2.16, 3.18] none -
Empty sella configuration 7 0.18 [0.08, 0.38] none -
Congenital 
malformations
Chiari I malformation 25 0.63 [0.42, 0.94] n=1 MRI follow-up
Partial agenesis corpus callosum 2 0.05 [0.01, 0.20] n=2 Neurological examination
Septum pellucidum agenesis 3 0.08 [0.02, 0.24] none -
Ventriculomegaly 2 0.05 [0.01, 0.20] n=1 MRI follow-up
Cysts Arachnoid cyst 86 2.17 [1.75, 2.68] -
< 3 cm 75 1.89 [1.50, 2.38] none -
> 3 cm 11 0.28 [0.15, 0.51] n=2 MRI follow-up
Pineal gland cyst 665 16.8 [15.6, 18.0]
< 1 cm 652 16.4 [15.3, 17.6] none -
> 1 cm 13 0.33 [0.18, 0.58] N=1 CE-MRI, lumbar puncture
Porencephalic cyst 3 0.08 [0.02, 0.24] none -
Intraventricular cysts 7 0.18 [0.08, 0.38] N=1 MRI follow-up
Vascular anomalies Developmental venous anomaly 63 1.59 [0.12, 2.04] none -
Cavernous angioma 7 0.18 [0.08 0.38] none -
Capillary teleangiectasia 2 0.05 [0.01, 0.20] none -
Migration disorders Supependymal gray matter heterotopia 19 0.48 [0.30, 0.76] none -
Transmantle dysplasia 1 0.03 [0.01, 0.16] none -
Focal cortical dysplasia 1 0.03 [0.01, 0.16] none -
White-matter 
abnormalities
Focal white matter hyperintensity 7 0.18 [0.08, 0.38] none -
Radiological Isolated Syndrome 1 0.03 [0.01, 0.16] n=1 CE-MRI
Neoplasms Low-grade gliomaa 4 0.10 [0.03, 0.28] n=4 CE-MRI
DNETa 1 0.03 [0.01, 0.16] n=1 CE-MRI
Ependymomab 1 0.03 [0.01, 0.16] n=1 CE-MRI, neurosurgery
Craniopharyngeomab 1 0.03 [0.01, 0.16] n=1 CE-MRI, neurosurgery
Other Fibrous Dysplasia 1 0.03 [0.01, 0.16] n=1 CT
 a = radiological diagnosis, b = confirmed by histopathology, CE-MRI = contrast-enhanced MRI
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Fig. 1 | Incidental findings observed in the study population. A) Large arachnoid cyst of the temporal lobe with mass-effect on 
the basal ganglia of the left hemisphere; B) Cascading tonsillar tissue herniating through the foramen magnum, Chiari I mal-
formation; C) Isolated abnormal gyral patterning and cortical thickening extending towards the lateral ventricle, focal cortical 
dysplasia; D) Partial corpus callosum agenesis with only remnant rostral and genu.
mainly consisting of additional (contrast enhanced) MRI 
scanning. In the other two cases, subsequent neurolog-
ical examination was considered sufficient and no fur-
ther clinical follow-up was indicated. Two main factors 
may contribute to a low prevalence of clinically relevant 
findings in our sample. First, our study population con-
sisted entirely of individuals from an unselected popu-
lation-based sample with a correspondingly low likeli-
hood of carrying asymptomatic abnormalities of clinical 
importance. Second, considering that our study sample 
consisted of children from a non-clinical study sample, 
we maintained a high threshold for referring participants 
for clinical follow-up on a case consensus basis, given the 
higher probability of false positive findings leading to un-
necessary distress for children and their parents21.
Importantly, we observed an unexpected high number 
of brain tumor cases in our study cohort. Our popula-
tion-based sample included two children (0.05%) with 
an asymptomatic histologically confirmed primary brain 
tumor, whereas five other children showed imaging find-
ings consistent with the radiological diagnosis of a pri-
mary brain tumor (0.13%). These numbers are higher 
than the prevalence estimated from cancer registries of 
symptomatic primary brain tumors that have reported a 
prevalence of approximately 3 in 10,000 (0.003%) in the 
US for individuals below 19 years of age22. However, in the 
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current pediatric literature no reliable statistics are avail-
able of asymptomatic brain tumors in children13. The rel-
atively high rate of asymptomatic primary brain tumors 
suggests that these are possibly more common in children 
than estimated from clinical cases, but can stay asymp-
tomatic for a longer period of time. Longitudinal studies 
are necessary to provide the course of asymptomatic tu-
mors in these individuals, as these results would aid in the 
decision whether or not these lesions should be treated. 
Absence of clinical symptoms or tumor growth during 
follow-up in the cases in our sample supports a watch-
ful-waiting policy over immediate surgical treatment of 
asymptomatic low-grade gliomas23,24. In contrast, several 
findings were not observed that may have been expected 
given their prevalence and our large sample size, such as 
arteriovenous malformations25, pituitary adenomas26, and 
vascular aneurysms27. 
There is an increasing need for standardized protocols for 
incidental findings management in children, including 
standardized reporting, disclosure to parents and subse-
quent follow-up when deemed necessary28,29. Considering 
the fact that we found serious incidental abnormalities, in-
cluding primary brain tumors, that could have detrimen-
tal consequences if not referred timely, we recommend 
Fig. 2 | Incidental brain tumors. A) Mixed cystic and solid heterogeneous mass in the temporal horn of the lateral ventricle, 
histologically proven ependymoma (WHO Grade II); B) Suprasellar lesion, with calcifications and cystic components with T1 
shortening corresponding to proteinaceous contents, craniopharyngeoma; C) Focal well defined small hypo-intense lesion in the 
globus pallidus, suspected low-grade glioma; D) Well-defined, cortically based lesion with typical lobulated internal architecture, 
dysembryoplastic neuroepithelial tumour (DNET).
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the development of systematic image evaluation protocols 
in close collaboration with radiologists and neurologists. 
The responsibility of creating the protocols and necessary 
infrastructure for the detection and follow-up of inciden-
tal findings should be carried out carefully by researchers 
before neuroimaging studies in children are initiated30. 
The current study has several strengths. Our study popu-
lation comprised a community-based sample that reflects 
the healthy pediatric population at large. Moreover, the 
current study has an adequate sample size for estimat-
ing the prevalence of frequent, as well as less frequent-
ly observed incidental findings. There are also several 
limitations. Primary evaluation of the images were per-
formed by trained researchers rather than neuroradiolo-
gists, which could potentially lead to underreporting of 
subtle abnormalities. In addition, the MRI protocol was 
optimized for scientific research related to brain develop-
ment. Sequences developed primarily for the detection 
of brain abnormalities, such as T2 fluid-attention inverse 
recovery (T2 FLAIR), might have increased the detection 
rate of abnormalities, such as focal or diffuse supratento-
rial white matter intensities. 
In conclusion, our study provides insight in the preva-
lence of incidental findings on brain MRI in the general 
Table 3  | Overview of previous studies that reported intracranial incidental findings in children.
Study population Study (ref) N Age range Exclusion criteria Findings* Referred cases
Clinical 
population
Gupta et al. (9)a 666 0 − 21 Prematurity Total: 25.7%
Referral: 0.3%
Arachnoid cyst, venous 
malformation
Jordan et al. (10)b 953 8 − 14 Stroke Total: 6.6%
Referral: 3.2%
Chiari I with syringomyelia, 
primary brain tumors
Gur et al. (20) c 1,400 8 – 23 General health 
issues
Total: 10.6%
Referral: 0.85%
Healthy controls Kim et al. (8)d 225 0 − 18 Neurological, 
developmental or 
psychiatric disorders
Total: 7.56%
Referral: 4.44%
Focal white matter lesion, 
tonsillar ectopia, hypoplasia 
pons, cerebellar tonsil lesion
General 
population
Seki et al.  (11) 110 5 − 8 N.S. Total: 9.1%
Referral: 0.9%
Cervical syringomyelia
Sullivan et al. (12) 833 12 − 21 Alcohol / drug use 
criteria
Total: 11.8%
Referral: 0.48%
Cranio-cervical stenosis, 
parietal cortical mass, 
Chiari I malformation, demy-
elinating disorders
General 
population
Current study 3,966 8 – 12 None Total: 25.6%
Referral: 0.43%
* = Prevalence estimates from these studies are intracranial findings and do not cover extra-cranial abnormalities (e.g. sinusitis), N.S = not stated, CC = corpus 
callosum, RIS = radiological isolated syndrome, a = tertiary pediatric neurology clinic, b = sickle cell patients, c = sampled from individuals who underwent clinical 
care, d = healthy controls for fMRI studies
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Objective: This study examined the relation between polygenic scores (PGSs) for 5 major psychiatric disorders 
and 2 cognitive traits with brain magnetic resonance imaging morphologic measurements in a large population-
based sample of children. In addition, this study tested for differences in brain morphology-mediated associations 
between PGSs for psychiatric disorders and PGSs for related behavioral phenotypes.
Method: Participants included 1,139 children from the Generation R Study assessed at 10 years of age with 
genotype and neuroimaging data available. PGSs were calculated for schizophrenia, bipolar disorder, major 
depression disorder, attention-deficit hyperactivity disorder (ADHD), autism spectrum disorder, intelligence, and 
educational attainment using results from the most recent genome-wide association studies. Image processing 
was performed using FreeSurfer to extract cortical and subcortical brain volumes.
Results: Greater genetic susceptibility for ADHD was associated with smaller caudate volume (strongest prior = 
0.01: β = −0.07, P = 0.006). In boys, mediation analysis estimates showed that 11% of the association between the 
PGS for ADHD and the PGS attention problems was mediated by differences in caudate volume (n = 535), whereas 
mediation was not significant in girls or the entire sample. PGSs for educational attainment and intelligence 
showed positive associations with total brain volume (strongest prior = 0.5: β = 0.14, P = 7.12 × 10−8; and β = 
0.12, P = 6.87 × 10−7, respectively).
Conclusion: The present findings indicate that the neurobiological manifestation of polygenic susceptibility for 
ADHD, educational attainment, and intelligence involve early morphologic differences in caudate and total brain 
volumes in childhood. Furthermore, the genetic risk for ADHD might influence attention problems through the 
caudate nucleus in boys.
Findings from genome-wide association studies (GWASs) 
indicate that multiple common genetic variants of small 
effect contribute to the etiology of psychiatric disorders, 
implying a highly polygenic architecture1. However, it re-
mains largely unknown how these common genetic vari-
ants ultimately contribute to the development of psychi-
atric symptoms. 
Polygenic scores (PGSs) are increasingly being used to 
index individual genetic susceptibility for a given disor-
der or trait and explore shared genetic influences across 
phenotypes to improve understanding of disease etiolo-
gy2.  Studies in childhood have shown that the polygen-
ic risk for schizophrenia (SCZ) is associated with lower 
cognitive abilities, greater social impairments, more be-
havioral problems, and psychopathology3-5. Interestingly, 
previous work from our group found that genetic suscep-
tibility for educational attainment (EA; years of school-
ing) was inversely related to child behavioral problems4. 
In a large prospective study, polygenic risk for major de-
pressive disorder (MDD) was associated with emotional 
problems in adulthood, but not earlier in life6. Similarly, 
a study of genetic risk for bipolar disorder (BD) in adult 
samples suggested an association with increased risk for 
different psychiatric disorders7. For childhood-onset psy-
chiatric disorders, PGSs for attention-deficit/hyperactiv-
ity disorder (ADHD) have been associated with inatten-
tive and hyperactive-impulsive traits, worse educational 
outcomes, and lower IQ in children and adolescents from 
the general population8,9. 
Genetic susceptibility to psychopathology and cognitive 
function has been linked to behavior4,  which could 
imply that heritable neurobiological mechanisms 
are at play in the early presentation of symptoms. 
Within this context, it is well established that brain 
morphology during development is strongly influenced 
by genetic factors10.  Furthermore, widespread 
morphologic brain abnormalities have been associated 
with the pathophysiology of major psychiatric 
disorders11-15.  Although genetic and environmental 
factors can account for these brain abnormalities, we 
expect that genetic susceptibility for psychiatric disorders 
are associated with variations in brain morphology. 
Indeed, several studies have reported relations between 
PGSs for psychiatric disorders and PGSs for structural 
brain magnetic resonance imaging (MRI) measurements 
in adults using medium to large samples in the context 
of imaging genetics16-19. Higher genetic risk for SCZ was 
related to total brain volume (TBV) in patients with SCZ 
(n = 152) and controls (n = 142)16, although this finding 
was not replicated using 2 large general population-based 
samples (n = 763 and n = 707)17. Other studies in healthy 
populations have related polygenic risk for SCZ and BD 
to reduced globus pallidus and amygdala volumes (n  = 
274)18. However, one of the largest studies to date did not 
find evidence for associations between polygenic risk for 
SCZ, BD, or MDD and subcortical brain volumes using 
data from the UK Biobank study (n = 978)19. 
Furthermore, to our knowledge, no study has yet been 
conducted in a pediatric MRI sample representative of 
the general population. Thus, whether associations of 
polygenic susceptibility for major psychiatric disorders 
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Introduction
and brain morphology are present earlier in life is largely 
unclear. Because ASD and ADHD are childhood-onset 
psychiatric disorders, the study of polygenic risk for these 
traits in pediatric samples is particularly relevant. To date, 
this has been hampered by the lack of large-scale imaging 
studies in children that include genetic data.
Against this backdrop, the goal of this study was to 
examine the association of polygenic susceptibility for 5 
psychiatric disorders and 2 cognitive outcomes with global 
and subcortical brain volumes in a large population-based 
sample of school-age children. As a secondary aim, this 
study investigated the potential mediating role of brain 
morphologic variation in associations between PGSs for 
psychiatric disorders and those for related behavioral 
phenotypes.
We hypothesized that polygenic susceptibility for SCZ, 
BD, MDD, autism spectrum disorders (ASDs), and 
ADHD would be associated with brain morphologic 
characteristics that overlap with brain abnormalities 
consistently reported in patients affected by these 
disorders. For EA and intelligence, we hypothesized that 
PGSs for these traits would be positively associated with 
global brain morphology measures.
Methods
Study Population
Participants were drawn from the Generation R Study, an 
ongoing population-based cohort study of many domains 
of child development20. As part of the cohort’s MRI study, 
3,992 children were scanned from March 2013 through 
November 2015, corresponding to visits of the 9- to-11-
year-old Generation R sample21. Of these children, 3,937 
had images that were reconstructed using FreeSurfer 6.0. 
One hundred thirty-one children were excluded due to 
the use of a different sequence (n  = 22), dental braces 
(n  = 87), and the presence of incidental findings (n  = 
22)22.  Of the remaining 3,806, 620 scans were excluded 
due to data rated as unusable after visual inspection of 
segmentation quality. This left 3,186 children with good-
quality MRI data. Of these, genotype data were available 
for 1,189 children with European ancestry. Relatedness 
and genotype quality resulted in an additional exclusion 
of 50 children. Thus, the final sample included 1,139 
participants (flowchart in  Figure  S1, available online). 
The study protocol was approved by the medical ethics 
committee of the Erasmus University Medical Center 
(Rotterdam, the Netherlands). Written informed consent 
was obtained from the legal representatives of all 
participants.
Magnetic Resonance Imaging
To familiarize participants with the MRI scanning 
environment, all children underwent a mock scanning 
session. Structural MRI scans were obtained on a 
3-T scanner (Discovery MR750W; GE Worldwide, 
Milwaukee, WI). Whole-brain high-resolution T1-
weighted inversion recovery fast spoiled gradient recalled 
sequences were obtained using an 8-channel head coil. 
The scan parameters were repetition time of 8.77 ms, 
echo time of 3.4 ms, inversion time of 600 ms, flip angle 
of 10°, field of view of 220 × 220 mm, acquisition matrix 
of 220  × 220, asset acceleration factor of 2, b of 900 s/
mm2, 230 contiguous slices with a thickness of 1.0 mm, 
and in-plane resolution of 1.0 × 1.0 mm. Further details 
on the design and protocol of the Generation R cohort’s 
MRI study can be found elsewhere21. 
Cortical reconstruction and volumetric segmentation 
were carried out with FreeSurfer Image Analysis Suite 
6.023. Specifically, automatic parcellation and segmentation 
protocols were conducted using the recon-all stream to 
obtain total, cortical, and subcortical brain volumes. 
All images were inspected for surface reconstruction 
accuracy using automated and manual methods24. Based 
on previous research investigating brain abnormalities in 
psychiatric disorders11,15,  10 volumetric brain measures 
were studied as outcomes: TBV, cortical gray matter (GM), 
total white matter, subcortical GM, ventricular volume, 
and cerebellum as global segmented brain measurements; 
and amygdala-hippocampus complex, caudate, putamen, 
and thalamus as subcortical brain volumes. Correlations 
between brain measurements are shown in  Figure  S2, 
available online.
 
Genotyping
DNA samples were collected from cord blood at birth 
or from venipuncture during a visit to the research 
center on Illumina 610K and 660K single-nucleotide 
polymorphism arrays depending on collection time 
(Illumina, San Diego, CA). Further details on genotype 
calling procedures in the Generation R Study can be found 
elsewhere25. Information on quality control procedures of 
the genotype data and principal component analysis can 
be found in Supplement 1, available online.
 
Polygenic Scoring
Only participants with European ancestry were selected 
for polygenic scoring. Genotype data that passed 
quality control were used to compute PGSs based on 
GWAS results for 5 psychiatric traits—SCZ, BD, MDD, 
ADHD, and ASD—from the Psychiatric Genomics 
Consortium. In addition, we calculated PGSs for EA 
168 | CHAPTER 8
and intelligence.  Table  S1, available online, provides 
an overview of the GWASs used for PGS calculation. 
For intelligence, we repeated the GWAS meta-analysis 
after exclusion of the Generation R sample to ensure 
independence of discovery and target sample. The PGSs 
were computed using LDpred26.  This polygenic scoring 
method infers the posterior mean effect size of each 
marker using a prior on effect size distribution and linkage 
disequilibrium information from a reference genotype 
panel. The LDpred algorithm has improved prediction 
accuracy compared with traditional methods. Six PGSs 
were computed for each trait corresponding to 6 priors 
that determined the proportion of single-nucleotide 
polymorphisms with a causal effect (0.01, 0.05, 0.1, 0.5, 1, 
and infinitesimal). All PGSs were standardized to a mean 
of 0 and a standard deviation (SD) of 1. Correlations 
between PGSs are shown in Figure S3, available online.
Statistical Analysis
Multiple linear regression analyses were conducted using 
R 3.3.1 (https://www.r-project.org/). To examine whether 
genetic susceptibility for major psychiatric disorders 
and cognition is related to brain morphology, each 
PGS was tested for association with each brain measure 
individually. In these models, brain measurements were 
assigned as dependent variables with PGSs for SCZ, BD, 
ADHD, ASD, EA, or intelligence generated at 6 LDpred 
priors as independent variables. Models with TBV as 
the outcome were adjusted by sex, age, and 4 genetic 
principal components. Models for the remaining brain 
measurements also were adjusted by total intracranial 
volume.
We corrected for multiple testing across all PGSs, 
generated at 6 different priors, for association with 10 
brain measurements using the false discovery rate (FDR) 
method27.  Results at a  P-value less than 0.05 by FDR 
correction were considered statistically significant.
For statistically significant associations showing a 
consistent pattern of results, we performed mediation 
analyses to examine whether differences in the associated 
brain regions mediated associations between the PGS 
and the phenotypic manifestation of the polygenic trait. 
Multiple linear regressions analyses were conducted to 
examine associations among PGSs, brain measurements, 
and behavioral phenotypes by adjusting for the same 
covariates included in the primary analyses and age at 
behavioral assessment. Direct, indirect, and total effects 
were estimated using the “mediation” package in R. 
As long as the assumptions of the mediation analysis 
are met, the direct effect represents the effect of genetic 
susceptibility on behavioral phenotypes after controlling 
for variation in brain morphology, and the indirect effect 
represents the estimated effect of polygenic susceptibility 
operating through brain morphology28.  The proportion 
of mediation by brain morphology can be calculated as 
the ratio of indirect effect to total effect. Given the data 
available in Generation R, mediation analyses were 
feasible only for associations with PGSs for psychiatric 
disorders for which behavioral data were assessed when 
children were 8 to 11 years of age (mean 9.7, SD 0.23, 
range 8.85–11.54) using the (Child Behavior Checklist 
[CBCL]/6-18)29.  Genetic, neuroimaging, and behavioral 
data were available for 1,053 participants. Further details 
on behavioral assessment can be found elsewhere21. For 
psychiatric disorders with sex differences in prevalence, 
we also conducted stratified analysis by sex.
To elucidate whether each cognitive trait independently 
contributed to the variation in brain measurement, we 
performed sensitivity analyses for analyses between the 
PGSs for EA and intelligence and for TBV by mutually 
adjusting using the PGSs for intelligence and EA, 
respectively.
Results
Sample Characteristics
A total of 1,139 children were included in the present 
study (561 girls [49.30%]), and the mean age was 10.16 
years (SD 0.60, range 8.72–11.99).
Effects of PGS on Brain Morphology
Figure 1 presents a summary of the associations between 
the PGS for psychiatric disorders and the PGS for 
cognition calculated at 6 priors and brain volumes. Full 
results for these associations are presented in  Table  S2, 
available online. 
No significant associations were observed between PGSs 
for SCZ and BD and brain measurements.
Greater genetic susceptibility for MDD was consistently 
related to smaller TBV, with the strongest association 
for the infinitesimal prior (β  =  −0.07, standard error 
[s.e.] 0.03; Puncorrected = 0.009). PGS for MDD also showed 
negative associations with total white matter (prior  = 
0.01: β = −0.03, s.e. = 0.01, Puncorrected = 0.043), cerebellum 
volume (prior  = 0.5: β  =  −0.05, s.e. = 0.02,  Puncorrected  = 
0.042; prior = 1: β = −0.05, s.e. = 0.02, Puncorrected = 0.040), 
and thalamus volume (prior  = 0.01: β  =  −0.05, s.e. = 
0.02,  Puncorrected  = 0.009). However, after FDR correction, 
none of these associations remained significant.
PGSs for ADHD were associated with smaller TBV and 
caudate volume across all priors, although associations 
did not reach statistical significance for prior 0.01 in the 
case of TBV and prior 1 in the case of caudate volume. 
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The strongest association with TBV was observed at the 
infinitesimal prior (β  =  −0.07, s.e. = 0.03,  Puncorrected  = 
0.006), and the strongest association with caudate 
volume was observed at prior 0.01 (β  =  −0.08, s.e. = 
0.03,  Puncorrected  = 7.49  × 10−4) and remained significant 
after FDR correction.
PGS for ASD showed positive associations with TBV 
at all priors except at prior 0.01, which did not reach 
significance but did show the same direction of effect. 
The largest magnitude of the association was observed at 
prior 1 (β = 0.07, s.e. = 0.03; Puncorrected = 7.75 × 10−3). These 
associations did not surpass FDR correction.
The EA PGSs were consistently associated with larger TBV 
(strongest prior 0.5: β = 0.14, s.e. = 0.03, Puncorrected = 7.12 × 
10−8) and remained significant after FDR correction. 
Associations at prior 0.05 did not reach significance 
but showed the same direction of effect. Greater genetic 
susceptibility for EA also was associated with larger 
volumes of subcortical GM (prior  = 0.05: β  = 0.04, s.e. 
= 0.02,  Puncorrected  = 0.046), cerebellum (prior  = 0.1: β  = 
0.05, s.e. = 0.02,  Puncorrected  = 0.047), putamen (prior  = 
0.05: β = 0.06, s.e. = 0.03, Puncorrected = 0.016), and thalamus 
at multiples priors (strongest prior  = 1: β  = 0.05, s.e. = 
0.02, Puncorrected = 0.012).
Greater genetic susceptibility for intelligence was 
significantly related to larger TBV for most priors, even 
after FDR correction (strongest prior 0.5: β  = 0.12, s.e. 
= 0.03,  Puncorrected  = 6.87  × 10−7). Other associations not 
surviving FDR correction included a positive association 
with subcortical GM (infinitesimal prior: β  = 0.04, s.e. 
= 0.02, Puncorrected = 0.024) and positive associations with 
cerebellum volume (priors 0.01 and 0.05: β = 0.07, s.e. = 
0.02, Puncorrected = 0.003).
Mediation Analysis
Only the association between polygenic risk for ADHD 
and caudate volume survived FDR correction; therefore, 
we tested whether caudate volume mediated the 
association between polygenic risk for ADHD and the 
attention problems CBCL syndrome scale. The caudate 
nucleus met the conditions to act as a mediator, because 
it showed a negative significant association with attention 
problems (β  =  −0.06, s.e. = 0.00,  P  = 0.029). Similarly, 
polygenic risk for ADHD was significantly associated 
with attention problems (β = 0.12, s.e. = 0.00, P = 5.36 × 
10−5). However, mediation was 4.6% and not significant 
within the entire sample (Figure 2). 
In analyses stratified by sex, mediation was significant 
only in boys, indicating that 11% of the association 
between polygenic risk for ADHD (prior  = 0.01) and 
attention problems might be mediated by differences in 
caudate volume (Figure 2).
Sensitivity Analysis
Analyses mutually adjusting for polygenic susceptibility 
for EA and intelligence at prior 0.05 showed that the PGSs 
Fig. 1 | Associations Between Polygenic Scores for Psychiatric Disorders and Cognition and Brain Volumes (n = 1,139).
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for these 2 traits were independently associated with TBV 
(PGS for EA: β = 0.10, s.e. = 0.03. P = 2.6 × 10−4; PGS for 
intelligence: β = 0.08, SE = 0.03, P = 0.003).
Discussion
We examined whether polygenic susceptibility for 
psychiatric disorders and cognition was associated with 
brain morphology in children. 
We found a consistent pattern of results across priors, 
indicating that the polygenic risk for ADHD was negatively 
associated with caudate volume, with the finding of a 
prior of 0.01 surviving multiple testing correction. 
Polygenic susceptibility for intelligence and EA showed 
a positive relation with TBV that was consistent across 
all priors used, although generally not significant for the 
more stringent priors (i.e., 0.05 and 0.01). Polygenic risk 
for SCZ and BD did not show significant associations with 
brain morphology; however, several brain measurements 
were related to PGSs for MDD and ASD, although none 
of these associations survived multiple testing correction. 
These findings indicate the neurobiological manifestation 
of polygenic susceptibility for ADHD, intelligence, 
and EA involves early morphologic differences in 
caudate volume and TBV during development. 
Whole-brain and caudate volume reductions have been 
related to ADHD in a recent mega-analysis14. Given the 
high heritability of ADHD30,  we expected that regions 
previously associated with the disorder also would be 
associated with polygenic risk for ADHD. To the best of 
our knowledge, this is the first study providing evidence 
Fig. 2 | Mediation analysis of estimated effect (95% CI) of polygenic risk for attention-deficit/hyperactivity disorder (ADHD; 
prior = 0.01) on attention problems (Child Behavior Checklist Syndrome Scale) through caudate volume in the entire sample (n = 
1,053) and stratified by sex (n = 535 boys; n = 518 girls)
indicating that polygenic risk for ADHD might be, at 
least in part, underlying TBV and caudate reductions in 
childhood. These findings are particularly relevant for 
caudate volume reduction, one of the most replicated 
findings in ADHD31.  Interestingly, our results suggest 
that reduced caudate volume might be mediating the 
association between polygenic risk for ADHD and 
attention problems in boys. ADHD is 2 to 9 times more 
prevalent in boys during childhood and adolescence32. 
Sex differences in brain morphology have been used to 
investigate whether ADHD-related brain abnormalities 
are more pronounced in male versus female individuals. 
Although caudate volume did not show sex effects in the 
mega-analysis conducted by Hoogman  et  al.14,  another 
study examining the volume and shape of basal ganglia 
observed smaller caudate volumes in boys with ADHD 
compared with male controls and no differences among 
girls33.  Similarly, smaller caudate volumes have been 
found in adult male patients with ADHD compared 
with male controls, whereas no differences were 
observed in women34. Our findings are in line with these 
studies supporting that different genetically influenced 
neurobiological mechanisms might be operating in male 
and female individuals in the context of ADHD.
The EA PGSs were associated with larger TBV. 
Intracranial volume has been previously related to EA 
genetic variants by applying linkage disequilibrium 
score regression methodology35. Genetic variants for EA 
or other traits can affect TBV directly, through direct 
gene expression, through gene-environment interaction 
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or correlation mechanisms, or through intermediate 
phenotypes. Remarkably, an important number of single-
nucleotide polymorphisms related to EA are located 
within genomic regions regulating gene expression in 
the fetal brain and genes mainly expressed in neural 
tissue35.  These genes are especially active during the 
prenatal period and enriched for biological pathways 
involved in neural development35.  Thus, it is likely that 
polygenic susceptibility for EA includes variants that 
directly promote optimal brain development. 
Another possibility would be that EA genetic variants 
could influence brain morphology through environmental 
exposures that positively affect brain development, which 
would imply gene-environment correlation effects. In fact, 
children with higher genetic loading for EA tend to be 
raised in socioeconomically advantaged environments36, 
which positively affects brain development37.  It also is 
important to note that genetic associations with EA can 
be mediated by other phenotypes such as intelligence 
or personality traits, which are considered intermediate 
phenotypes for EA38. 
In addition, higher genetic loading for EA was nominally 
associated with larger thalamus volumes at multiple 
priors. The thalamus is a major hub in the brain, 
relaying multimodal information covering a wide range 
of cognitive functions, including learning, memory, 
inhibitory control, decision making, control of visual 
orienting responses, and attention39.  Thus, a relation 
between polygenic susceptibility for cognitive functions 
relevant for EA with increased volume of the thalamus is 
neurobiologically plausible.
Not surprisingly, our findings on polygenic susceptibility 
for intelligence and EA largely overlap in the strength of 
the association and variance explained by TBV. Similarly 
to EA, genetic variants related to intelligence were 
identified in genes predominantly expressed in brain 
tissue40. Interestingly, polygenic susceptibility for EA and 
for intelligence influenced TBV independently of each 
other. Because the correlation between the PGSs for EA 
and intelligence was not extremely strong (Figure  S3, 
available online), we speculate that genetic variants related 
to these traits might act through different pathways. 
Studies have shown that TBV is positively correlated 
with intelligence, accounting for approximately 16% of 
the variance in IQ41. Furthermore, our results indicate a 
shared genetic overlap between IQ and brain size, which 
is in line with twin studies suggesting that the association 
between these phenotypes is mainly of genetic origin42. 
Contrary to our hypothesis, polygenic risk for SCZ was 
not associated with brain morphologic variation at 9 to 
11 years of age. This is in line with previous research in 
adults17,19. However, this null finding was surprising, 
because we found an association between the PGSs for 
SCZ and internalizing symptoms, and especially thought 
problems4.  Behavioral effects of polygenic risk for SCZ 
must have neural correlates that we could not detect 
for several potential reasons. First, the neural correlates 
of SCZ PGS might be related to other neurobiological 
phenotypes not quantified in our study. This would not 
be the case for white matter measurements, including 
global and tract-specific fractional anisotropy and 
mean diffusivity, that were tested for an association 
with polygenic risk for SCZ in this sample and showed 
negative results43. Also, polygenic risk for SCZ has been 
associated with functional brain parameters, such as 
brain activation patterns detectable with functional MRI 
during cognitive tasks in adolescents44,45. Second, brain 
structural abnormalities related to genetic risk for SCZ 
might be detectable only in young individuals beginning 
in the prodromal phase, when the illness has begun to 
show clinical manifestations. These finding is “unmasked” 
as the illness progresses, making it very difficult to 
observe in general population samples, especially early 
in life. Third, genetic risk for SCZ has been related to 
nonparticipation in a large longitudinal population-
based cohort study46,  implying that individuals at high 
genetic risk might be underrepresented. This would lead 
to underestimating effects of these genetic variants on 
neurodevelopmental outcomes. However, PGSs for SCZ 
were very similar among Generation R participants with 
European ancestry when comparing those included with 
those excluded in the present study (Table S3, available 
online).
Other interesting findings, albeit not surpassing multiple 
testing correction, include positive relations between 
PGS for ASD and TBV and negative associations between 
MDD PGS and TBV. Converging evidence points to an 
increased brain size as a characteristic brain abnormality 
of young children with ASD47.  Our results suggest that 
this association could be accounted for by common 
genetic variants increasing the risk for ASD. Although it 
might seem counterintuitive that polygenic risk for ASD 
shows the same direction of effects on TBV as PGSs for 
EA and intelligence, it has been shown that polygenic risk 
for these traits is highly correlated and that genetic risk 
for ASD might act through different etiologic pathways48. 
For MDD PGS, widespread GM and subcortical volume 
reductions have been reported in individuals affected by 
MDD49. In contrast, less research has been conducted on 
global structural brain measures such as TBV. Overall, 
further research is needed to confirm these potential 
associations.
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Our results should be interpreted in the context of 
several strengths and limitations. The strengths of the 
present study include the large sample and homogeneity 
with respect to recruitment, exclusion criteria, scanner, 
image acquisition, and preprocessing methods, which 
are especially valuable in imaging genetics. That said, the 
present sample is adequate for detecting significant effect 
sizes larger than 0.08 at 80% power; thus, reported smaller 
effect sizes, which correspond to negative findings, should 
be interpreted with caution. The main limitation of the 
study is the cross-sectional design. Studies including brain 
morphologic measurements at multiple time points are 
needed to examine whether polygenic risk for psychiatric 
disorders and cognition contributes to changes in 
developmental trajectories. Another limitation is that 
the PGSs typically explain only a small proportion of the 
total phenotypic variance of complex traits1,2. Moreover, 
it is important to note that the predictive accuracy of the 
PGS is related to sample size in the discovery sample, 
which substantially varies among different traits for the 
PGSs examined in the present study50.  This should be 
considered when comparing results for the different traits 
examined. Nevertheless, we used summary statistics 
from the most recent, and thus more powerful, GWASs 
conducted on psychiatric disorders to date, which 
represents an advantage over previous studies using PGSs 
based on GWASs conducted on smaller samples.
To conclude, we found a relation between polygenic 
susceptibility for intelligence and EA and TBV in school-
age children. We also found effects of ADHD polygenic 
risk for caudate volume. Interestingly, we found evidence 
for mediation only in boys, in whom differences in caudate 
volume accounted for 11% of the association between 
polygenic risk for ADHD and attention problems at 9 years 
of age. Overall, our findings provide molecular genetic 
evidence for the relation between polygenic susceptibility 
for cognition and ADHD with early differences in brain 
morphology.
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Chapter 9
Polygenic Scores for Neuropsychiatric Traits and White Matter 
Microstructure in the Pediatric Population
Philip R. Jansen, Ryan L. Muetzel, Tinca J.C. Polderman, Vincent W. Jaddoe, Frank C. Verhulst, 
Aad van der Lugt, Henning Tiemeier, Danielle Posthuma, Tonya White
Published in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. 2019 Mar 1;4(3):243-50

Background: Genome-wide association studies (GWAS) have identified numerous genetic variants that pre-
dispose to neuropsychiatric traits. Identification of mechanisms in the brain that underlie these associa-
tions is essential for understanding manifestations of genetic predisposition within the general popula-
tion. Here, we investigate the association between polygenic scores (PGS) for seven neuropsychiatric traits 
and white matter microstructure of the brain on diffusion tensor imaging (DTI) in the pediatric population. 
Methods: Participants from the Generation R Study that had genotype and DTI data available (n = 1,138, mean 
age = 0.2 years, range = 8.7–12.0) were included. PGS were calculated for five psychiatric disorders (ADHD, bipo-
lar disorder, autism, major depressive disorder, schiszophrenia) and two cognitive traits (intelligence and educa-
tional attainment), and tested for associatios with global and tract-specific fractiona anisotropy (FA) and mean 
diffusivity (MD).
Results: Significant positive associations with global FA were observed for the PGS of intelligence (β=0.109, SE = 
0.029, P < 0.001, ΔR2 = 0.012) and educational attaiment (β = 0.118, SE = 0.029, P < 0.001, ΔR2 = 0.014). No signifi-
cant associations were observed with FA for the PGSs for psychiatric disorders. Tract-specific analysis showed that 
the PGS for intelligence and educational attainment were associated with FA of several association and projection 
fibers of the brain.
Conclusions: Our results show that genetic prediposition for cognition-related traits, but not psychiatric disor-
ders, is associated with microstructural diffusion measures of white matter tracts at an early age. These results 
suggest a shared genetic etiology among structural connectivity, intelligence and educational attainment. 
Recent genome-wide association studies (GWAS) have improved insight into the highly complex polygenic architecture of human behavioral traits, 
including psychiatric disorders1-3 and cognitive ability4,5. 
The rapid discovery of genetic variants has created the 
need for identification of downstream mechanisms in or-
der to understand the biological impact of genetic risk on 
a system level6-8. 
Recent studies have utilized polygenic scoring analy-
ses (PGS) to estimate overall genetic risk for psychiatric 
disorders and test the combined effects of thousands on 
SNPs on brain-imaging derived phenotypes using mag-
netic resonance imaging (MRI)9. Indeed, structural brain 
imaging studies in the general population have shown 
associations with disease-related alterations in healthy 
individuals carrying a high polygenic score for psychiat-
ric illness, including differences in gyrification patterns10 
and cortical thickness11. Functional imaging studies have 
shown that polygenic risk for schizophrenia can be linked 
to different brain activity during tasks12,13, and during 
rest14, illustrating the complex combined downstream ef-
fects on brain functioning. In addition, evidence of brain 
differences in healthy subjects at high genetic risk has also 
been suggested by imaging studies in high risk individu-
als with a first-degree relative with a psychiatric disorder, 
which showed abnormalities in a variety of structural15-17 
and functional measures of the brain17-19. 
However, so far only few studies have investigated asso-
ciations of polygenic risk with white matter fibers of the 
brain20,21, even though the structural connectivity of the 
brain is known to be related to major psychiatric disor-
ders, including schizophrenia22 and bipolar disorder23,24, 
as well as in normal cognitive functioning25,26, and white 
matter changes have been observed in healthy relatives 
of psychiatric patients27,28. In addition, most prior genet-
ic studies only included GWAS significant SNPs (P < 5 × 
10-8) in the polygenic score, and do not take the contribu-
tion in genetic signal of subthreshold SNPs into account29. 
Moreover, prior studies have almost exclusively focused 
on adolescents or adults, while deviation from normal 
brain development may be present much earlier in life. 
Here, we investigate whether genome-wide polygenic 
scores for psychiatric traits and cognitive ability are as-
sociated with white mater microstructure on diffusion 
tensor imaging (DTI) of the brain in a large popula-
tion-based cohort of children between nine and twelve 
years of age. Insight into a possible shared genetic etiology 
between psychiatric disorders, cognitive ability and white 
matter microstructure provides further understanding 
neurobiological manifestations of genetic predisposition 
for psychopathology and cognition at early age in the gen-
eral population
Methods and materials
Study Sample 
The current study was conducted within the Generation 
R Study, a population-based cohort studying multifaceted 
aspects of child development30. Between March 2013 and 
November 2015, participants were enrolled in the cohort’s 
MRI study with the aim of studying brain development in 
the general population by collecting, high quality, single 
scanner MRI data of the brain31. The current study includ-
ed unrelated participants of European ancestry that had 
Introduction
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good quality MRI data available and from whom geno-
type data had been collected previously. The Medical Eth-
ics Committee of the Erasmus University Medical Center 
approved the study protocol, and the legal representative 
of the participants provided written informed consent. 
Diffusion Tensor Imaging 
Diffusion Tensor Imaging (DTI) of the brain was per-
formed on a single study-dedicated 3 Tesla MR750w 
Discovery MRI scanner (General Electric, Milwaukee, 
WI, USA). Twelve major WM tracts were identified us-
ing probabilistic tractography. Diffusion characteristics 
within these tracts were used to quantify mean fractional 
anisotropy (FA) and mean diffusivity (MD). A detailed 
description of the imaging procedures, scan protocol and 
subsequent processing of the DTI data is provided in Sup-
plementary Information 1.1-1.5. Confirmatory factor 
analysis (CFA) was applied using the Lavaan R package32 
to model a single latent factor of global fractional anisot-
ropy (FA) and mean diffusivity (MD), as described by 
Muetzel et al.25. White matter tracts included in the model 
and standardized factor loadings on the global factor are 
shown in Figure 1 and Supplementary Table 1-2. The 
global factors were tested for association with the PGS in 
univariate analyses. 
Genotype data
Genotype data was collected at birth or during a visit to 
the research center using Illumina 610K and 660K gen-
otype arrays (Illumina, San Diego, CA, USA). Data col-
lection and subsequent processing procedures have been 
described previously33. Additional quality control proce-
dures of the genotype data and genotype imputation are 
described in the Supplementary Information 2.1-2.4.
Fig. 1 | Standardized factor loadings of white matter tracts included in the global factor of fractional anisotropy (FA). 
Global factors for FA were estimated using confirmatory factor analysis (cfa). White matter tracts are color-coded according to 
subcategory. SLF: superior longitudinal fasciculus; ILF: interior longitudinal fasciculus; UNC: uncinate fasciculus; CGC: cingulum 
bundle; CST: corticospinal tract. 
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Polygenic Scoring 
Polygenic scores (PGS) were calculated on imputed gen-
otype data using publicly available GWAS results for five 
psychiatric disorders and two cognitive traits, including 
attention-deficit hyperactive disorder (ADHD), autism 
spectrum disorder, bipolar disorder, major depressive 
disorder, schizophrenia, intelligence, and educational at-
tainment. An overview of the discovery GWAS studies is 
provided in Supplementary Table 3. As the Generation 
R cohort was included in the GWAS of intelligence, the 
GWAS was repeated after exclusion of the Generation R 
cohort (sample size after exclusion n = 267,938). Gener-
ation R was not included in any of the other six GWAS 
studies. PGS were calculated using PRSice34, a script for 
calculation of PGS in PLINK35. We calculated PGS based 
on several P-value thresholds (pT) for inclusions of SNPs 
in the score (pT <0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1)
We tested multiple thresholds to find the optimal thresh-
old that has the strongest association
with the outcome. PGS were subsequently standardized 
to a mean of 0 and standard deviation of 1 for interpret-
ability. The number of SNPs that were included in each 
PGS and threshold is shown in Supplementary Table 4.
Statistical analysis
Statistical analyses were performed using the R statistical 
software36 (version 3.2.1). Association testing was per-
formed in a hierarchical approach. First, a global factor 
of white matter microstructure was predicted from the 
CFA model and regressed on the PGS. Next, in secondary 
analyses we studied tract-specific associations by regress-
ing the individual white matter tracts on the PGS P-value 
threshold that showed the strongest association with the 
global factor in the primary analysis (lowest P-value). All 
analyses were corrected for age, gender and four genet-
ic principal components as covariates. False Discovery 
Rate was used to correct for multiple testing (FDR)37. 
Correction was applied to the total number of statistical 
tests for each risk score, P-value threshold, and global and 
tract-specific diffusion measures. An FDR-corrected sig-
nificance threshold was applied and P-values below 0.004, 
were considered statistically significant. 
Results
Sample characteristics 
A total number of 3,992 participants underwent MR im-
aging of the brain. DTI was completed in 3,786 of these 
participants. After DTI image quality control procedures, 
3,279 participants remained. Of these participants, 1,920 
individuals had genotype data available. Subsequent fil-
tering based on European ancestry, relatedness and gen-
otype quality resulted in 1,138 participants that were in-
cluded in the study (flowchart in Supplementary Figure 
1). The mean age of the sample was 10.2 years (range: 8.72 
– 11.99), with a balanced distribution of sex (50.6% boys). 
The mean standardized polygenic scores for education-
al attainment and intelligence were slightly higher com-
pared to the genotyped participants of European ancestry 
that did not participate in the MRI study (Educational at-
tainment: 0.058 vs. –0.039, t = 2.56, P = 0.01; intelligence: 
0.099 vs. –0.067, t = 4.39, P = 1.17 × 10-5) (Supplementary 
Table 5), and lower for ADHD (–0.055 vs. 0.036, t = –2.39, 
P=0.02) and depression (–0.071 vs. 0.047, t = –3.09, P = 
0.002) There was a moderate correlation between several 
polygenic scores (correlation heatmap shown in Supple-
mentary Figure 2), showing the largest correlation be-
tween the educational attainment and intelligence poly-
genic scores (r2 = 0.38 to 0.47 between different P-value 
thresholds). 
Associations with IQ 
We tested whether the PGS of intelligence and educa-
tional attainment were associated with non-verbal IQ, 
measured in a subsample of 982 participants around the 
age of six years. The PGS of intelligence and educational 
attainment were strongly associated with non-verbal IQ, 
explaining approximately 5% by the PGS of intelligence (β 
= 0.222, s.e. = 0.032, P = 1.87×10-12, ∆R2 = 0.050) (Supple-
mentary Table 6).
Global FA / MD 
Explained variance (∆R2) in the global factor of FA and 
MD by the PGS are shown in Figure 2 and Figure 3 re-
spectively, full regression results are shown in Supple-
mentary Tables 7-8. The PGS of intelligence showed pos-
itive associations with global FA across different P-value 
thresholds and was the strongest for the PGS based on a 
P-value threshold of pT (β = 0.118, s.e. = 0.029, P < 0.001, 
∆R2 = 0.014). We did not observe significant associations 
were between the global factor of FA and the PGS of the 
five psychiatric traits after correcting for multiple testing. 
In addition, none of the seven PGS showed associations 
with the global factor MD that survived multiple testing 
correction (Figure 3). 
Tract-specific analysis
To test whether associations with specific white matter 
tracts could explain the association between the PGS and 
global FA, we performed univariate associations with dif-
fusion measures FA and MD of individual white matter 
tracts. PGS based on the P-value threshold that showed 
the strongest association with the global factor of FA and 
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Fig. 2 | Variance explained in global fractional anisotropy by polygenic scores. (a) Variance explained (∆R2) in global fractional 
anisotropy (FA) by the polygenic score (PGS). (b) Standardized regression coefficients of associations between the different PGS 
and global FA for each P-value threshold, corrected for age, gender and ten genetic principal components.
Fig. 3 | Variance explained in global mean diffusivity by polygenic scores. (a) Variance explained (∆R2) in the global factor of 
mean diffusivity (MD) by the polygenic score (PGS). (b) Standardized regression coefficients of the PGS on global MD for each 
individual P-value threshold, corrected for age, gender and four genetic principal components. 
MD in the primary analysis (lowest P-value) were tested 
for tract-specific associations. Figure 4 shows the asso-
ciation results between the PGS and FA and MD in each 
white matter tract, a full overview of the regression results 
is provided in Supplementary Table 9-10. Effect sizes for 
intelligence and educational attainment are represent-
ed visually in Figure 5. The PGS of intelligence showed 
positive associations with tract-specific FA in four major 
white matter tracts: the right superior longitudinal fascic-
ulus (SLF; β = 0.125, s.e. = 0.029, P < 0.001), the left in-
ferior longitudinal fasciculus (ILF; β = 0.087, s.e. = 0.029, 
P < 0.001), and both the left and right corticospinal tract 
(CST; left: β = 0.132, s.e. = 0.029, P < 0.001; right: β = 
0.148, s.e. = 0.029, P < 0.001). Associations between edu-
cational attainment PGS and white matter tract partially 
overlapped with results of intelligence PGS, and showed 
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similar positive associations with the right SLF (β= 0.118, 
s.e. = 0.029, P < 0.001) and the left and right CST (left: 
β = 0.107, s.e. =0.029, P<0.001; right: β = 0.092, s.e. = 
0.029, P < 0.001). In addition, significant associations 
were observed with the right ILF (β = 0.105, s.e. = 0.029, 
P  < 0.001) and the forceps minor (FMI; β = 0.088, s.e. 
= 0.029, P < 0.001). Tract-specific FA was not associated 
with the psychiatric PGS. For tract-specific MD values, 
we observed a significant positive association between the 
intelligence PGS and the forceps major (β = 0.105, s.e. = 
0.029, P < 0.001) whereas a negative association was ob-
served between the ADHD PGS and MD of the FMI (β = 
–0.088, s.e. = 0.029, P < 0.001).
Discussion
In this study, we observed positive associations between 
genetic predisposition for cognition-related traits and 
white matter microstructure on MRI in the pediatric 
population, with the PGS of intelligence and educational 
attainment explaining approximately 1% of the variance 
in global fractional anisotropy. Tract-specific analyses 
showed that these associations driven by several associ-
ation and project fibers of the brain. These results may 
suggest a shared genetic etiology between global white 
matter integrity, general cognitive functioning and pre-
dicted later-life educational achievement. 
Previous research showed that the PGS of educational at-
tainment is associated with general intelligence, but has 
also been associated with socio-economic status38, and 
later-life outcomes, including reproductive behavior39 and 
longevity40. To date, genetic variants related to cognitive 
traits have only been linked to total intracranial volume on 
MRI based on GWAS summary statistics using LD Score 
regression41. Our study is the first to report significant as-
Fig. 4 | Tract-specific associations between polygenic scores and white matter tracts. Associations between polygenic scores 
and tract-specific fractional anisotropy (FA) and mean diffusivity (MD). Coefficients are standardized regression coefficients, 
corrected for age, gender and four genetic principal components.
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sociations between PGS for intelligence and educational 
attainment, and structural connectivity of the brain, em-
phasizing the important role of white matter microstruc-
ture in cognitive functioning. This finding is in line with 
previous work from our group that reported associations 
between non-verbal IQ and global fractional anisotropy25, 
and specific associations with the superior longitudinal 
fasciculus. Our study adds to these findings that cogni-
tion and white matter microstructure are likely to share 
a common genetic architecture. We hypothesize that two 
underlying mechanisms may explain these observed as-
sociations. First, the discovery GWAS of educational at-
tainment by Okbay et al.5 reported that candidate genes 
near the 74 genome-wide significant variants showed ele-
vated expression in the central nervous system. Moreover, 
these candidate genes were highly enriched for gene-sets 
related to neurodevelopment, such as sprouting of den-
drites and synaptic plasticity. Similar gene-set results were 
observed by Savage et al.42 in the GWAS of intelligence, 
which highlighted that genes related to several cellular 
processes in neurons influence cognitive functioning. 
Given the associations between PGS of intelligence and 
educational attainment and white matter microstructure 
in our study, it may be possible that similar molecular 
pathways and neurobiological processes lead to higher 
developed states of microstructural organization, which 
subsequently leads to a higher fractional anisotropy on 
DTI. Genetic studies of white matter integrity on DTI in-
deed confirmed that genes involved in synaptic process-
es, such as neuronal transmission and cell adhesion, are 
important contributors to white matter microstructure43. 
Second, given previously described associations between 
the educational attainment PGS of the child and parental 
socioeconomic status44, gene-environment correlations 
with environmental factors that positively impact white 
matter microstructure, including prenatal factors45, par-
enting strategies46 and a healthy lifestyle47 may amplify 
the observed associations. Considering that educational 
achievement is correlated with a broad range of environ-
mental factors, it is possible that the educational attain-
Fig. 5 | Visual representation of tract-specific associations been PGS and white matter tracts. (a) Associations between the 
PGS for intelligence and tract weighted-average fractional anisotropy (FA), (b) PGS of educational attainment and tract weighted-
average FA. Coefficients are standardized regression coefficients, corrected for age, gender and four genetic principal components. 
Regression results are shown in Supplementary Table S8-S9.
182 | CHAPTER 9
a b
ment PGS captures the combined effect of a diverse array 
of factors that impact white matter development. 
Interestingly, we did not observe associations between 
the schizophrenia PGS and white matter microstruc-
ture, which is surprising given extensive literature on 
white matter abnormalities in schizophrenia patients22, 
individuals at high genetic risk for schizophrenia, as de-
fined by family history48,49, and associations between the 
schizophrenia PGS and behavioral problems in our sam-
ple as previously reported50. We argue that several factors 
may explain this negative finding. First, at the age of our 
study sample (mean age of 10.2 years), white matter ab-
normalities described in schizophrenia patients may be 
not yet present, not present on a scale detectable by DTI, 
or present but obscured by increased variance associated 
with different rates of white matter maturation between 
individuals. Moreover, MR imaging modalities examin-
ing structural phenotypes and activation patterns of the 
brain may be more sensitive to developmental changes 
related to the genetic risk for schizophrenia. Previous 
studies in healthy individuals indeed have shown associ-
ations between schizophrenia PGS and cortical morphol-
ogy on structural imaging10,11, and activation patterns 
during cognitive tasks on functional MRI (fMRI)13,51. 
Second, the PGS in this study only captures genetic sig-
nal from common variants (MAF >0.01) of typically low 
individual effect sizes52. White matter alterations found 
in schizophrenia patients may follow from more delete-
rious rare variants with comparatively larger effects and 
higher penetrance. Compelling evidence exists that these 
rare mutations contribute substantially to schizophrenia 
risk53,54 and commonly disrupt neurodevelopmental pro-
cesses55,56, which could potentially underlie the observed 
microstructural abnormalities. Third, nonparticipation 
among high-risk compared to low-risk individuals in 
population-based research have been previously de-
scribed57. Subsequent underrepresentation of individuals 
with the highest risk of schizophrenia may further explain 
this null result. In addition, no associations were observed 
for the PGS of four other psychiatric traits. The absence of 
association for these traits may be partially explained by 
the GWAS small sample sizes (autism, depression, bipo-
lar), the later onset of these disorders (depression, bipolar 
disorder), or an absent relation between white matter and 
these psychiatric disorders. 
The current study has several strengths. First, the sam-
ple is large for imaging standards, especially in pediatric 
populations. Second, the sample comprised a narrow age 
range, and was performed in a population-based cohort, 
which can minimize, but certainly not remove, age-re-
lated differences in white matter development. Third, all 
subjects were scanned on a single, research-dedicated 
MRI scanner using the same software version, removing 
possible noise from inter-scanner differences or changes 
associated with scanner upgrades. Fourth, PGS for mul-
tiple traits were simultaneously tested, allowing for com-
parisons across traits in a single study sample. 
Some limitations are also present. First, the associations 
between PGS and white matter microstructure were test-
ed using a cross-sectional design. Prospectively collected 
brain imaging data could provide evidence on wheth-
er polygenic scores are associated with variation in tra-
jectories of white matter development in children over 
time. Second, the current largest discovery GWAS studies 
used for calculating the PGS of ADHD, autism and bi-
polar disorder are less powered compared to other traits 
that were tested. As discovery sample sizes increase rap-
idly, we expect that PGS studies based on well-powered 
GWAS results will lead to more robust associations with 
brain imaging phenotypes. Lastly, polygenic risk scores 
do not provide insights into which SNPs contribute most 
to the observed associations with structural connectivity. 
Future genome-wide studies of structural connectivity in 
large DTI imaging samples may further aid in identifying 
SNPs linked to both traits, and in estimating genetic over-
lap between cognitive functioning, psychiatric disorders 
and structural connectivity. 
In conclusion, we report evidence that genetic predispo-
sition for cognitive traits is associated with higher white 
matter microstructural integrity in children, whereas no 
associations were found for five major psychiatric disor-
ders. Future studies are necessary to explore associations 
with longitudinal developmental trajectories of white 
matter microstructure over time. 
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Supplementary information
Supplementary Fig. S1 | Participant selection. Flowchart showing the selection of participants from the Generation R Study for 
the current analysis.
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Supplementary Fig. S2 | Heatmap showing correlations between the different polygenic scores and P-value thresholds. The 
highlighted squares show the strongest correlations between polygenic scores. The correlation estimates in the square show the 
range of correlations between different P-value thresholds for these traits.
Part III:  
Appendix
Chapter 10: General discussion and summary
After more than a century of scientific milestones in genetics, from experiments in a small number of peas by 
Gregor Mendel to populations larger than one million individuals (see introduction, Fig. 1a), the identification 
of single genes that ae related to human behavior has only recently become possible. The current generation of 
scientists are the first to discover the human genome and find genes related to human characteristics, just as 
previous generations of scientific researchers in neuroscience were the first to look at the living human brain 
through new brain imaging techniques such as MRI and CT. Prior scientific steps that led to the discovery of the 
DNA structure, the first complete map of the human genome and subsequent mapping of variations in single 
base pairs between individuals ultimately paved the way to start searching for single genetic variants in genes that 
predispose to many different outcomes. The current thesis aimed to build forth on these steps by identifying novel 
genes and pathways that underlie human behavior through unprecedented sample sizes and investigate how these 
genes relate to differences in the brain. An important factor driving the discoveries in this thesis is the availability 
of large-scale datasets and improved statistical software that can handle analyses on a big data scale. Around the 
start of the thesis in 2014, the shift towards larger and larger studies led to important milestones in psychiatric 
genetics, among which was the identification of 108 genomic loci for schizophrenia that were discovered in a 
genome-wide association study (GWAS) in over 100,000 individuals1. This large-scale GWAS pointed towards 
novel interesting disease biology and new promises for pharmacological treatment options. Importantly, this 
study evidently demonstrated that, despite disappointing results in the smaller earlier studies, increases in study 
size unlocked the potential of GWAS for understanding the complexity of psychiatric disorders2.
1. Summary of research findings
The research projects in this thesis were centered around two main research aims: 1) The first aim was to understand genetic factors 
that explain the heritability of complex human behavior 
in the population. The most important starting point 
for these analyses is a well-powered GWAS to obtain 
associations for each SNP in the genome. These SNP 
effects can be used as input for a wide variety of follow-up 
analyses to find genes and neurobiological mechanisms 
related to these traits, or to estimate genetic risk for these 
traits through the use of a polygenic risk score (PRS). The 
results related to this objective are described in the first 
part of the thesis.
2) The second aim was to use magnetic resonance imaging 
(MRI) of the brain collected in thousands to hundreds of 
thousands of individuals, including adults and children, 
to study how genetic variation between individuals relates 
to differences in the morphology of the brain. To this 
end we performed GWAS of brain MRI data and used 
PRS to investigate whether differences in polygenic risk 
for psychiatric disorders and cognition associate with 
deviations in brain morphology in a population-based 
sample of over a thousand children. These findings are 
reported in the second part of the thesis.
In the first part of the thesis (aim 1), we investigated the 
genetic architecture of several behavioral traits in the 
general population. 
In Chapter 2, we described our study in which genetic 
data and behavioral measures collected in over 2,000 
children from the age of 3 years onwards, were used to 
investigate whether genetic risk for psychiatric disorders is 
associated with problem behavior during early childhood. 
By calculating a PRS for five psychiatric disorders and 
educational attainment, we were able to show that variation 
in polygenic predisposition for schizophrenia based on 
common genetic variants is associated with higher levels 
of behavioral problems already at the age of three years, as 
reported by their mother. This was in particular reflected 
in higher levels of broad-scale internalizing problems. 
These associations persisted during follow-up reports 
at the age of 6 and 10 years of age. Interestingly, when 
examining specific problem scales, we found that the 
schizophrenia PRS was most strongly associated with the 
Thought Problem scale of the Child Behavior Checklist 
(CBCL), which may reflect positive symptoms such as 
that are associated with schizophrenia. In contrast, the 
polygenic score for educational attainment was negatively 
correlated with most scales on the CBCL and showed 
the strongest negative association with the Attention 
Problems scale at the age of 10. The reported results show 
clear evidence of behavioral manifestations of genetic risk 
INTRODUCTION |  189
in early childhood and may suggest a potential role of 
PRS for these disorders to identify those children most at 
risk of developing behavioral problems at an early age, in 
combination with traditional environmental risk factors 
for this disease.
In Chapter 3, we report our findings investigating the 
genetic architecture of insomnia and sleep-related traits 
by carrying out the largest GWAS to date in a population 
aged 18-80 years of over one million individuals in 
the UK Biobank and 23andMe datasets, both which 
contained completed sleep questionnaires and genotype 
data. We identified more than 200 loci and nearly 1,000 
genes for insomnia and showed that much of the genetic 
signal is shared with a variety of psychiatric disorders, 
including anxiety and depression. Based on Mendelian 
Randomization using these GWAS summary statistics, our 
results showed that insomnia shows a causal association 
with obesity, type 2 diabetes, and coronary artery disease, 
but not vice versa, emphasizing that sleep problems are an 
important risk factor for many negative health outcomes. 
RNA sequencing data from single neurons showed that 
there was enrichment of genetic signal of insomnia in 
neurons located in the hypothalamus and claustrum 
of the brain, confirming a suggested role of these brain 
structures in sleep regulation. These results provide genes 
and cell-types as novel targets for functional follow-up 
studies and illustrate how large-scale studies can greatly 
improve our knowledge of complex traits
To further uncover the genetic architecture of neuroticism 
and depression, Chapter 4 describes a large-scale meta-
analysis of GWAS studies on neuroticism and depression 
in over 400,000 adult individuals. These analyses showed 
nearly 200 loci to be involved in neuroticism. By carrying 
out cluster analysis, we showed that the total neuroticism 
questionnaire score is genetically heterogenous and 
that the questionnaire items can be broadly subdivided 
into subgroups of depressed affect and worrying with 
differential SNP and gene associations, and genetic 
correlations with previous GWAS studies. By analyzing 
gene-expression in single-cells, we showed evidence of the 
involvement of serotonergic neurons and dopaminergic 
neuroblasts in the brain, confirming the serotonergic and 
dopaminergic pathways as a target for antidepressant 
therapy. Neuronal involvement was further evidenced 
by enrichment of genetic signal in a number of neuronal 
processes, such as neuron differentiation, neurogenesis, 
neurodevelopment and neuron differentiation. In 
addition, we observed that many genes identified 
for neuroticism and depression may form targets for 
pharmacological treatment as indicated by a large drug-
gene interaction database.
In Chapter 5, we report findings of our combined GWAS 
data on intelligence test scores of 14 cohorts and over 
200,000 individuals, including both children and adults, 
to find genes associated with intelligence. We were able to 
detect over 200 loci of which most were new findings. We 
showed that several brain areas are significantly enriched 
for genetic signals, in particular in the frontal cortical 
areas of the brain. In addition, significant enrichment was 
observed for several types of pyramidal neurons, a major 
cell-type in the cortex and hippocampus of the brain, and 
neurons located in the CA1 region of the hippocampus. 
These findings are in line with observed significant 
enrichment in gene-sets and pathways associated 
with neurogenesis, a key process that takes place in 
the hippocampus of the brain. This large scale genetic 
analysis of intelligence provides many links between 
genetic variation and variation in intelligence scores and 
suggested functional pathways in neuronal cell-types.
In the second part of the thesis, we used magnetic 
resonance imaging (MRI) of the brain in two large 
population-based studies of both children and adults to 
study genetic influences on brain morphology and white 
matter microstructure. 
In Chapter 6, we described the prevalence of incidental 
findings in brain MRI scans that were observed during 
the large-scale data collection of MRI brain imaging 
data in over 4,000 children of the Generation R cohort 
between the age of 8 and 12 years old. Our results clearly 
demonstrate that incidental findings are highly prevalent 
in children, which warrant careful screening of collected 
research data and streamlined protocols for clinical follow-
up of the findings. In total, there were seven children 
where a suspected brain tumor was found, of which two 
children underwent surgery as a direct consequence of 
study participation shortly after participating in the study. 
These results are the most precise estimate of incidental 
findings prevalence in brain MRI scans in children to 
date. 
In Chapter 7, we reported the results of GWAS meta-
analysis of brain volume (BV) using brain scan data of 
over 40,000 individuals. We observed many novel loci 
related to BV and found that associated genes play a role 
in several interesting signaling pathways related to cell 
division, differentiation and apoptosis regulation, such as 
the Erbb2/Erbb4-signaling pathways. Interestingly, rare 
mutations in many of these genes are known to cause 
severe monogenic disorders characterized by intellectual 
disability and abnormal brain development, including 
micro-, macro- and megalocephaly. Prior evidence 
suggested that the phenotypic correlation between brain 
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volume and intelligence is completely due to overlap in 
genetic factors3. To further highlight which genes are 
involved in BV and intelligence, we carried out extensive 
cross-trait analyses of shared loci and genes between the 
BV GWAS results, and the GWAS of intelligence that we 
performed previously (Chapter 5). In total, we observed 
that 64 genes are implicated in both brain volume and our 
GWAS study of intelligence, and that the function of these 
genes is located in important signaling pathways of the 
brain involved in cell division and differentiation.  These 
results are a step forward in understanding the genes 
associated with BV and illustrate how GWAS summary 
statistics alone can be used to find novel interesting 
overlapping biological mechanisms between genetically 
correlated traits. 
In Chapter 8, we used structural brain imaging data 
and PRS of psychiatric disorders and cognition-related 
traits to study whether structural differences in brain 
morphology can be explained by variation in these 
polygenic scores. There were strong positive associations 
between PRS for cognition-related scores and total brain 
volume and suggested negative associations between the 
PRS of ADHD and brain volume. More specifically, a 
higher ADHD PRS was associated with smaller caudate 
nucleus volumes. This latter effect was most pronounced 
in boys. Using data on behavioral measures of ADHD 
symptoms in the same population, we observed that 
the caudate nucleus volume mediated the association 
between the ADHD PRS and ADHD symptoms in the 
population. These results suggest that caudate nucleus 
volume may be an endophenotype between polygenic 
predisposition for ADHD and ADHD symptoms in the 
general pediatric population. In contrast, the PRS for 
cognition was mostly linked to global differences in brain 
morphology, as evidenced by significant associations with 
total brain volume.
In the following Chapter 9, we used PRS for five 
psychiatric disorders (ADHD, autism, bipolar disorder, 
major depression, schizophrenia) and for cognition-
related traits (educational attainment and intelligence) to 
study whether genetic predisposition for these traits can 
be translated to abnormal white matter tract connections 
in children. We used diffusion tensor imaging (DTI) data, 
collected in a large group of children in the Generation R 
Study to investigate associations between these PRSs and 
white matter microstructure. Although schizophrenia 
has repeatedly been linked to abnormal white matter 
microstructure in vivo4, there were no associations 
between the schizophrenia PRS and white matter 
integrity. In contrast, we showed clear evidence that 
genetic predisposition for cognition-related traits such 
as educational attainment and intelligence is associated 
with higher fractional anisotropy. This may suggest a 
more optimal myelinization of the white matter tracts, a 
healthier state of white matter, in the brains of children 
who have a higher genetic predisposition to intelligence 
and educational achievement later in life. We demonstrate 
a clear link between genetic predisposition for cognition 
and white matter tracts of the brain, but not for PRS of 
psychiatric disorders. These results show the promising 
role of PRS to find associations with imaging biomarkers 
that correspond with the genetic predisposition for 
certain behavioral traits. 
2. Interpretation of research finding
2.1 GWAS 
In the GWAS that were carried out in this thesis, we have 
identified over 500 genomic loci in total for insomnia, 
neuroticism and intelligence, showing a non-uniform 
distribution across the genome. We observed genetic 
overlap between these traits (genetic correlations rg= -0.19 
to 0.44) that clusters in certain genomic regions (See Fig. 
1), as evidenced by overlap in the number of loci (range 
noverlap=18 to 20 loci) and several loci that are found in all 
three traits (e.g. loci on chromosome 22, where the genetic 
signal for all three traits is localized on the long q-arm of 
the chromosome only). This considerable pleiotropy of 
multiple genomic loci clearly shows that the boundaries 
between the genetic architectures of seemingly distinct 
behavioral traits are diffuse, in line with what has been 
observed in psychiatric and behavioral traits in general. 
The interpretation of this pleiotropy of shared loci is not 
straightforward, as these statistical pleiotropic effects can 
be explained by true genetic effects of a locus on multiple 
traits (biological pleiotropy), by a mediating effect of 
one phenotype on the other (mediated pleiotropy), or 
pleiotropy caused by different causal variants tagged 
by the same locus though LD (spurious pleiotropy)5. 
Recent analysis based on over 500 GWAS studies showed 
that this pleiotropy across the genome is highly present 
across several domains of human characteristics and 
estimated that over 90% of the loci and 80.9% of the 
genes are associated with multiple traits. Particularly in 
psychiatric traits, the pleiotropy tends to be high, whereas 
neurological diseases are known to be more genetically 
distinct6, possibly explained by more objective diagnostic 
criteria (e.g., brain imaging, blood tests) compared to 
psychiatric disorders and more robust neurobiological 
differences. 
Comparing the genetic architectures of the three studied 
traits, it is interesting to note that there is clear variation 
in the number of loci that were discovered for each trait 
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given the sample size of each study. In the GWAS of 
insomnia, the largest study in over 1 million individuals, 
we observed a comparable number of loci (n=202) as the 
much smaller GWAS of intelligence in almost 300,000 
individuals (n=205 loci). This may be explained by a 
much higher SNP heritability for intelligence (h2snp=0.19, 
SE=0.01, Chapter 5) than insomnia (h2snp=0.07, SE=0.002, 
Chapter 3), differences in discoverability (effect size 
variants) and polygenicity (the proportion of causal 
variants) of these traits7, and possibly more reliability in 
the measurement of sleep problems through questionnaire 
compared to cognitive test scores. Interestingly, the 
genetic signal in all three studies was associated with 
expression in the medium spiny neuron, a neuron cell-
type that was significant in all three studies. These GABA-
ergic inhibitory neurons make up the majority of the 
cells within the human striatum8. Prior evidence indeed 
suggests that the striatium is involved in a large number of 
brain functions, including emotion regulation9, including 
cognition10 and sleep-wake activity11. This finding of a 
Fig. 1 | Overview of the independent genomic loci identified in the three GWAS studies of insomnia, neuroticism and 
intelligence, as presented in this thesis. Genomic positions of genome-wide significant loci are shown for insomnia (yellow, 
Chapter 3), intelligence (blue, Chapter 5) and neuroticism (pink, Chapter 4). The 3-by-3 matrix highlights the genetic 
correlations between these traits (lower side of the matrix) and number of overlapping loci (upper side of the matrix).
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shared implicated neuronal cell-type may explain the 
multitude of neurobiological functions of the striatum. 
In addition to the large number of significant loci, gene-
mapping efforts in these GWAS studies led to over 1,000 
genes (i.e., more than 5% of the genome) that were 
observed through different gene-mapping methods (see 
introduction, Fig. 3). These results are a step forward 
in understanding variation in these traits compared to 
previous GWAS studies carried out in smaller samples12–14. 
The wealth of novel loci and genes in the reported analyses 
illustrate that GWAS studies are reaching a critical size 
where novel findings are discovered more rapidly with 
increase in sample size. In addition, these results show 
that larger samples are not only necessary for detecting 
novel loci and genes, but that sufficient power is necessary 
for robustly identifying pathways and gene-sets, which 
can only be achieved when reaching sample sizes of well 
over 100,000 individuals for these three traits. 
Future research is able to build forth on results reported 
in this thesis in a variety of ways. First, the large number 
of genes that are implicated in our work provide many 
previously undiscovered targets for follow-up studies. 
The functional effects of variants in individual genes can 
be studied on a cellular level by manipulating genes in 
induced-pluripotent stem cell (IPSC) cultures that may 
be differentiated to neuronal cell types to observe how 
these variants alter cellular characteristics. More recently, 
the emergence of high-throughput genome editing with 
CRISPR-CAS has made it possible to highly efficiently 
assert the functional consequences of single variants by 
introducing these in specific cell-lines15. On a larger scale, 
knock-out models of these genes using animal models 
may help understand the exact role of the identified gene 
on the level of a complete organism. These potential 
functional follow-up studies based on our GWAS results 
fulfill a strong need to fully grasp the functional role of the 
identified genes in cellular mechanisms and underlying 
biology that explain the association of these variants 
with observed behavioral differences. Second, we show 
that GWAS can be used to point towards specific tissue 
and cell-types through the analysis of RNA sequencing 
data, for example claustrum neurons and medium spiny 
neurons in insomnia in Chapter 3, serotonergic neurons 
in neuroticism and depression in Chapter 4, and CA1 
hippocampal neurons in intelligence in Chapter 5. 
Experimental studies aimed at specifically manipulating 
these individual neuronal cell-types can be carried out to 
confirm the role of these cells in the biology of the trait. 
Third, PRS calculations based on these large GWAS results 
can be used to study trait-associated outcomes or find 
novel associations between PRS and endophenotypes, 
including biomarkers and brain imaging-derived 
parameters16. This is illustrated in Chapter 8 and 9, where 
polygenic scores based on the GWAS results of intelligence 
reported in Chapter 5 was studied in association with 
brain MRI phenotypes including brain white matter tract 
integrity and brain volumes. Fourth, by making GWAS 
summary statistics of our GWAS studies available, future 
studies will be able to use our results by combining the 
GWAS results with novel bioinformatics data for insights 
into the studied traits, by performing meta-analysis with 
our results and GWAS performed in newly collected 
datasets to expand the number of identified variants, or 
by using our results for GWAS on correlated traits using 
multivariate GWAS approaches17.
2.2 Brain imaging studies
In the second part of the thesis, we report results of the 
population-based studies that utilized brain imaging 
techniques. 
In parallel to the upscaling in population size in genetics, 
larger studies that contain brain imaging data are 
essential for understanding the link between genes and 
the brain and how the mechanisms in the brain mediate 
gene-behavior associations (see introduction, Fig. 2a). 
However, the ambition to obtain more and more brain 
images through brain imaging research is not entirely 
without consequences. The reported incidental findings 
in the Generation R cohort in Chapter 6, caution that 
adequate follow-up protocols need to be in place prior 
to the collection of imaging data in large numbers of 
individuals given the reportedly high rate of incidental 
findings in children that warrant follow-up. The rate of 
incidental findings, especially suspected brain tumors, 
was higher than expected based on previous studies, and 
shows that incidental findings are not only an important 
issue to consider in adults but are highly relevant 
in pediatric neuroimaging as well. This is especially 
important in the advent of multiple large neuroimaging 
efforts that are ongoing or planned in the near future. In 
the field of genetics, incidental findings are also more and 
more frequently encountered, in both the clinical18,19 and 
research20 setting, where more accurate whole-exome and 
whole-genome sequencing increases the detection rate of 
unsuspected findings. The abundance of genetic variants 
across the human genome also in healthy participants, 
requires well-documented a priori agreement on which 
variants to report or not. Exchanging experience in 
reporting incidental findings in both scientific fields may 
improve protocols for handling these findings, which 
should include opinions and experiences from research 
participants and patients, as well as input from different 
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medical disciplines, including medical specialists, 
psychologists and medical ethicists.
In Chapter 7, we used these large imaging datasets to 
perform extensive genetic analyses on brain MRI data. 
These analyses showed that brain imaging phenotypes 
are highly polygenic, influenced by potentially hundreds 
to thousands of loci, in line with previous observations 
in complex traits21. In this chapter, we showed overlap 
between genes identified through GWAS, and genes that 
are known to lead to monogenic disorders characterized 
by abnormal brain growth. This is a particular interesting 
finding, as this suggests that both low-penetrant 
common variants present in the general population and 
highly penetrant rare mutations that cause monogenic 
(Mendelian) disorders in patients may converge on 
similar neurobiological mechanisms and pathways. 
Moreover, this overlap implies that the two apparently 
distinct areas of genetics, namely those concerned with 
monogenic causes of rare diseases and common variation 
in common polygenic traits and disorders, may not be as 
separate as often described. Findings in both fields may 
be translated between disciplines and support each other 
in generating hypothesis about genes and pathways that 
may be involved. Analysis of the overlap between rare and 
common variation in these same genes and the pathways 
is an exciting new area of research22 that will lead to novel 
insights now that GWAS is bringing forth larger numbers 
of common genetic variants genes for a variety of traits. 
In follow-up analyses of the BV GWAS, we showed several 
significant gene-sets to be involved in signaling pathways 
that are involved in brain developmental processes. 
Interestingly, we showed that specific genes within these 
pathways appear in the gene-mapping based on the 
GWAS results, either through mapping in FUMA23 or by 
gene-based association testing in MAGMA24, whereas for 
other genes that are part of the same signaling pathway, 
we found no evidence of being implicated in the trait. This 
observation is interesting, as it suggests that variation 
along several steps of the pathway has differential effects 
on the phenotype at the end of the pathway. The use of 
pathway analysis indicates that GWAS on macroscale 
brain-imaging phenotypes can lead to exciting new 
conclusions and hypothesis about which processes are 
driving variation on the microscale level in the brain. 
In addition to GWAS analyses, we used brain imaging 
to study the link between PRS and brain morphology 
and microstructure in Chapter 8 and 9, respectively. In 
both chapters, we observed a much stronger association 
for polygenic scores based on cognitive trait GWAS 
(intelligence and educational attainment) than for those 
based on GWAS of psychiatric disorders. Interestingly, 
these associations were mostly found with global 
differences in brain structure rather than being confined 
to specific brain areas or tracts, including associations 
with total brain volume in Chapter 8, and global white 
matter microstructure in Chapter 9. 
The contrast between associations based on polygenic 
scores for cognitive traits and psychiatric disorders 
suggests that cognitive polygenic scores may lead to 
measurable differences even at an early age. In contrast, 
the largely negative findings for PRS of psychiatric 
disorders may suggest that the underlying neurobiological 
differences as a product of these PRSs may not (yet) 
be present in this specific age range, or not at a scale 
that could be detected by the imaging modalities that 
were used for this thesis. An exception to this was the 
significant association we found for the ADHD polygenic 
score and caudate volumes in boys, where we showed that 
brain structure mediates the association between PRS 
and behavior. This association confirms prior evidence 
that found smaller caudate nucleus volumes in ADHD 
patients compared to controls25,26. 
The caudate nucleus is a C-shaped structure located along 
the lateral ventricles of the brain and forms a part of the 
human striatum and the large network of connections with 
the cortex and thalamus (cortico-basal ganglia-thalamic-
cortical network). Among important brain functions of 
the caudate nucleus are cognitive processing27, learning28, 
attention29 and response inhibition30, several of which 
are impaired in ADHD31. A role of the caudate nucleus 
in ADHD was recently demonstrated in a large meta-
analysis of children and adults carried out by the ENIGMA 
consortium, that found several gray matter structures to 
be smaller in ADHD cases32. Interestingly, the largest 
pooled effect size in the meta-analysis was observed for 
volumes of the amygdala and putamen, structures that 
are also part of the basal ganglia, for which we did not 
observe significant associations in our analyses. A possible 
explanation may be that our analyses included children 
only, whereas the meta-analysis included both children 
and adults, covering an age range of 4 to 63 years32. An 
earlier meta-analysis that included children-only samples 
indeed showed smaller volumes in the caudate nucleus33, 
and no evidence of other sub-cortical structures being 
involved. Whereas meta-analyses including also older 
patients may be more sensitive to detecting differences 
related to the disease over a longer time period, the use 
of PRS in children samples may find associations with 
brain structures that are involved in an earlier stage of the 
disease16. However, it needs to be taken into account that 
reported associations with the caudate nucleus reflects 
the link between predisposition for ADHD and brain 
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morphology in a general population sample (in contrast 
to a case-control sample in these meta-analyses), and it is 
yet unclear whether these findings can be extrapolated to 
clinical samples. 
3. Consideration in genetic research
Several important methodological considerations need to 
be taken into account when interpreting the results from 
this thesis. 
In Chapter 3, 4 and 5 of this thesis, we performed three 
GWAS studies that combined a number of large datasets, 
where we report a number of discussion points. 
First, the enormous scale of the UK Biobank and 
23andMe cohorts requires cost- and time-efficient data 
collection in large sets of individuals. The large sample 
size of these studies comes at the expense of a reduction in 
the depth and dimensionality of the collected phenotypes, 
which are often reduced to a limited set of questions. For 
example, the single insomnia question that was used 
in UK Biobank in the insomnia GWAS in Chapter 3 is 
a proxy for more complex correlated phenotypes that 
may be present in the population. Although we report 
a high accuracy of this question for the detection of 
insomnia disorder by validation of this question in an 
external sample containing insomnia disorder patients, 
phenotyping based on a single question that is correlated 
with the phenotype of interest may be more susceptible 
to noise compared to extensive questionnaires, requiring 
larger samples to distill the same genetic signal. It is 
yet unclear whether the same genetic signal would be 
observed in a more extensive phenotype definition of 
insomnia. More extensive phenotyping or longitudinal 
data collection of sleep-measures would provide a 
more precise estimate of genetic effects on insomnia. 
Second, our GWAS results reported in Chapter 3, 4 and 
5, show that the contribution of individual risk loci is 
limited, with typical odds ratios below 1.1, and absolute 
standardized effect estimates below 0.02. GWAS has 
indeed frequently been criticized for discovering only 
(very) small associations of genetic variants with disease 
which are often difficult to interpret34. While we report 
exceptions (e.g. MEIS1 (OR=1.1-1.2) locus in insomnia 
in Chapter 3), these results clearly emphasize that these 
traits are highly polygenic and that small individual effect 
sizes are part of their genetic architecture. In this thesis 
we show that, although focusing on the interpretation 
single risk loci does not lead to valuable new insights 
because of their small effect, performing extensive follow-
up analyses based on the GWAS results by gene mapping, 
gene-set and gene-expression does lead to new insights 
into the genetics of the phenotype. GWAS studies should 
thus be regarded as a starting point of further follow-up 
analyses using methods that take the combined effects of 
multiple SNPs into account. 
Third, research projects in this thesis took place in large 
population-based studies that sample from the general 
population, including the Generation R cohort, the UK 
Biobank, and 23andMe. These studies aim to include 
individuals that are a representative sample of the general 
population in order to find associations that can be 
extrapolated to the population at large. However, non-
participation and attrition over time are more common in 
individuals with psychiatric disorders35, or at high genetic 
risk for psychiatric disorders36, and those with a lower 
educational level37. In this regard, the population-based 
studies in this thesis oversample for higher education 
and intellectual level, and under sample genetic risk of 
psychiatric disorders. However, with the large size of 
these population-based studies, there is a high probability 
of also including participants with clinical and subclinical 
disorders. 
Forth, in the reported GWAS, we made use of meta-
analyses and combined separate datasets to maximize 
statistical power. Due to variation in the genetic 
background of these cohorts, differences in phenotype 
definitions and data collection, in addition to random 
variation, the genetic correlations between meta-analyzed 
samples is not perfect (although high in Chapter 3, 4, 
and 7). This may lead to a loss of information and has 
the effect of lowering the estimate of heritability and the 
variation that can be explained by the GWAS in a PRS. In 
Chapter 3, we performed a meta-analysis of UK Biobank 
and 23andMe. Although this was the largest GWAS study 
performed to date, the explained variance in holdout 
samples did not exceed an estimated 3% explained 
variance, possibly due to imperfect correlations between 
these samples38(rg=0.69). Higher homogeneity between 
samples in data collection, study population and phenotype 
definition would have led to more homogeneity in the 
genetic signal, and subsequent better-powered PRS based 
on the meta-analysis. At the same time, meta-analysis 
provides an internal replication between samples, and 
loci that are shared between samples are likely to remain 
significant in the meta-analysis. For the same reason, we 
chose to meta-analyze several different test score domains 
in Chapter 6 instead of performing GWAS on individual 
cognitive domains, in order to boost statistical power by 
combining correlated domain scores and find loci that are 
likely to be shared across different domains. 
Fifth, we reported several gene-mapping strategies in 
these GWAS studies (see introduction, Fig. 3). Here, we 
chose an inclusive approach by mapping genes through 
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different mechanisms, including by gene-expression 
by eQTL, and by physical interactions through the 3D 
folding of the genome, showing considerable overlap 
in Chapter 3, 4, and 5. Because of this combination of 
different methods, we were able to map a large number 
of genes, which is likely an upper estimate of the number 
of genes that can be mapped based on these GWASs. We 
argue that none of these methods is superior to others and 
they contribute equal evidence, albeit through different 
mechanisms, that a gene may be implicated in a certain 
trait. 
With regard to the PRS studies that were reported in 
Chapter 2, 8 and 9, it is important to consider that the 
usefulness of PRS for finding novel associations with 
behavior or brain phenotypes strongly depends on 
the availability of a sufficiently powered GWAS study. 
Although increasing much in size since the start of this 
thesis, increase in scale of GWAS studies of psychiatric 
disorders tend to be slow due to more hurdles in collecting 
patient data for genetic studies compared to healthy 
research participants. The asymmetry of sample sizes 
of GWAS studies used in the reported PRS studies may 
partly distort comparison of associations for psychiatric 
disorder PRS and PRS for cognitive tracts, since the 
educational attainment and intelligence GWAS studies 
were performed in much larger samples (educational 
attainment39: N=293,723, intelligence40: 269,867)  than 
those in psychiatric disorders. In this light, several 
reported associations between PRS and the outcomes 
studied in this thesis, such as the link between the ADHD 
PRS and caudate nucleus volume, may be just the tip of 
the ice-berg, and may show much stronger associations 
with these outcomes or several new associations when the 
discovery sample size of GWAS in psychiatry increases.
In addition, there are considerations when interpreting 
the findings from brain imaging studies carried out in 
the second part of the thesis. In Chapter 8, we found 
significant negative associations between genetic risk for 
ADHD and the volume of the caudate nucleus. Although 
these results are interesting given prior evidence of 
ADHD symptoms and their association with volumes of 
this brain structure, the results do not generate hypotheses 
about the microstructural changes or mechanisms that 
can explain these smaller volumes and how they relate 
to genetic risk. Structural brain imaging, including T1 
and T2-weighted sequences have traditionally been 
used to diagnose neurological disorders that alter brain 
anatomy, including brain tumors, white matter lesions 
and cerebrovascular disease. For these diseases, it is 
quite clear that the pathophysiological mechanism 
results in an abnormal appearance of the brain on CT or 
MRI. In psychiatric disorders, these pathophysiological 
mechanisms are much less clear, and future research is 
necessary to investigate how microstructural changes 
lead to smaller macrostructural volumes quantifiable on 
MRI. Considering that accepted hypotheses about disease 
mechanisms in psychiatry are on the microscopic scale 
(NMDA theory in schizophrenia41, dopamine theory in 
ADHD42) it remains to be investigated how findings on 
the micro- and macrostructural scale can be reconciled. 
Along these lines, the reported positive associations 
between polygenic scores and higher fractional anisotropy 
on DTI in Chapter 9 need to be interpreted in the context 
of the underlying biological substrate of DTI measures. 
DTI models the primary diffusion directions of hydrogen 
within individual voxels, expressed in diffusion metrics 
such as fractional anisotropy (FA) and mean diffusivity 
(MD), which are thought to represent primarily 
myelinization and fiber density43. The interpretation of 
anisotropic diffusion in white matter varies widely in 
the neuroimaging literature44, including ‘white matter 
microstructure’ and ‘microstructural integrity’. Although 
the links between anisotropic diffusion and myelinization 
are evidenced by lower FA in demyelinating diseases 
such as multiple sclerosis45,46 and clear overlap between 
DTI tracts and postmortem white matter bundles overlap 
quite elegantly, the knowledge of the correlation between 
diffusion measures and histological features of brain 
tissue is still lacking in the current literature. It remains 
to be seen whether a clear neurobiological substrate for 
DTI measures will be found for these measures, as it is 
currently not possible to study these in a living human 
brain. More detailed MR sequences of microscopic 
features in living tissue may further aid in understanding 
the exact neurobiological background of DTI. 
4. Future directions
4.1 Big data and genetics
During the preceding four years of this thesis, GWAS 
discovery samples have seen a remarkable expansion 
in scale that reached the ‘one-million-milestone’ in 
2018. The wealth of results that come from these studies 
demonstrates that this big data approach is not merely a 
‘buzz-term’ but forms the basis for novel insights about 
human genetic architecture, now and in the years to come. 
Given the major steps forward in GWAS, it is often 
mentioned that we have already arrived in the post-GWAS 
era47–49. However, for many traits larger GWAS studies 
are just starting to uncover its genetic architecture. In 
this thesis, we have shown that larger studies are indeed 
leading to many more genes being associated with a trait: 
In our GWAS meta-analysis of insomnia in Chapter 3, we 
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show that an approximate tenfold increase in sample size 
lead to a hundred-fold increase in number of discovered 
independent loci compared to a previous GWAS13. These 
enormous samples raise the obvious question to what 
extent costly increases in study sample size will still return 
additional insights into the genetics of human behavior. 
Next to these datasets containing a larger number of 
individuals (i.e. more rows in the data set), the improved 
coverage of new genotyping arrays and larger reference 
panels will lead to many more variants that can be 
tested (i.e. more columns in the data set), leading to 
large datasets that are even more difficult to handle50. 
This will require research groups to have access to more 
computational resources such as high performance and 
parallel computing, and necessitates the use of cloud-
operated computing systems51 such as the Hadoop 
distributed file system52.
The collection of larger datasets (even well beyond 1 
million individuals) in future studies is still going to be 
important for a number of reasons. First, many phenotype 
have not yet reached the tipping point where the number 
of discovered variants increases exponentially with larger 
samples, which strongly depend on the polygenicity and 
discoverability that make up the genetic architecture of 
a trait or disorder7. For many phenotypes, the first few 
genomic loci are just starting to be found, including 
ADHD53, autism54 and depression55. Second, the genetic 
signal within subgroups that constitute a phenotype 
definition have been shown to be heterogeneous56. Larger 
samples allow sufficient power to investigate genetic 
effects that are shared and specific to subgroups within 
broadly defined phenotypes. Third, larger datasets 
allow more complex statistical modelling including 
interactions between SNPs (epistasis57,58) and between 
SNPs and environmental factors (gene-environment 
interactions)59,60. Fourth, although the yield of novel loci 
may reduce with increasing sample size, an increase in 
statistical power of follow-up analysis based on these 
even better powered GWAS studies will be beneficial for 
detecting enrichment in novel pathways61, tissue types 
and neuronal cell types. Fifth, polygenic scores based on 
even larger discovery samples will be a more powerful 
tool for a wide range of applications, including prediction 
of the same phenotype, and finding novel associations 
with related phenotypes. Especially for polygenic scores 
for disease-related phenotypes that may become clinically 
useful for risk stratification of patient groups, even small 
increases in explained variation may still be desirable. 
Whether researchers, consortia, funding agencies and 
scientific journals will indeed support the endeavor of 
even larger genetic studies beyond 1 million individuals 
remains an open question. 
Several major sources of big data will lead to even larger 
genetic studies in the near future. First, in the coming 
year the UK Biobank is expected to release whole exome 
data in approximately 100,000 individuals, which will 
possibly lead to another wave of discoveries by fine-
scale analyses of exonic regions in the genome. Second, 
following an example of the UK Biobank study, there 
are several biobank initiatives that gather data in the 
general population, including large-scale genotyping. 
These include the Kadoori Biobank62 in China that 
includes 500,000 million individuals enrolled between 
2004 and 2008 (which is also regulated open-access to 
researchers), the FinnGen biobank in Finland in up to 
500,000 individuals by 2023, and the ambitious ‘All of Us’ 
research program carried out by the National Institute 
of Health (NIH)63 that was initiated in 2016 and aims to 
include 1 million individuals throughout the US. Third, 
a wealth of high dimensional studies is already stored in 
electronic health record systems. Linking these records to 
genotype data forms a great opportunity to study genetic 
variation in relation to a massive number of outcomes64,65. 
An example of such an ongoing initiative is carried out 
by the Geisinger health care system66 in the US, a data 
base that includes health care record data and exome chip 
data in over 100,000 patients. Fourth, direct-to-consumer 
genotyping companies such as 23andMe will continue 
to be a major source of data for genetic analysis, as this 
company is aiming to reach 10 million customers in the 
near future67, with many opting in for use of their data in 
genetic research. These companies have clear advantages 
compared to the coordination of large cohort studies: the 
data set will continue to grow as new customers are being 
included to the customer database, and the online data 
collection is much more flexible as it can easily be updated 
by adding new questions to existing questionnaires. At 
the same time, phenotype operationalizations in online 
data collection like in 23andMe is still limited to online 
questionnaire data that is often quite general (referred to 
as “minimal phenotyping”68) and may not reach the level 
of phenotyping that is achieved at research centers of 
smaller population cohorts69. 
4.2 Precision phenotyping
In these ongoing increases in study scale, it becomes 
more challenging to measure phenotypes at a sufficient 
depth due to increasing costs and time constraints. To 
fully understand genomic risk loci related to psychiatric 
disorders, smaller-scale studies that contain extensively 
phenotyped individuals, including detailed disease 
biomarkers and omics data collected in longitudinal 
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designs, can provide more information about associations 
between risk loci and a multitude of (endo)phenotypes. 
With ongoing technological advances in the use of 
portable devices and biosensors, there are opportunities 
for continuous data collection in participants that are 
able to capture variation and fluctuation in measures 
longitudinally in contrast to single cross-sectional 
measures. In future studies, more data will be collected 
from electronic devices that can be carried by participants 
and continuously measure health-related data70. This 
digital phenotyping holds promise to be able to better 
capture behavioral determinants and outcomes through 
the use of sensory devices and continuous monitoring71. 
In combination with advanced artificial intelligence 
and deep learning algorithms, a myriad of complex 
phenotypes may be assessed or predicted from the 
collected data. Combining these fine-grain resolution 
data with previously collected genotype data, a much 
more detailed understanding of the link between genetic 
and phenotypic variation may be obtained. 
4.3 Polygenic risk prediction
In this thesis, we showed the usefulness of PRSs to 
investigate early childhood reflections of genetic risk for 
psychiatric disorders using questionnaire (Chapter 2) 
and brain imaging data (Chapter 8 and 9). 
Population-based studies have greatly benefited from 
using polygenic scores as a valuable estimate of overall 
genetic risk, leading to a variety of novel insights 
into associations between genetic predisposition and 
behavioral and health-related measures72–75. In the clinical 
setting, the utility of risk stratification for common 
diseases (cancer, cardiovascular and metabolic health) 
based on polygenic scores is expected to be even higher. 
Recently, many novel risk loci of common variants have 
been discovered for breast cancer76 and colon cancer77, 
and cardiovascular disease78. Polygenic scores based on 
these GWAS are shown to accurately separate high risk 
from low-risk groups, with individuals in the highest 
polygenic risk groups having a comparable risk (relative 
risk of 2 to 3 compared to the lowest quintile) as those 
that carry a rare monogenic mutation with a strong effect 
on the disease79. These relative risks for diseases that 
are already common in the population (breast cancer 
incidence in the Netherlands is roughly 1 in 8 or 13%80) 
means a very strong change in absolute risk of disease. By 
including polygenic scores in risk stratification, certain 
groups that were not identified as high risk may be shifted 
towards earlier screening risk categories, while others 
may be classified as at low risk may have less need for 
early screening81. 
For cardiovascular and coronary artery disease, 
individuals in certain unfavorable high genetic risk groups 
may undergo regular check-up, start cholesterol-lowering 
drugs earlier and may even more strongly advised to 
take up a healthier lifestyle82. In psychiatric disorders, 
a higher PRS in patients with schizophrenia has been 
linked to a higher likelihood of a more chronic disease 
course and one that is often more difficult to treat83,84. 
Based on genetic predisposition and symptoms during 
presentation, polygenic scores may eventually be used 
in presymptomatic healthy individuals to modulate well-
known risk factors for the disease or patients with a high 
genetic load for the disease to treat certain risk groups 
with higher dose of medication or according to a more 
intensive follow-up routine. Given the lack of reliable 
biomarkers or diagnostic tests compared to diseases such 
as heart disease and cancer types, the implementation and 
validation of these scores in psychiatric patient groups 
will be much more difficult.
Several limitations exist that preclude the implementation 
of PRSs in routine clinical practice. First, most GWAS 
study samples exclude non-European subjects to 
improve external validity and prevent confounding 
due to population stratification. PRSs building forth on 
these results thus tend to have a poor predictive value 
in non-European populations85. Unless large-scale 
GWAS are carried out in populations of different ethnic 
backgrounds, the PRS will only be useful for a specific 
group of patients mostly from European ancestry. 
Second, studies reporting the value of combing PRSs with 
traditional modifiable and non-modifiable risk factors are 
scarce, and are necessary to estimate the value of genetic 
risk profiles in addition to risk estimation based on e.g. 
family history86. Third, validation studies are necessary 
to define the optimal threshold for defining high and low 
risk of disease. Current PRS studies estimate predictive 
accuracy in defining cases based on cross-sectional data. 
The optimal implementation and cut-off of genetic risk 
based on PRS requires long-term follow-up studies to 
estimate whether the PRS actually contributes to better 
treatment strategies and prognosis. Fourth, for many 
diseases, data collection has notoriously been slow due 
to difficulties in patient enrollment compared to the 
study of healthy individuals. PRSs based on smaller 
GWAS do not yet provide useful information, and use 
of these low-predictive scores leads to overdiagnosis or 
underestimation of risk87. Fifth, implementation of novel 
genetic tests requires patients, clinical geneticists, and 
health professionals to be well-informed about what PRSs 
exactly capture, before they can be considered in clinical 
practice.
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4.4 Artificial intelligence in genetics
Another limitation in the predictive accuracy of PRS is 
the fact that GWAS and PRS have so far applied a linear 
model for estimation of SNP associations (GWAS) or 
prediction of the phenotype (PRS). Although linear 
models are highly interpretable and have excellent 
computational tractability for large datasets, it may 
not capture the complex non-linear associations of 
individual genetic variants that may be found in nature. 
In addition, PRS includes a weighted combination of 
thousands of SNP effects based on their linear association 
with the phenotype in GWAS which does not take the 
concurrent effects of other SNPs into account. Next to 
the classical statistical modelling techniques, there has 
been an emergence of algorithmic modelling in the last 
decade88. Machine learning and artificial intelligence 
using deep learning methods such as artificial neural 
networks89 have shown promising results and improved 
prediction in almost all areas of scientific research, owing 
to its superior ability to capture non-linear relationships 
between predictor and outcome90. In the field of genetics, 
highly flexible algorithms such as neural networks are 
used to predict regulatory functions and pathogenicity 
of genetic variants91,92. While deep learning has shown 
to be promising in predicting the relevance of functional 
categories of variants in disease risk93, prediction of 
phenotypes based on just genotype data has proven to be 
challenging due to the high computational demand, the 
high dimensional genetic data (i.e. many more variables 
than subjects), and complex level of layers through which 
variants act upon a phenotype94. This task of predicting 
phenotype from genotype is referred to as a ‘supervised 
problem’ in machine learning, as the training data of the 
algorithm is labeled with the true outcome that needs to 
be predicted in the unlabeled test dataset95. Moreover, 
given that genetic constitution and ethnic background are 
strongly related, prediction algorithms may be prone to 
predicting ancestry differences instead of actual disease 
status between groups96. 
Although several barriers still exist, machine learning and 
artificial intelligence are a promising and sophisticated 
alternative to the linear risk prediction models in genetics 
now that technological developments allow sufficient 
computing power for using these complex algorithms. 
Whether this will lead to better accuracy of targeting 
genetic risk predictors compared to standard linear 
models needs to be further explored in future research.
4.5 Clinical applications of GWAS results
There are several ways how the great abundance of 
knowledge brought forth by GWAS studies will contribute 
to improved clinical care of patients. First, GWAS has 
had an impact on nosology, the study of how we classify 
disease, by showing overlap in genetic factors and 
neurobiological mechanisms between seemingly distinct 
disorders6, which may aid in future disease classification 
systems. Second, GWAS studies are pointing towards a 
large number of genes that can potentially be targeted 
with pharmacological intervention97. This opportunity 
is particularly needed for psychiatric disorders, where 
progress in pharmaceutical treatment over the last decades 
has been notoriously slow98. In addition, gene-targets may 
be identified that are currently targeted for other medical 
indications97 (i.e. ‘drug repositioning’), such as the 
calcium-channel genes (CACNA1C) that are implicated 
in schizophrenia1, and are targeted with calcium-channel 
blockers to treat hypertension99. It is hoped that targeting 
these same gene products may indeed lead to alleviation 
of symptoms in schizophrenic patients in clinical trials. In 
Chapter 4, we observe a large number of genes implicated 
in neuroticism and depression that are known to interact 
with existing drugs, or genes that code for a protein or 
pathway that could potentially be targeted by novel drug 
therapies. In the clinical setting, genetic screening for 
drug susceptibility (e.g. cytochrome-related genes, or 
CYP) in patient that receive pharmaceutical may find 
opportunities for distinguishing ‘rapid metabolizers’ that 
are insensitive to the drug from those from those that are 
more sensitive and can be treated with lower doses. Third, 
as mentioned in previous sections, PRSs may contribute 
to diagnostic information for personalised screening, 
treatment strategies and prognosis, which may improve 
patient care in the near future. The results in Chapter 2 
illustrate that the PRS of schizophrenia may eventually be 
lead to additional information in distinguishing those at a 
low and high risk of developing internalizing (emotional) 
and externalizing (behavioral) problems. Future clinical 
studies are necessary to investigate whether the PRS 
may eventually have a potential role in more accurate 
diagnosis and ultimately in individual-tailored treatment 
plans in psychiatric care.
4.6 Neuroimaging
In the coming years, neuroimaging techniques will be 
an increasingly useful tool for studying relationships 
between genetic variance and structural or functional 
brain imaging-derived phenotypes. By using ultra-high-
field imaging (field strength of 7 Tesla and higher100) MRI 
scanners will be able to capture more fine-grained images 
of the brain well below millimeter scale101 at a faster pace. 
Also, the ongoing trend towards quantitative MRI will 
take a prominent place in neuroimaging102, with strong 
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emphasis on novel sequences that assess microstructural 
characteristics of brain tissue, including MR spectroscopy 
for measuring neurotransmitter concentrations in 
the brain103, and perfusion MRI to quantify the small 
vasculature of the brain. These fine-scale measurements 
of the brain will lead to a better visualization of variation 
in brain structure related to genomic variation that take 
place at a scale closer to the microscopic scale of genetic 
mechanisms.
In addition to further development of single MRI 
sequences, future brain imaging studies will increasingly 
use a combination (or integration) of different MRI 
sequences in a multimodal and multivariate brain 
imaging approach104, which broadens the searchlight of 
finding neuroanatomical differences related to genetic 
variation. Also, novel approaches that integrate structural 
and functional sequences in network approaches may 
be better able to model the inner workings on the brain 
in connectome-based analyses compared to traditional 
structural imaging of the brain105.
5. Conclusions
To conclude, the reported research findings contribute to 
our understanding of the genetic architecture of human 
behavior and the neurobiological tissues, cell-types and 
mechanisms through which they act. Genetic studies will 
continue to be central to lifting the veil of the infinitely 
complex biological background of human characteristics 
and will hopefully improve clinical care and human health 
and wellbeing. Despite the importance of larger sample 
sizes, big data and more advanced statistical modelling 
and software, the last decade of breakthroughs in genetics 
has above all taught us that these discoveries can only be 
achieved through teamwork and scientific collaboration.
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In Hoofdstuk 2 gebruikten we genetische data en 
gedragsmaten, verzameld in meer dan 2,000 kinderen 
vanaf de leeftijd van 3 jaar en hoger, om te onderzoeken 
of genetische aanleg voor psychiatrische ziektebeelden 
geassocieerd is met afwijkend gedrag op jonge 
kinderleeftijd. Door polygene risico scores van vijf 
psychiatrische ziektebeelden te berekenen, konden we 
aantonen dat variatie in genetische predispositie voor 
schizofrenie geassocieerd is met verschillen in door 
hun moeder gerapporteerde gedragsproblemen vanaf 
de leeftijd van drie jaar, met name in internaliserende 
problemen. Deze associaties bleven bestaan tijdens follow 
up op de leeftijd van zes en 10 jaar. De polygene score voor 
opleidingsniveau daarentegen was negatief geassocieerd 
met vrijwel alle gedragsschalen en liet de sterkste 
negatieve associatie zien met aandachtsproblemen. Deze 
bevindingen lieten duidelijk zien dat gedragsmanifestaties 
zijn geassocieerd met genetisch risico in de vroege 
kindertijd, en suggeren dat polygene risico scores voor 
deze ziekten mogelijk een rol kunnen spelen in het 
vroeg identificeren van kinderen met het grootste risico 
op gedragsproblemen, en een mogelijk risico voor 
schizofrenie op volwassen leeftijd. Dit suggereert dat 
verschillen in hersenstructuur en functie gerelateerd aan 
het genetisch risico mogelijk op vroege leeftijd aanwezig 
zijn. 
In Hoofdstuk 3 voerden we de grootste genetische 
studie tot nu toe uit door een meta-analyse van GWAS 
studies naar slapeloosheid uit te voeren in meer dan 
1,000,000 individuen in twee grootschalige cohorten 
waarin slaapvragenlijsten en genetische data verzameld 
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zijn. We identificeerden meer dan 200 loci en bijna 
1,000 genen. De resultaten lieten zien dat veel van het 
genetische signaal voor slapeloosheid overlapt met een 
ruim aantal psychiatrische ziektebeelden, waaronder 
angststoornissen en depressie. Gebaseerd op Mendelian 
Randomization met GWAS resultaten konden wij laten 
zien dat slapeloosheid een causale lijkt te spelen in 
obesitas, type 2 diabetes en coronaire hartziekten, maar 
niet vice versa. Door RNA sequencing data in individuele 
neuronen te analyseren, lieten we zien date er verrijking is 
van genetisch signaal in neuronen gelocaliseerd in onder 
andere de hypothalamus en het claustrum. Dit bevestigt 
de rol van deze hersenstructuren in slaapregulatie. Deze 
resultaten tonen nieuwe genen en celsoorten aan als 
mogelijk nieuw doel van functioneel vervolgonderzoek. 
Om de genetische architectuur van neuroticisme en 
depressie beter te begrijpen, voerden we in Hoofdstuk 
4 een grootschalige meta-analyse uit van GWAS 
naar neuroticisme en depressie in meer dan 400,000 
individuen. Deze analyses onhulden meer dan 100 loci 
in het genoom die betrokken zijn bij neuroticisme. Door 
een clusteranalyse uit te voeren op alle neuroticisme items 
van de vragenlijst lieten we zien dat de totaalscore van 
neuroticisme  genetisch heterogeen is en deze individuele 
items kunnen worden onderverdeeld in subgroepen 
die verschillen in significante SNPs, gen associaties en 
genetische correlaties met eerdere GWAS studies. Voor 
depressie toonden we bewijs dat serotonerge neuronen 
in het brein betrokken zijn. Dit bevestigt de rol van 
serotonerge mechanismen als doel van serotonerg 
aangrijpende antidepressiva. Ook vonden we vele nieuwe 
Het doel van mijn thesis was het beantwoorden van een tweetal onderzoeksvragen:
1) Het eerste onderzoeksdoel was om de genetische factoren te begrijpen die de erfelijkheid verklaren van menselijk 
gedrag in de algemene populatie Het belangrijkste beginpunt van alle analyses die hiernaar zijn uitgevoerd is een 
genoomwijde associatie studie (GWAS) om voor vele SNPs (genetische varianten) in het genoom de associatie 
met de uitkomstmaat te verkrijgen. Deze SNP-effecten kunnen vervolgens worden gebruikt als input voor velerlei 
analyses die daarop volgen, waarmee genen en neurobiologische mechanismen gevonden kunnen worden, en om 
het totale genetische risico met polygene risicoscores te schatten. 
2) Het tweede doel was om magnetic resonance imaging (MRI) van het brein toe te passen, verzameld in een paar 
duizend individuen, waaronder kinderen en volwassenen, om te verklaren hoe genetische variatie tussen individuen 
leidt tot verschillen in de morfologie van het brein. Om dit te onderzoeken voerden we een genoomwijde associatie 
studie uit en gebruikten we polygene risicoscores om vast te stellen of verschillen in genetische predispositie voor 
psychiatrische ziekten leiden tot een andere hersenontwikkeling in een studiepopulatie van kinderen.
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genen waarvan bekend is dat ze interacties vertonen in een 
grote referentiedatabase naar farmacologische interactie 
met bepaalde medicijnen, en die mogelijk hierdoor een 
nieuw doel vormen voor behandeling.
In Hoofdstuk 5 combineerden we GWAS resultaten 
van cognitieve test scores verzameld in 14 cohorten en 
meer dan 200,000 individuen om genen te vinden die 
geassocieerd zijn met intelligentie. We waren in staat 
om meer dan 200 geassocieerde locaties in het DNA te 
ontdekken waarin variaties gerelateerd zijn aan variatie 
in intelligentie. Een groot deel, hiervan waren nieuwe 
ontdekkingen. We lieten met genexpressie zien dat 
verschillende hersenregio’s significant verrijkt zijn voor 
genen betrokken bij intelligentie, met name corticale 
gebieden van het brein. Ook vonden we significante 
verrijking van genetisch signaal in verschillende soorten 
pyramidale neuronen, en neuronen gelegen in de CA1 
regio van de menselijke hippocampus. Deze bevindingen 
zijn in overeenstemming met significante verrijking van 
genetisch signaal in gen-sets en biologische mechanismen 
betrokken bij neurogenese, de aanmaak van neuronen, 
een belangrijk process dat in de hippocampus plaats vindt. 
These grootschalige analyse van intelligentie biedt vele 
links tussen genetische variatie en variatie in intelligentie 
scores, en duidt specifieke mechanismen aan die deze link 
kunnen verklaren.
In het tweede deel van deze thesis, gebruikten we 
magnetic resonance imaging (MRI) van het brein van 
zowel kinderen als volwassenen uit grote populatiestudies 
om de genetische effecten op brain morfologie en witte 
stof microstructuur te bestuderen.
Het gebruik van grootschalige data van scans van het 
menselijk lichaam heeft het duidelijke voordeel dat er 
veel statististische rekenkracht in deze data zit, waardoor 
subtiele associaties met genetische en omgevingsfactoren 
gedetecteerd kunnen worden. Een grote dataverzameling 
gaat echter ook gepaard met een grote kans op het vinden 
van toevalsbevindingen die gezondheidsconsequenties 
voor de deelnemer kunnen hebben. In Hoofdstuk 6 
rapporteren we de prevalentie van incidentele bevindingen 
op hersen MRI scans die werden waargenomen tijdens 
de grootschalige verzameling van hersen MRI data in 
meer dan 4,000 kinderen. Onze resultaten lieten duidelijk 
zien dat incidentele bevindingen zeer prevalent zijn in 
kinderen, en dat nauwkeurige screening van deze data en 
een gestreamlined protocol voor de klinische follow-up 
hiervan zeer belangrijk zijn. De incidentele bevindingen 
betroffen zeven kinderen waar de klinische verdenking 
op een hersentumor bestond. Van hen zijn twee kinderen 
geopereerd als direct gevolg van het meedoen aan het 
populatie onderzoek. 
In Hoofdstuk 7, deden we een GWAS meta-analyse van 
brein volume (BV) op basis van hersen MRI data in meer 
dan 40,000 individuen. We vonden vele nieuwe genetische 
loci voor breinvolume en vonden genen betrokken bij 
verschillende interessante signaleringsmechanismen in 
het brein gerelateerd aan celdeling, celdifferentiatie en 
apoptose regulatie. Interessant genoeg vonden dat veel van 
deze genen gelinkt zijn aan het optreden van monogene 
ziekte door zeldzame varianten en ziektebeelden waar 
vaak een abnormale hersenontwikkeling bij optreedt, 
zoals micro- macro- en megalencephalie. Eerder bewijs 
suggereert dat de fenotypische correlatie tussen brein 
volume en intelligentie wordt verklaard door overlap in 
genetische factoren. Om genen te vinden die betrokken 
zijn in zowel brein volume als intelligentie, voerden we een 
uitgebreide genetische analyse uit van de overlap in loci 
en genen tussen intracranieel volume en onze genetische 
studie naar intelligentie. De functie van deze genen is met 
name gerelateerd aan signaalmechanismen betrokken 
bij celcyclusregulatie. Deze resultaten zijn een grote stap 
vooruit in het begrip van genen geassocieerd met brein 
volume, en illustreren hoe GWAS resultaten kunnen 
worden gebruikt om interessante overlap in genetische 
factoren te vinden tussen genetisch gecorreleerde 
eigenschappen.
Voortbouwend op deze beinvingen, gebruikten we in 
Hoofdstuk 8 polygene risico scores voor psychiatrische 
ziektebeelden en cognitie-gerelateerde eigenschappen 
om te bestuderen of variatie in hersenstructuur verklaard 
kan worden door verschillen in genetische predispositie. 
Er waren sterke positieve associaties tussen cognitie-
gerelateerde genetische scores en brein volume, en 
suggestieve associaties in de negatieve richting met 
ADHD polygene risicoscores en brein volume. Meer 
specifiek toonden we associaties aan tussen hogere 
polygene risicoscores voor ADHD en kleinere volumes 
van de nucleus caudatus, dit effect was met name in 
jongens waarneembaar. Door gedragsuitkomsten van 
ADHD symptomen in deze kinderen te gebruiken, 
konden we aantonen dat het volume van de nucleus 
caudatus de associatie tussen ADHD polygene scores en 
ADHD symptomen medieerde, en dat deze structuur de 
associatie tussen predispositie voor ADHD en ADHD 
symptomen verklaart. 
In het daarop volgende Hoofdstuk 9, berekenden 
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we polygene risico scores voor vijf psychiatrische 
ziektebeelden (ADHD, autism, bipolaire stoornis, 
depressie en schizofrenie), en voor cognitie-gerelateerde 
eigenschappen (opleidingsniveau en intelligentie) 
om te onderzoeken of genetische aanleg voor deze 
eigenschappen kan worden vertaald naar een abnormaal 
ontwikkelingspatroon van de witte stofbanen van het 
brein. We gebruikten opnieuw DTI, verzameld in een 
grote groep deelnemers, om de microstructuur van witte 
stof te onderzoeken. Hoewel schizofrenie herhaaldelijk 
in verband is gebracht met een abnormale ontwikkeling 
van witte stof op hersenimaging data, vonden we geen 
associatie tussen genetisch risico voor schizofrenie en witte 
stof integriteit. Daarentegen vonden we duidelijk bewijs 
dat genetische predispositie voor cognitie-gerelateerde 
eigenschappen zoals opleidingsniveau en intelligentie 
geassocieerd zijn met hogere fractional anisotropy (FA) 
van meerdere witte stof banen, dit suggereert een meer 
optimale myelinizatie van witte stof banen van het brein 
in kinderen met een hogere genetische aanleg voor 
intelligentie en opleidingsniveau later in het leven.
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